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urgently	needed	 to	help	meet	 the	WHO	goal	of	 tuberculosis	elimination	by	2050.	
However,	 insufficient	 epidemiological	 evidence	 exists	 to	 inform	 TB	 vaccine	
development	strategies	and	to	assist	clinical	trial	site	selection	and	design.	Research	
to	 meet	 these	 data	 needs	 is	 critical	 to	 accelerate	 TB	 vaccine	 development.	 To	
maximise	 the	 future	 impact	of	new	TB	vaccines,	estimates	of	 the	population-level	
impact	 of	 vaccine	 characteristics	 and	 implementation	 strategies	 are	 needed	 to	
inform	design	of	TB	vaccine	target	product	profiles.	To	accelerate	and	de-risk	clinical	





thesis	 were	 to	 1)	 estimate	 the	 epidemiological	 impact	 of	 new	 TB	 vaccine	
characteristics	 and	 implementation	 in	 China	 to	 inform	 design	 of	 target	 product	
profiles;	and	2)	to	develop	a	novel	epidemiological	spatial	mapping	tool	capable	of	
informing	 clinical	 trial	 design	 for	 new	 TB	 vaccines	 in	 low-income,	 high-burden	
settings.	
Methods:	A	deterministic,	age-structured,	Mycobacterium	tuberculosis	transmission	








satellite	 maps,	 within	 an	 electronic	 tablet-based	 case	 report	 form.	 The	 app	 was	
integrated	 in	 to	 the	 National	 Tuberculosis	 Programme	 in	 Blantyre,	 Malawi,	 for	
collection	of	demographics,	health	status	and	coordinates	of	place	of	residence	for	
patients	≥18	years	initiating	TB	treatment.	Accuracy	of	ePAL-recorded	co-ordinates	
was	 evaluated	 against	 GPS	 coordinates	 obtained	 at	 the	 participant’s	 place	 of	
residence.	 	




impact	 than	 vaccinating	 adolescents	 for	 all	 equivalent	 vaccines	 explored,	 even	 if	
much	lower	coverage	were	achieved	in	older	adult	vaccination.	Recommendations	






patient	 acceptance	 (98.7%,	 1,899/1,924).	 ePAL	 achieved	 clinic-based	 collection	 of	
patient	location	of	residence	accurate	to	a	median	of	84	metres	(IQR:	35-317	metres)	
in	 a	 high	 population	 density	 urban	 setting	 without	 a	 municipal	 address	 system.	
Advantages	 of	 the	 ePAL	 system	 included	 real-time	 availability	 of	 high-resolution	
spatial	data,	low	set	up	costs,	and	ease	of	use	by	health	staff	as	part	of	routine	TB	
registration.	 Data	 were	 used	 to	 identify	 areas	 with	 high	 TB	 burden,	 potentially	
suitable	for	TB	vaccine	trials.	





Adolescent-targeted	 tuberculosis	vaccines	are	 likely	 to	have	 low	 impact	 in	ageing,	
reactivation-driven	epidemics	like	China,	which	suggests	a	modification	of	the	current	
strategic	 focus	on	adolescents	 among	 certain	 funders.	 Clinical	 trials	 should	 assess	































































6.4	 Contribution	 of	 the	 thesis	 to	 advancing	 knowledge	 in	 TB	 vaccine	
development	.......................................................................................................	372	





















Table	2.5:	Summary	of	existing	 studies	or	 tools	 that	 could	be	employed	 to	collect	
spatial	TB	burden	data	......................................................................................	84	
Table	3.1:	Vaccine	characteristics	and	implementation	assumptions	....................	105	
Table	 3.2:	 Median	 and	 range	 of	 vaccine	 efficacies	 required	 to	 achieve	 20-80%	
incidence	rate	reduction	 (in	10%	steps)	 in	2050	compared	to	no	new	vaccine	
baseline	 for	 5	 and	 10	 year	 durations	 of	 protection	 and	 10-yearly	 mass	
vaccination	campaigns	....................................................................................	125	




Table	 3.4:	 Suggested	 TPP	 values	 for	 VE-POI,	 VE-POD	 and	 duration	 of	 protection	
required	 to	 achieve	 20-29%,	 50-59%	 and	 70-79%	 incidence	 rate	 reduction	 in	
2050	with	10-yearly	mass	campaigns.	Other	ranges	are	available	in	Appendix	B.
	.........................................................................................................................	127	
Table	 3.5:	 Epidemiological	 impact	 of	 POI-only	 and	 POD-only	 vaccines	 with	 60%	
vaccine	efficacy	pre-	and	post-infection	.........................................................	139	





























with	 permission,	 from	 the	 WHO	 End	 TB	 Strategy,	 WHO/HTM/TB/2015.19,	
http://www.who.int/tb/End_TB_brochure.pdf?ua=1,	 Accessed	 3rd	 January	
2017.	26	..............................................................................................................	45	
Figure	 2.2:	 New	 TB	 vaccine	 pipeline	 as	 at	 7th	 October	 2016.45	 Reproduced	 with	
permission	from	Aeras.	.....................................................................................	48	
Figure	3.1:	Model	structure,	showing	the	unvaccinated	natural	history	stratum	(top)	






Figure	 3.4:	Modelled	mortality	 rate	 per	 100,000	population	 2000-2050	 for	 all-age	
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Figure	 5.14:	 Estimated	 enumeration	 area	 notification	 rates	 for	 A)	 all	 TB	 cases,	 B)	
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and	 the	 rationale	 for	 the	 development	 of	 new	 mathematical	 models	 and	 an	
epidemiological	 tool	 to	help	 inform	and	accelerate	development	of	TB	vaccines	 is	
described.	The	two	overall	aims	of	the	thesis	are	defined,	and	translated	into	research	
objectives.	






The	 global	 Millennium	 Development	 Goal	 to	 halt	 and	 reverse	 tuberculosis	 (TB)	
incidence	trends	by	2015	was	achieved,	yet	with	an	estimated	10.4	million	incident	
TB	cases	and	1.8	million	deaths	in	2015,	a	substantial	burden	of	disease	still	exists.1	
The	 current	 trajectory	 of	 incidence	decline	 (1.5%/year)	will	 not	 achieve	 the	WHO	
2050	goal	of	eliminating	TB	as	a	public	health	problem,	defined	as	less	than	1	case	

















against	 extrapulmonary	 disease.9	 However,	 highly	 variable	 protection	 has	 been	
observed	in	adults,	ranging	by	setting	from	0%	to	80%	against	pulmonary	disease.9	



















For	 the	 first	 research	 need,	 mathematical	 modelling	 provides	 a	 data-driven	
framework	 for	 estimating	 the	 potential	 impact	 of	 vaccine	 characteristics	 and	




impact.	 This	 research	 is	needed	 to	 inform	development	of	 target	product	profiles	
(TPPs)	 for	 TB	 vaccines.	 TPPs	 are	 strategic	 documents	 outlining	 the	 desired	 and	
minimum	 vaccine	 label.	 Vaccine	 characteristics	 and	 implementation	 strategies	
considered	 in	 the	 TPP	 include,	 but	 are	 not	 limited	 to,	 the	 vaccine	 efficacy	 for	
prevention	of	 infection	or	disease,	whether	 the	vaccine	 is	effective	 in	populations	





vaccine	 development.	 A	 comprehensive	 exploration	 of	 possible	 vaccine	
characteristics	 and	 implementation	 strategies	 using	 mathematical	 modelling	 is	
required.		
Results	 from	a	phase	 III	 prophylactic	 TB	 vaccine	 trial	 in	China	are	 anticipated	 this	




the	 global	 burden.	 Available	 TB	 vaccine	 modelling	 in	 China	 is	 limited,	 exploring	




ageing	 populations	 in	 several	 of	 the	WHO	 high	 TB	 burden	 countries	 (e.g.	 China,	
Russia,	Brazil	 and	Thailand),1,16	 it	 is	 surprising	 that	 vaccinating	older	 adults	or	 the	




Target	 product	 profiles,	 ideally	 informed	by	mathematical	modelling	 as	 described	
above,	are	 translated	 in	 to	clinical	development	plans	 (CDPs)	designed	to	develop	
appropriate	 candidates	 ready	 for	 delivery	 to	 identified	 target	 populations.	 As	





TB	 disease	 can	 be	 long,	 large,	 expensive,	 and	 challenging	 to	 design.	 As	 has	 been	
discussed	in	the	literature,	there	is	a	dearth	of	trial-ready	research	sites	with	known	
sufficient	 TB	burden	 for	 vaccine	 trials.17	 Country	 and	 regional	 level	 programmatic	
tuberculosis	data,	and	prevalence	surveys	where	available,	can	be	used	to	identify	
regions	 experiencing	 a	 trial-suitable	 burden	 of	 disease.	 However,	 data	 of	 greater	
granularity	 and	 specific	 to	 communities	where	 recruitment	 is	 planned	 is	 needed.	
Such	 data	 inform	 sample	 size	 calculations	 that	 balance	 the	 risk	 of	 failure	 from	
insufficient	 endpoints	 against	 minimising	 costs	 and	 the	 number	 of	 participants	
exposed	to	the	investigational	product.	Such	data	can	also	help	direct	recruitment	














two	 research	 assistants	 only	 able	 to	 identify	 the	 cluster	 (mean	 cluster	 size:	 1,342	
adults)	 in	 which	 the	 participant	 was	 resident	 for	 40.3%	 and	 68.2%	 of	 129	 ART-
initiators.18	Therefore,	existing	data	may	be	of	limited	use	for	improving	granularity	
of	available	data	for	study	design.		
In	 the	 same	 research	 site	 in	Malawi,	 a	 low	 cost	 “Map	 book”	 was	 developed	 for	
identification	of	place	of	residence,	and	was	found	to	improve	the	accuracy	of	cluster	
residency	 identification	to	97%	(95%	CI,	90-100%).	Already	this	rapid	and	 low	cost	
approach	 could	 greatly	 improve	 the	 granularity	 of	 TB	 notification	 data	 in	 low	
resource,	high	burden	settings.	However,	this	concept	could	be	further	developed,	
with	the	aim	of	providing	granularity	closer	to	the	household	level,	combined	with	
information	 regarding	 patient	 characteristics	 and	 real-time	 reporting.	 Such	 a	
validated,	 low	cost,	rapidly	 implementable	tool	could	meet	the	need	for	 improved	




and	 urgent	 public	 health	 need.	 However,	 to	 inform	 TPPs	 for	 new	 TB	 vaccines,	
research	to	fully	explore	the	vaccine	characteristics	and	target	populations	that	could	
provide	 the	 greatest	 epidemiological	 impact	 is	 required.	 In	 terms	 of	 target	
populations,	given	the	ageing	demographics	 in	several	high	burden	countries	 (e.g.	
China),	 comparing	 vaccinating	 the	 currently	 prioritised	 adolescent	 population	 to	
vaccinating	older	adult	populations	is	an	important	research	gap.	To	help	carry	these	
TPPs	through	to	implementable	clinical	trials,	appropriate	data	are	needed	to	inform	







in	 the	 greatest	 reduction	 in	 TB	 disease	 burden	 in	 China;	 and	 develops	 a	 new	
methodology	for	empirical	data	collection	for	determining	spatial	distribution	of	TB	
notifications	in	potential	trial	populations.		















1. Generate	 mathematical	 models	 of	 age-stratified	 demography	 and	 TB	
epidemiology	to	explore	the	population-level	epidemiological	impact	of	vaccine	
characteristics	 and	 implementation	 strategies	 for	 potential	 new	 TB	 vaccines,	
using	China	as	a	case	study.	











vaccine	 characteristics	 and	 implementation	 strategies	 for	 new	 TB	 vaccines	
(Chapter	2).	
2. a)	 Develop	 a	 mathematical	 model	 calibrated	 to	 epidemiological	 and	
demographic	 temporal	 and	 age	 distribution	 trends	 in	 China,	 accounting	 for	
uncertainty	 in	 natural	 history	 parameters,	 to	 predict	 the	 evolution	 of	 the	 TB	
epidemic	over	the	2050	time	horizon	(Chapter	3).	







3. Using	 the	 calibrated	 model	 of	 the	 TB	 epidemic	 in	 China	 and	 main	 vaccine	
characteristics	 (objective	2),	 investigate	 the	 impact	of	 age-targeted	 vaccination	
programmes	 to	 adolescents	 versus	 older	 adults	 on	 population-level	 TB	
epidemiology	(Chapter	4).	
Aim	2	 (development	of	epidemiological	 tool	 for	 informing	 future	 trial	design)	was	
achieved	through	the	following	objectives:	
4. a)	 Develop	 and	 implement	 a	 novel,	 low	 resource,	 rapidly	 implementable	 and	











are	 included	 without	 adaptation;	 therefore,	 although	 minimised	 where	 possible,	
some	repetition	exists	between	chapters.	Chapters	containing	research	papers	are	
structured	around	the	manuscript,	starting	with	an	introduction	to	provide	context	




The	 thesis	 consists	 of	 four	 sections,	 and	 contains	 six	 chapters,	which	 include	 one	
published,	 one	 submitted,	 and	 one	 unpublished	 manuscript.	 The	 first	 section	
(Chapters	1	and	2)	comprises	the	background	materials,	aims	and	objectives	of	the	













This	 chapter	 includes	 research	 paper	 1,	 a	 systematic	 review	 published	 in	 Human	












2a).	 Using	 this	 calibrated	 epidemiological	 model,	 the	 population-level	









White	 RG.	New	 tuberculosis	 vaccines	 –	 the	 impact	 of	 age	 targeted	 vaccination	 in	
China	and	implications	for	vaccine	development.	Under	review	
As	 a	 body	 of	 work,	 these	 models	 give	 insight	 in	 to	 the	 characteristics	 and	
implementation	 strategies	 for	 new	 TB	 vaccines	 that	 need	 to	 be	 developed	 to	











spatial	 heatmaps	 (objective	 4c)	 of	 all	 TB,	 and	demographic	 and	 clinical	 subgroups	
relevant	to	TB	trial	recruitment	populations	or	outcomes.		







strengths,	 limitations	 and	 contributions	 to	 the	 field	 are	 discussed.	 I	 provide	
recommendations	for	development	of	TB	vaccines	from	the	perspective	of	vaccine	




was	 identified,	 and	 initial	 research	 questions	 developed,	 by	myself	 and	 Professor	
Richard	 White.	 These	 research	 questions	 evolved	 during	 the	 PhD	 based	 upon	
research	 needs	 identified	 from	 the	 systematic	 literature	 review,	 and	 feedback	 by	
stakeholders	 and	 collaborators	 (including	 Aeras,	 BMGF,	 WHO	 and	 TBVI).	 From	
previous	 work,	 I	 had	 identified	 the	 need	 for	 new	 solutions	 for	 generating	
epidemiological	data	to	support	TB	vaccine	clinical	trial	design,	which	was	fortuitously	
married	 with	 the	 idea	 for	 an	 electronic	 mapping	 tool	 proposed	 by	 Professor	 Liz	
Corbett	and	Dr	Peter	MacPherson.	
Contributors	to	the	research	presented	in	the	three	research	papers	are	detailed	in	
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TB	 vaccines,	 and	 for	 new	 tools	 and	 data	 to	 provide	 the	 evidence	 base	 for	
development	 and	 implementation	 planning	 for	 new	 TB	 vaccines.	 This	 chapter	
includes	 research	paper	1,	 a	 systematic	 review	published	 in	Human	Vaccines	 and	
Immunotherapeutics,	 summarising	 the	modelling	 literature	of	 the	epidemiological	
impact	 of	 new	 TB	 vaccines	 and	 implementation	 strategies	 (objective	 1).1	 This	 is	
followed	by	a	 summary	of	 the	 current	options	 for	epidemiological	data	 collection	
tools	to	inform	trial	recruitment	of	populations.	Research	gaps	in	both	of	these	areas	
are	identified	(objective	1).	
Citation	 (research	 paper	 1):	 Harris	 RC,	 Sumner	 T,	 Knight	 GM,	 and	 White	 RG.	
Systematic	review	of	mathematical	models	exploring	the	epidemiological	impact	of	
future	TB	vaccines.	Hum	Vaccin	Immunother	2016;	12(11):	2813-32.	
This	 chapter	 is	derived	 in	part	 from	an	article	 I	published	 in	Human	Vaccines	and	







pathogen	 Mycobacterium	 tuberculosis	 (M.tb).2	 There	 are	 seven	 other	 related	
Mycobacterium	species,	some	of	which	are	also	capable	of	causing	disease	to	varying	
degrees.2	TB	disease	symptoms	depend	upon	factors	such	as	the	site	of	infection,	but	
common	 symptoms	 include	 night	 sweats,	 weight	 loss,	 chronic	 cough	 and	
haemoptysis.3	Confirmation	of	TB	disease	is	most	commonly	via	one	or	a	combination	
of	 chest	 x-ray,	 sputum	 smear	 testing,	 culture,	 and	 Genexpert	 nucleic	 acid	
amplification	test.	




disease,4	 susceptibility	 and	 extent	 of	 exposure	 of	 the	 exposed	 individual,	 and	
environmental	factors.5	Infectiousness	can	be	modified	by	the	location	of	disease	foci	
(i.e.	 pulmonary	 vs.	 extrapulmonary),	 bacterial	 load,	 comorbidities	 (e.g.	 HIV),	 and	
clinical	symptoms	such	as	cough;	whereas	susceptibility	is	mostly	associated	with	co-











12%	 in	 low	transmission	settings.10	This	 risk	 is	elevated	 in	certain	populations,	 for	
example	 the	 risk	 of	 progression	 in	 HIV	 co-infected	 populations	 is	 estimated	 at	
approximately	10%	per	year.11	The	risk	of	developing	disease	also	varies	by	age	at	
infection	and	time	since	infection,	with	incubation	periods	becoming	shorter	in	older	
age	 groups.10,12	 Risk	 of	 progression	 to	 disease	 is	 highest	 in	 the	 first	 year	 after	
infection,	falling	year-on-year	beyond	this.11-14	







immune	 system.	 Disruption	 of	 this	 equilibrium	 leads	 to	 bacterial	 replication	 and	
development	of	“reactivation”	active	disease.11	
Pulmonary	disease	 is	 the	most	 frequent	presentation.	Given	the	airborne	route	of	













were	 an	 estimated	 10.4	 million	 incident	 TB	 cases,	 including	 480,000	 multi-drug	
resistant	 (MDR)	 cases.	 Although	 the	 current	 burden	 of	 disease	 remains	 the	most	
immediate	public	health	concern,	a	substantial	reservoir	of	latent	TB	infection	(LTBI)	
exists,	 estimated	 at	 approximately	 1.7	 billion	 of	 the	 global	 population.20	 This	
population	 remains	 at	 risk	 of	 developing	 reactivation	 disease,	 so	 should	 be	
considered	when	planning	for	TB	prevention	in	the	long	term.	
Regional	heterogeneity	exists	in	the	distribution	of	TB	burden.	South-East	Asia	and	
sub-Saharan	Africa	contributed	46%	and	26%	of	 the	global	 incident	cases	 in	2015,	
respectively.19	More	specifically,	six	countries	account	for	60%	of	incident	TB	cases:	
India,	 Indonesia,	 China,	 Nigeria,	 Pakistan	 and	 South	 Africa.	 Populations	 in	 sub-
Saharan	Africa	have	experienced	some	of	the	highest	TB	 incidence	rates,	 reaching	
834/100,000	population	per	year	in	South	Africa.19		
Heterogeneity	also	exists	 in	 the	distribution	of	disease	within	populations,	due	 to	
environmental,	biological	and	social	risk	factors.	Environmental	risk	factors	include	
exposure	 to	 smoking	 or	 indoor	 air	 pollution,	 and	 collectively	 are	 thought	 to	 be	 a	
contributory	risk	factor	for	an	estimated	38.1%	of	TB	cases	across	the	pre-2015	WHO	
22	high	burden	countries	(HBCs).21	Key	biological	factors	that	weaken	immunity	and	







(26.9%).	 Immunological	 changes	 with	 age	 also	 influence	 the	 risk	 of	 disease,	 with	
immune	immaturity	in	infants	and	immune	senescence	in	older	adults	and	the	elderly	
Chapter	2:	Background	 42	






influence	 the	 risk	 of	 exposure	 and	 therefore	 infection.	 In	 addition,	 time	 spent	 in	
particular	 settings	 with	 crowding	 or	 poor	 ventilation	 can	 increase	 the	 risk	 of	
infection.5	This	is	particularly	pronounced	in	prison	populations	or	crowded	places	of	
residence,	 and	 may	 also	 be	 associated	 with	 crowded	 social	 locations	 such	 as	
workplaces	or	churches.22		
2.3 Global	TB	targets	




























milestones	 and	 targets	 have	 been	 developed	 in	 tandem	with	 the	 UN	 sustainable	
Development	Goals	(SDGs)	as	checkpoints	on	the	road	to	elimination	(Table	2.1).26	
SDG	3.3	aims	to	“end	the	epidemic	of…	tuberculosis”	by	2030,	with	the	indicator	for	









Target	 2020	 2025	 2030	 2035	 2050	
Reduction	in	absolute	number	
of	TB	deaths	compared	to	2015	 35%	 75%	 90%	 95%	 -	
Reduction	in	TB	incidence	rate	


































20%	 decline	 per	 year	 from	 2015	 has	 been	 estimated	 as	 necessary	 to	 achieve	
elimination	 by	 2050.31	 This	 is	 beyond	 the	 acceleration	 that	 has	 been	 achieved	
historically	or	has	been	estimated	to	be	possible	with	existing	measures	in	modelling	




















of	 resistance.33	 With	 the	 anticipation	 of	 longer-term	 protection	 and	 reduced	





effective	 pre-	 and	 post-exposure	 vaccines”,	 in	 addition	 to	 better	 diagnostics,	
treatment	regimens	and	LTBI	treatment.26	
2.4 BCG:	an	effective	vaccine	for	prevention	of	TB?	
Unlike	many	other	high-burden	 infectious	diseases,	 an	effective	 vaccine	exists	 for	
tuberculosis:	 Bacillus	 Calmette-Guérin	 (BCG).	 BCG	 is	 a	 live,	 attenuated	
Mycobacterium	bovis	vaccine,	used	for	neonatal	vaccination	as	part	of	the	Expanded	
Program	on	Immunization	(EPI)	schedule.	In	2015,	global	coverage	was	estimated	at	
88%,	with	 the	 vaccine	 provided	 to	 over	 100	million	 neonates	 annually	 to	 protect	
against	childhood	tuberculosis.34	Recent	meta	analyses	suggesting	59%	(95%	CI,	42-
71%)	vaccine	efficacy	against	pulmonary	TB,35	90%	(95%	CI,	23-99%)	efficacy	against	
miliary	 and	 meningeal	 TB,35,36	 	 and	 66%	 (95%	 CI,	 8-88%)	 efficacy	 against	 TB	
mortality.36	 BCG	 is	 estimated	 to	 prevent	 one	 case	 of	 miliary	 TB	 and	 one	 of	 TB	
meningitis	 in	 the	 first	 five	 years	 of	 life	 per	 9314	 and	 3453	 vaccinated	 children,	
respectively.37	 However,	 BCG	 has	 exhibited	 highly	 variable	 efficacy	 against	 adult	
pulmonary	 forms	of	 tuberculosis,	 ranging	 from	an	“absence	of	clinically	 important	
benefit”36	in	studies	in	Malawi	and	India,36,38,39	to	almost	80%	protection	in	the	UK	
MRC	 trial	 and	 in	 a	 North	 American	 Indian	 population.36,39,40	 Many	 factors	 may	
influence	 these	 age	 and	 regional	 differences	 in	 efficacy,	 but	 prior	 infection	 or	





conclusions	 that	 can	 be	 drawn	 based	 upon	 available	 data	 beyond	 10	 years	 after	
vaccination.		
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BCG	 is	 contraindicated	 in	 HIV-infected	 populations	 due	 to	 the	 increased	 risk	 of	
disseminated	BCG	disease.41	Therefore,	HIV-infected	children	and	adults	at	high	risk	
of	TB	remain	unprotected.	
A	 combination	 of	 variable	 geographical	 efficacy	 against	 adult	 disease,	 insufficient	
duration	 of	 efficacy	 to	 protect	 from	 birth	 to	 adulthood,	 and	 safety	 concerns	 in	
epidemiologically	important	populations,	mean	that	BCG	is	not	an	appropriate	tool	






able	 to	 reduce	 the	burden	of	 TB	 in	 adults,	 no	new	prophylactic	 vaccine	has	been	





However,	 DAR-901	 is	 not	 the	 only	 vaccine	 in	 development,	 with	 13	 candidates	
currently	 in	 clinical	 trials,	 the	 TB	 vaccine	 pipeline	 is	 the	 strongest	 to-date.	 One	
candidate	 is	being	tested	in	a	phase	III	efficacy	trial,	two	candidates	 in	addition	to	
DAR-901	in	phase	IIB	proof	of	concept	trials,	four	are	undergoing	phase	IIA	safety	and	
immunogenicity	studies,	and	 five	are	 in	phase	 I	 first-in-human	safety	 trials	 (Figure	
2.2).45		
The	 phase	 III	 Vaccae	 candidate	 is	 currently	 under	 evaluation	 for	 efficacy	 against	
disease	in	10,000	participants	in	China,	with	results	anticipated	in	2017.46	In	addition,	
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resources	 to	 develop	 these	 candidates	 remain	 limited.	 Progression	 through	 the	
pipeline	is	slow,	in	part	due	to	limited	and	risk-averse	allocation	of	funding,	and	in	
part	 due	 to	 relatively	 low	 incidence	 rates	 and	 lack	 of	 a	 correlate	 of	 protection	
necessitating	large	efficacy	trials	with	long	duration	of	follow	up.		











With	 several	 candidates	 progressing	 through	 phase	 IIB/III	 efficacy	 trials,	 research	
activities	 to	 fill	 these	data	needs	are	urgently	 required.	 In	 this	 thesis,	 I	aim	to	use	
mathematical	modelling	to	inform	which	vaccine	characteristics	and	implementation	
strategies	could	help	achieve	greatest	 reduction	 in	disease	burden,	and	develop	a	










strategies.	With	maximisation	 of	 the	 reduction	 of	 disease	 burden	 as	 the	 primary	
goal,51	modelling	at	the	country	and	global	level	can	help	inform	decisions	in	vaccine	
development,	 clinical	 trial	 design	 including	 enrolment	 populations,	 and	
implementation	strategy.	This	mostly	occurs	through	the	use	of	modelling	to	inform	
the	vaccine	Target	Product	Profile	(TPP)	–	a	summary	of	the	desired	eventual	product	
labeling,	 critical	 for	 guiding	 efficient	 vaccine	 development	 strategy	 and	 ensuring	
development	 of	 products	 that	 are	 fit	 for	 purpose.	 TPPs	may	 include,	 but	 are	 not	
limited	 to,	 the	 strategic	 targets	 for	 key	 vaccine	 characteristics,	 such	 as	 vaccine	
efficacy,	duration	of	protection,	safety	profile	and	target	population.	
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Development	of	 a	TPP	 requires	 consideration	of	 three	main	 factors:	 the	 technical	
feasibility,	clinical	trial	feasibility	and	potential	population-level	impact	of	the	vaccine	
profiles	 under	 consideration.	 The	 former	 are	 mostly	 informed	 by	 laboratory	 and	




the	potential	 future	 impact	of	new	TB	vaccines,	 forming	the	quantitative	basis	 for	





and	 the	 ‘ideal’	 based	 upon	 the	 characteristics	 required	 to	 maximise	 impact,	
combined	 with	 consideration	 of	 technical	 feasibility.	 For	 TB	 vaccines,	 TPP	
characteristics	 that	 can	 be	 informed	 by	modelling	 include	 duration	 of	 protection,	
vaccine	efficacy,	efficacy	 for	prevention	of	 infection	and/or	disease	 (‘effect	 type’),	
whether	the	vaccine	efficacy	is	modulated	by	the	infection	status	or	disease	history	




This	 is	 dependent	 upon	 the	 antigens	 included	 in	 the	 vaccine,	 and	 may	 also	 be	
dependent	upon	the	vaccine	platform	(i.e.	attenuated	whole	cell,	subunit	vaccine,	
viral	vector).	The	anticipated	effect	type	of	a	candidate	will	affect	the	trial	endpoints	




































clear	 differences	 in	 anticipated	 characteristics,	 as	 indicated	 by	 vaccine	 candidate	
antigens,	trial	endpoints,	and	trial	recruitment	criteria.	For	example,	the	M72-AS01	
candidate	contains	possible	latency-phase	antigens,	and	the	phase	IIB	study	recruited	
Quantiferon	 (QFN)-positive	 adults	 (18-50	 years)	 to	 study	 TB	 disease	 outcomes.	
Therefore,	this	vaccine	is	anticipated	to	be	effective	for	prevention	of	disease	(POD),	
in	populations	already	latently	infected	with	M.tb	(‘post-infection’).	Conversely,	the	
Aeras-404	 candidate	 is	 currently	being	 trialed	 in	QFN-negative	adolescents	 (12-17	
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The	 direction	 of	 impact	 of	 some	 of	 the	 described	 vaccine	 characteristics	 and	











is	dependent	upon	age	at	 vaccination,	 contact	patterns	between	age	groups,	 and	
epidemiological	 trends	over	 time.	 Therefore,	mathematical	modelling	provides	 an	
appropriate	 framework	 for	 exploring	 the	 impact	 of	 these	 characteristics	 using	 an	
explicit	and	logical	approach.		





























and	 appendix	 A.	 An	 adapted	 risk	 of	 bias	 tool	 was	 developed	 for	 this	 study	 (see	
Appendix	A).		
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ABSTRACT
Mathematical models are useful for assessing the potential epidemiological impact of future tuberculosis
(TB) vaccines. We conducted a systematic review of mathematical models estimating the epidemiological
impact of future human TB vaccines. PubMed, Embase and WHO Global Health Library were searched, 3-
stage manual sifted, and citation- and reference-tracked, identifying 23 papers. An adapted quality
assessment tool was developed, with a resulting median study quality score of 20/28. The literature
remains divided as to whether vaccines effective pre- or post-infection would provide greatest
epidemiological impact. However, all-age or adolescent/adult targeted prevention of disease vaccines
achieve greater and more rapid impact than neonatal vaccines. Mass campaigns alongside routine
neonatal vaccination can have profound additional impact. Economic evaluations found TB vaccines
overwhelmingly cost-effective, particularly when targeted to adolescents/adults. The variability of impact
by setting, age group and vaccine characteristics must be accounted for in the development and delivery









Although Bacillus Calmette–Gu!erin (BCG) is a longstanding
cornerstone of the Expanded Programme on Immunization
(EPI) schedule, the only licensed vaccine against tuberculosis
(TB) disease, and one of the most widely used vaccines world-
wide, it provides variable protection against pulmonary forms
of tuberculosis disease and an uncertain duration of protec-
tion.1,2 Tuberculosis is responsible for the largest number of
annual deaths from a single infectious agent, estimated at
1.5 million in 2014, of which 91% were adults.3 Of 9.6 million
incident cases, 37% were undiagnosed or unreported.3 Hence
there remains a substantial unmet need for preventative meas-
ures such as new TB vaccines, particularly for protection
against pulmonary disease in adult populations, which is clini-
cally challenging to manage as well as being the source of most
on-going transmission. It is a widely held view that new TB
vaccines will be essential to the efforts to meet the World
Health Organization (WHO) End TB Strategy 2035 goals and
WHO 2050 goal of elimination of TB as a public health prob-
lem.3-5 With 15 candidates currently in clinical trials, including
one in each of phase IIb and III, the current TB vaccine pipeline
is the most promising to date.3
The ﬁeld is yet to see clinical efﬁcacy in a novel candidate
and the lack of an immunological correlate of protection for
TB makes identifying promising candidates challenging,
therefore clinical trials are long and costly, with limited guaran-
tee of success. Mathematical models are invaluable tools for
exploring the potential epidemiological impact of different
future vaccine proﬁles and implementation strategies. They can
inform the development of target product proﬁles and clinical
development plans leading to vaccine candidates ready for
licensure in the target populations in which they would have
the greatest population-level impact. Modeling results are also
important in advocating for vaccine development and
investment.
The TB vaccine pipeline consists of a variety of vaccine pro-
ﬁles. Novel TB vaccine proﬁles can be categorized into four
dimensions: the host infection status required for efﬁcacy (pre-,
post- or, pre- and post-infection: PRI, PSI and P&PI), an effect
type (prevention of infection, disease, or infection and disease:
POI, POD or POI&D), an efﬁcacy, and a duration of protection
(see Table 1 for deﬁnitions and abbreviations). Maximization
of vaccine efﬁcacy and duration of protection is obviously
desirable, but given the challenges faced in TB vaccine develop-
ment, a partially protective vaccine with limited duration of
protection is a likely outcome. Similarly, a P&PI and a POI&D
vaccine would have greatest impact, but given this may not be
possible, less is known about the relative advantages of efﬁcacy
with different host infection status and effect types, particularly
when considering extrinsic factors such as the age-structure
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and temporal trends of local epidemiology and other control
measures. Therefore, modeling is a logical framework for esti-
mating the inﬂuence of such factors on the population-level
impact of future vaccines. This is important for rational
development of target product proﬁles, minimum acceptable
proﬁles, identifying target populations for vaccination, and esti-
mating cost effectiveness of such vaccines.
As a growing ﬁeld of research, publication of mathematical
models assessing the potential impact of future TB vaccines has
increased in recent years, yet no systematic review exists of this
literature. Given the importance of this information for rational
decision making in TB vaccine development and the strength of
the current pipeline, a review of the literature was considered of
importance. We therefore conducted a systematic review of pub-
lished literature to answer the research question: what is the epi-
demiological impact of future human TB vaccines delivered to
any age group when compared to no vaccination, other future
vaccine proﬁles or other TB control interventions, as estimated
using mathematical models? The aim was to provide a summary
of the modeling methodology used, the characteristics of future
TB vaccines explored using modeling, and the comparative epi-
demiological impact of such novel vaccine proﬁles.
Methods
PICOS framework
The PICOS framework was employed to deﬁne the review
research question (Table S1). Searches were restricted to human
studies. The interventions of interest were future, new, pipeline
or theoretical vaccines for human tuberculosis. Papers exploring
the impact of a single, deﬁned-efﬁcacy BCG vaccine were
excluded; however, those exploring impact of a nominally BCG
vaccine but with varying vaccine efﬁcacy were considered for
inclusion as these could be considered reﬂective of other theoreti-
cal vaccines. A broad deﬁnition was applied for the comparator of
interest, therefore studies comparing new vaccines to no vaccine,
BCG-only, alternative new vaccines or alternative currently avail-
able interventions were considered. Only articles reporting epide-
miological outcomes, such as the impact on rates or absolute
numbers of incidence, prevalence or mortality, or alternatively
the number needed to vaccinate per case/death averted or cost-
effectiveness measures, were included. Within-host impact mod-
els exploring immunological outcomes were excluded. The
research question focused on the use of mathematical modeling
as the study design. Narrative reviews and commentaries were
excluded unless providing new modeling analyses or outcomes.
No limits were placed upon publication dates.
Search strategy
Three electronic healthcare sources (PubMed, Embase and
WHO Global Health Library) providing access to seven data-
bases (PubMed/Medline, Embase, African Index Medicus,
LILACS, SEARO Index Medicus, WPRO Index Medicus,
EMRO Index Medicus) were searched. A comprehensive search
strategy was developed using the deﬁned PICOS framework,
using free text and Mesh/Emtree/DeCS terms tailored by data-
base for groups of terms covering tuberculosis, vaccines and
modeling (Table S2). All searches were run with the “human”
ﬁlter, and the WHO Global Health Library search was limited
to regional databases to avoid duplication. No language or pub-
lication type limits were applied. Searches were conducted on
the 12th January 2016.
Study selection and data extraction
This research was conducted in accordance with the York Cen-
tre for Reviews and Dissemination guidance for undertaking
reviews in healthcare.6 Three-stage manual sifting of titles,
abstracts, then full texts was employed by the primary reviewer
to apply the pre-deﬁned inclusion/exclusion criteria described
in Table 2. Where uncertainty with regards to inclusion at full
text existed, a low threshold was used to trigger assessment by a
second reviewer (TS). Reasons for exclusion at the full text
stage were recorded. Data were extracted from eligible papers
into a piloted, standardized Excel database by a ﬁrst reviewer
(RH), and fully checked by a second (TS/RW). Reference lists
were hand searched and onward citation searching was con-
ducted using Web of Science for all included studies.
Table 1. Vaccine proﬁle deﬁnitions.
Vaccine characteristic Terminology Deﬁnition Abbreviation
Host infection status
required for efﬁcacy a
Pre-infection Protects when delivered to uninfected populations. Does not protect
when delivered to infected or previously infected populations.
PRI
Post-infection Protects when delivered to latent (and/or recovered) populations. Does
not protect when delivered to uninfected populations.
PSI





Prevention of infection Effective against the acquisition of M.tb infection (uninfected to infected
state)
POI
Prevention of disease Prevents progression to active disease (uninfected or infected to disease
state)
POD
Prevention of infection and disease Prevents both infection and development of disease POI&D
Efﬁcacy Vaccine efﬁcacy Protection provided by the vaccine. Can be “take” or “degree” VE
Duration of protection Duration of protection Time during which vaccine remains efﬁcacious. May include waning of
protection
—
aM.tb exposure without infection, and immune priming with BCG or another vaccine, are not included within this deﬁnition, as exposure would not impact vaccine
response, and priming could be under the control of the public health system.
2814 R. C. HARRIS ET AL.
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Qualitative synthesis of extracted data was employed to pro-
duce a narrative summary of included literature.
In accordance with PRISMA methodology, a protocol sum-
mary is registered on PROSPERO (reference: CRD42016033266)
and the full protocol and PRISMA checklist are available in sup-
plementarymaterials (Supplementary appendix C and Table S4).7
Assessment of quality
We developed a new adapted tool for assessment of modeling study
quality and risk of bias (Table S3). This built upon previously pub-
lished frameworks for health relatedmodeling and health economic
modeling.8,9 By adding four more criteria to the Fone tool we
allowed a more in-depth consideration of deﬁnition of model set-
ting and population, appropriateness of modeling methodology
and structure, ﬁtting methodology, and reporting of conﬂicts of
interest, which are essential for assessing the reproducibility of the
model, alignment of the model and research question, and risks of
bias.8 To improve usability, the adapted tool presented contains the
questions to be considered for each of the 14 criteria and clear guid-
ance on the rating of zero, one or two for each criterion. If a criterion
was not relevant for a particular paper, a score of one was assigned
so as not to unduly bias the scores in either direction. Papers were
scored 0-2 on each of 14 criteria, giving a maximum score of 28
points. A quality of “low” (<14), “medium”(14-18), “high” (19-22)
or “very high” (>22) was assigned based upon the overall score.
Assessment of quality was conducted by one reviewer
(RCH), but with a low threshold for examining any uncertain
scores by a second reviewer (TS). The second reviewer also
Table 2. Inclusion and exclusion criteria applied in manual screening of articles.
Inclusion Criteria
Mathematical model
Systematic review of models of novel/future/hypothetical TB vaccine, or
commentary adding to the analyses/interpretation of models reported
elsewhere
Intervention is novel/future/hypothetical vaccine against tuberculosis
or of an unspeciﬁed novel TB intervention with characteristics in-line
with a vaccine
Reported outcomes are of the epidemiological impact of vaccine(s)
(e.g. incidence, prevalence, mortality, number needed to vaccinate,
cost effectiveness)
Exclusion Criteria
Within-host/immunological vaccine impact models
Review or commentary not adding to existing body of knowledge
TB epidemiological models not reporting impact of vaccine
TB epidemiological models reporting only interventions other than
vaccines
Model only reporting on impact of BCG with single known/ﬁxed efﬁcacy
Disease or infection caused by Mycobacterium bovis or other
non-Mycobacterium tuberculosis strain.
Pubmed: n = 843 Embase: n = 64 WHO GHL: n = 12
Total hits, n = 919
Records screened at abstract 
level, n = 128
Records screened at full text 
level, n = 37
Studies included, n = 17 
Studies removed  
756
Studies removed at abstract 
level: 91
Studies removed at full text level, n=20:
Single profile BCG only: 3
Full text not available: 2
2
Commentary: 6
No epidemiological outcomes: 5
Other: 2
Final studies included, n = 23 
Studies included from (n=6):
References: 3
3
Duplicates removed, abstracts 
screened level, n = 884
Figure 1. Summary of systematic screening of identiﬁed articles.
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reviewed one paper from each quality level to check for agree-
ment with the scoring and overall assessment of quality. Due to




A total of 919 records, comprising 884 unique articles after
removal of duplicates, were identiﬁed (Fig. 1). Title screening
removed 756 articles, and abstract screening a further 91, yield-
ing 37 articles for review at full text. Twenty articles were
excluded from the review during full text screening. The two
most common reasons for exclusion were commentaries pro-
viding no additional analysis (n D 6) and articles without epi-
demiological outcomes (n D 5). Reference and citation sear-
ching identiﬁed 6 additional articles for inclusion, therefore 23
research articles were included in the review (Table 3).
Although one BCG-based TB vaccine model exists from the
1960s,10 two models published in 1998 were the ﬁrst to explore
entirely novel TB vaccine proﬁles,11,12 and the majority (20/23)
of included papers have been published since 2000,4,13-31 moti-
vated by the promising late-stage pipeline and the push to
attain challenging WHO/Stop TB global TB targets.
Modeling methods (n D 23)
The included studies comprised 18 deterministic, compartmen-
tal, dynamic models constructed using difference or differential
equations,4,10-14,16-21,23-25,27-29 3 Markov decision tree analy-
ses,15,22,31 one a simple mathematical model including a ﬁxed
number of transmissions per case,30 and one statistical model.26
A subset of these papers (n D 5) present analytical solutions of
models and discuss the theoretical implications of a range of
factors on the impact of vaccines.11,13,17,25,26 These 5 papers do
not provide any quantitative estimates of the epidemiological
impact of novel vaccines and are not discussed further. A sum-
mary of model structures and ﬁtting methods is provided in
supplementary appendix A.
Vaccine characteristics (n D 18)
Modeled vaccine characteristics are summarized in Table 3. An
anticipated vaccine efﬁcacy in the range of 40–80% was most com-
monly modeled,10,12,15,18,20-22,27-31 though some explored the public
health impact of the extremes above15,20,29 or below 10,12,22,29 this
range. Vaccine efﬁcacy was modeled as ‘take’ (i.e. a proportion of
those vaccinated are completely protected, also known as an “all-
or-nothing” vaccine) in 6 studies,4,16,22,24,27,30 and as ‘degree’ (i.e.,
all vaccinees receive some protection from the vaccine, sometimes
known as a ‘leaky’ vaccine) in 8 studies.10,12,14,15,18,20,21,31 One study
modeled efﬁcacy as a combination of take and degree.28 The type
of vaccine efﬁcacy was not possible to identify in three stud-
ies.19,23,29 Those studies explicitly modeling vaccine coverage
tended to model coverage of 80–100%,10,12,15,20-22,27-31 though
some included lower coverages.12,20,27 Only one study assumed
coverage using data reﬂective of country- and age-speciﬁc access to
the healthcare system.27 Some studies use a combined parameter
(‘proportion effectively immunized’) of vaccine efﬁcacy multiplied
by coverage.4,16,19,23,24Where the proportion effectively immunized
was not reported, we estimated the approximate proportion at
ﬁve years after vaccine implementation. The scenarios of the pro-
portion effectively immunized spanned a wide range in most stud-
ies, ranging from a lower limit of 9–38% to upper limit of 70–
95%,10,20,22,24,27,29,30,32 though some studies did employ lower upper
limits,4,12,15,16 and some explored just a single scenario of propor-
tion effectively immunized within the range 44-70%.19,21,23,28,31 In
two studies it was not possible to estimate the proportion effectively
immunized.14,18
Most often, duration of vaccine protection was assumed to
be 10 years15,20,22,24,27,30,31 or lifelong,4,16,27,28 with some assum-
ing alternative scenarios including 5, 30 and 33 years protec-
tion.20,21,27,31 Seven articles did not report the duration of
protection modeled,10,12,16,18,19,23,29 but several appeared to use
lifelong protection.10,16,29 Waning of protection has been mod-
eled as either exact (all depart the vaccinated state exactly at the
end of duration),4,14,16,24,27,28,31 or linear or exponential waning
throughout the duration of protection.15,21,31
Many of the modeling studies explored the impact of multi-
ple vaccine proﬁles assuming various effect types and/or host
infection statuses required for efﬁcacy. The post-infection (PSI)
vaccines modeled assumed a prevention of disease (POD) vac-
cine effect,4,12,14,19-21,28 or prevention of infection and disease
(POI&D) effect.4,16 Pre-infection (PRI) vaccines have been mod-
eled assuming a prevention of infection (POI),4,12,16,18,23,24,29
POD,4,10,15,19,21,22,30,31 or POI&D vaccine effect.14,20,28 Com-
bined pre- and post-infection (P&PI) vaccines have been mod-
eled assuming a POI&D16 or POD12,19,21,23,27 vaccine effect. The
most frequently explored effect types were pre-infection vac-
cines with prevention of disease 4,10,15,19,21,22,30,31 or prevention
of infection 4,12,16,18,23,24,29 effect, and post-infection vaccines
with prevention of disease effect.4,12,14,19-21,28
Targeting of vaccination to populations with a speciﬁc host
infection status (n D 12) was common in the models identi-
ﬁed,4,10,12,16,18-21,24,28,29,31 as was targeting to speciﬁc age groups
(n D 12).10,12,15,18,19,21,22,24,27,28,30,31 Pre-infection vaccines were
most frequently targeted to neonates as they were a mostly
uninfected population,10,15,18,19,21-23,28,30,31 occasionally with an
adolescent boost21,31 or with a one-off mass campaign to all
ages.10,19,23,28 However, several studies included an analysis of
the impact of pre-infection vaccines in adolescent,24 high
risk,18 or all-ages mass vaccination campaigns or routine
immunization.12,20,21,28,29 Post-infection vaccines have mostly
been modeled as delivered to all ages,4,19-21,28 and in several
studies age targeting is not stated but is thought to be delivered
to all ages.4,14,16 Pre- and post-infection vaccines have been
modeled as delivered to neonates,23,27 neonates with short term
all-age mass campaigns,12,23 routine adolescent vaccination
with adult mass campaigns,27 or delivered to all ages.19,21
Setting and population (n D 18)
Three were global studies,12,14,16 two regional studies (e.g.
WHO regions),19,21 one in low- and middle-income coun-
tries,27 four based upon hypothetical high burden set-
tings,4,10,20,28 three were set in South Africa,15,22,24 one in
Japan,30 one in Zambia,31 one in a hypothetical township,29 one
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in a developed country,18 and one where the setting was not
clearly stated.23 Two of the afore-mentioned studies also
reported on country- (China, India and South Africa) or
region-level models in addition to the main model reported.4,12
Only two of the 18 studies consider heterogeneous social
mixing patterns: one included mixing by HIV status,12 and one
household model considers different mixing patterns during
community, diurnal interactions and familial interactions at
night.29
A small number of studies included risk groups within the
modeled population. HIV status is largely neglected in TB vac-
cine modeling, a surprising fact given its importance as a driver
of the TB epidemic in Africa and parts of Asia, but perhaps
linked to this population being largely excluded from vaccine
trials. One model targeted vaccination exclusively to the HIV-
negative population.24 Only four models explicitly include HIV
stratiﬁcation.12,15,27,31 Two of the Markov decision tree models
included the impact of HIV on TB natural history parameters,
and assumed that the vaccine was equally efﬁcacious in early-
stage HIV infection and HIV uninfected individuals, but had
zero efﬁcacy in patients with AIDS.15,31 Two globally-focused
dynamic models included HIV strata, one of which did not
alter vaccine efﬁcacy in the HIV stratum,12 and the other
accounted for immunocompromise through reduced vaccine
efﬁcacy in HIV-infected patients.27 Two of the models with
HIV strata did not explicitly include antiretroviral therapy
(ART) in the model.12,31 The Ditkowsky study assumed 58%
ART coverage which provided a 75% and 9.8% decrease in
HIV-related annual mortality for those with early HIV and
clinical AIDS, respectively, and a 61% reduction in the risk of
progression to clinical AIDS (with associated higher risks of TB
disease).15 In the Knight model, receipt of ART doubled life
expectancy, decreased rates of progression to TB disease or
death, and halved the reduction in vaccine efﬁcacy experienced
due to HIV infection.27 Aggressive ART scale up was assumed
between 2012 and 2020, increasing from the 2009 coverage
value in each country by half the difference between the 2009
value and 100%.27
Epidemiological impact of future TB vaccines (n D 18)
Fourteen studies had the epidemiological impact4,12,16,18-
21,23,28,29 and/or cost effectiveness 15,22,27,31 of future TB vaccine
candidates as a primary focus. Three studies explored the
impact of a variable efﬁcacy BCG vaccination.10,24,30 One strain
competition model explored impact of differential vaccine
effectiveness by strain.14 Details of the vaccine proﬁles and out-
comes discussed are summarized in Table 3.
i. Age targeting: Neonatal versus all ages, adolescents
or adults
Only one study offered a clear comparison of targeting a given
vaccine to neonates compared to adolescents/adults.27 Two
studies model the impact of vaccines delivered to neonates
compared to delivery to all ages.21,28
In the study by Knight et al., implementation of routine ado-
lescent vaccination with periodic mass adult campaigns was
found to have a much greater impact than routine neonatal
vaccination with a prevention of disease vaccine in low- and
middle-income countries across the 2024-50 time horizon.27
For example, a 60% efﬁcacious vaccine providing 10 years pro-
tection could prevent 17 million (range 11–24m) cases between
2024-2050 when delivered to adolescent/adults compared to
just 0.89 million (range 0.42–1.58m) when delivered to neo-
nates.27 The vaccine coverage differed in each age targeting sce-
nario, based upon data from current vaccination campaigns
relevant to those populations and so might be considered a
more realistic reﬂection of achievable coverage. There are likely
greater cost and logistical implications of delivering an adoles-
cent/adult vaccine than a routine neonatal vaccine, however in
this study it was found that due to the greater impact achieved
when vaccinating older age groups, all of the vaccine proﬁles
explored in this age group had a cost effective price per vaccine
dose, whereas for neonatal vaccination some of the shorter
durations of protection and lower vaccine efﬁcacies were not
considered cost effective. It was noted in the article that some
conclusions may be timeframe dependent, as those receiving
neonatal vaccination with long durations of protection would
only just be reaching the age of high TB risk in 2050.
As would be expected, vaccinating all ages had a greater
impact (80% incidence rate reduction over a 35-year time hori-
zon) compared to vaccinating neonates with an adolescent
boost (39% incidence rate reduction) with a POD vaccine in
the Abu-Raddad study.21 Though it should be noted that the
number vaccinated would be much greater in the all-ages sce-
nario. In the other neonatal vs. all-ages study,28 routine neona-
tal vaccination was compared to a one-off mass campaign for
uninfected individuals of all ages with a POI&D vaccine. In this
study, mass vaccination of all ages initially provides greater epi-
demiological impact than neonatal vaccination. As the vacci-
nated cohort ages out the incidence rates rebound, whereas
with sustained routine neonatal vaccination incidence rates
continue to decline, and provide greater impact than a one-off
mass campaign after approximately 20 years.28
No studies were found comparing vaccinating neonates to
all ages or adults with prevention of infection vaccines, or of
combining such age targeting with targeting of post-infection
populations.
ii. Addition of mass campaigns or boosters to routine
neonatal vaccination
Three studies found that the addition of one-off mass vaccina-
tion campaigns on top of neonatal routine vaccination could
have profound effects on population-level impact.19,23,28 In a
South-East Asian study exploring impact of a pre-infection pre-
vention of disease vaccine over a 35 year time horizon, an inci-
dence rate reduction of approximately 65% was predicted with
a neonatal vaccine, compared to >90% when adding a one-off
mass campaign at launch.19 In another study, addition of a
one-off mass vaccination campaign to the routine neonatal pro-
gram (with 70% of the population protected in each group)
increased the reduction in incidence rate from around a quarter
to approximately 85% over 25 years.23 In the Lietman study,
addition of a one-off mass campaign to routine neonatal vacci-
nation greatly increased the short-term impact of the
program.28
One study assessed the impact of an adolescent booster in
addition to neonatal vaccination, which in a Markov model
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was found to double the number of cases averted compared to
neonatal vaccination alone.31
iii. Host infection status required for efﬁcacy: Pre-infection,
post-infection or pre- and post-infection
Eight studies report a comparison of vaccines effective in differ-
ent host infection statuses,4,12,14,16,19-21,28 of which six report
clear comparisons between vaccines effective pre- versus post-
infection.4,16,19-21,28
Exploring the impact on disease incidence, three studies sug-
gest post-infection vaccines would have the greatest
impact,4,20,28 two suggest pre-infection would provide greatest
impact,19,21 and one suggests that either could have greater
impact, dependent upon the rate of treatment of active dis-
ease.16 The six studies allowing comparison are described
below.
iii.a. Post-infection vaccines leading to greater impact on
disease incidence (n D 3). The Ziv, Lietman and Dye (2013)
models report post-infection vaccines as providing greater
impact on disease incidence than pre-infection vaccines.4,20,28
Ziv et al., compared the effect of POD vaccines targeted to
uninfected (pre-infection) or infected (post-infection) popula-
tions in a hypothetical high burden setting with 28-50% latently
infected and 40-60% of active cases treated and cured, and
reported that post-infection vaccines would have a greater and
more rapid effect on cumulative number of incident cases than
pre-infection vaccines.20 After 10 years, post-infection vaccines
prevented 34% of cumulative cases compared to 23% by pre-
infection vaccines.20 Given 28-50% of the population were
latently infected, the number vaccinated with the post-infection
vaccine will be lower in most scenarios, therefore greater
impact on overall disease incidence is achieved despite being
given to fewer individuals. Age targeting, vaccine efﬁcacy and
coverage of target population were identical between scenarios
and both were assumed to prevent development of disease,
though in the pre-infection scenario the vaccine was addition-
ally assumed to have POI activity, and therefore was a POI&D
vaccine.
Similarly, in the Lietman study the pre-infection vaccine was
POI&D whereas the post-infection vaccine was POD-only, but
again, when comparing otherwise identical vaccines, post-
infection vaccination provided the largest and fastest impact on
the disease incidence rate.28 In a background of 50% successful
cure of active disease, comparing 88% coverage of latents
with a post-infection vaccine, to vaccinating 88% of newborns
with a pre-infection vaccine, impact was observed more rapidly
with the post-infection vaccine, and 60 years later the disease
rates with a post-infection vaccine were still lower.28 The sizes
of the latent and newborn populations are not reported, but
they are unlikely to be equal, therefore the number of people
effectively vaccinated and therefore the number needed to vac-
cinate per case averted in each of these scenarios could be very
different. Even if routine neonatal pre-infection vaccination
was preceded by a one-off mass campaign, the initial impact
was still not as large as the post-infection vaccine, but in this
scenario after 40 years the overall incidence rate reduction was
similar.
In a study by Dye et al., in a “typical high burden country”
with 110 cases per 100,000 population per year and 65% case
detection, of which 70% are cured, effective immunization of
25%/year of the uninfected population (pre-infection) with a
POI vaccine reduced disease incidence rates to 130/million
population/year, whereas as little as 14%/year effective immu-
nization of latents (post-infection) with a POD vaccine reduced
the incidence much further to 20/million population/year.4
In all three studies reporting greater impact of post infection
vaccines, the proportion assumed effectively immunized was
lower in the post-infection vaccine target group.4,20,28 There-
fore, even with lower coverage, post-infection achieved greater
impact than pre-infection vaccines.
iii.b. Pre-infection vaccines leading to greater impact on
disease incidence (n D 2). In the Abu-Raddad and Young
models,19,21 pre-infection vaccines demonstrated greater
impact on disease incidence than post-infection vaccines. In
the Abu-Raddad model, campaigns targeted at latently infected
individuals (post-infection) compared to mass vaccination
campaigns using pre-infection or P&PI vaccines, predicted
incidence rate reductions of 37%, 80% and 92% over a 35 year
time horizon, respectively.21 The Young study was also a South
Asian model, which compared the impact of otherwise-identi-
cal PRI, PSI and P&PI vaccines implemented in 2015.19 The
model estimated an incidence rate of approximately 20, 50, and
14 per 100,000 population per year in 2050, indicating that the
most effective vaccine in this scenario would also be a pre-
infection or P&PI vaccine.19 Though it should be noted that
there was some ambiguity in the article as to the vaccine sched-
ule, therefore there may be confounding due to differences in
schedules modeled. Both the Abu-Raddad and Young models
assumed that the pre-infection vaccines were prevention of dis-
ease vaccines, so would not have had a direct effect on
infection.
iii.c. Research indicating a possible reason for such contrasting
results (n D 1). A ‘global’ study excluding sub-Saharan Africa
found that at low active disease treatment rates pre-infection
vaccines providing lifetime protection had greater impact on
disease incidence rates than equivalent targeting of post-infec-
tion vaccines.16 However, when treatment rates of active disease
were increased, reducing the proportion of disease from recent
infection compared to reactivation, the post-infection vaccine
was reported to have greater impact on disease incidence. We
discuss this more below.
iii.d. Other factors inﬂuencing comparison of impact of pre- or
post- infection vaccines. Although the proportions effectively
immunized (coverage multiplied by vaccine efﬁcacy) did not
differ markedly between studies favoring pre- or post-infection
vaccines, the proportion of the population latently infected will
co-determine the number of people that would receive either a
pre- or post-infection vaccine, and could be an important cause
of differences. However, only two of these six studies reported
the assumed infection prevalence.16,20
Time horizon could be important for this comparison. As
demonstrated in the Ziv and Lietman models,20,28 even though
post-infection vaccines may have greater initial impact, the
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impact of the vaccine types sometimes converge over longer
time horizons due to the greater time lag before impact is
observed with pre-infection vaccines. However, all six studies
explore outcomes over a narrow horizon of 35-43 years and
therefore between-study differences in the impact of pre- vs.
post-infection vaccines do not appear attributable to time hori-
zon.4,16,19-21,28 Durations of protection, and effect type for post-
infection or pre-infection vaccines all vary between models, but
were also somewhat similar in both groups.
iv. Disease stage protected against: POI, POD or POI&D
Dye et al. (2000) compared POI and POD vaccines with 70%
effective immunization in a mass campaign followed by neona-
tal vaccination. In this study, the incidence rate reduction was
greater with the POD vaccine than the POI vaccine over a 25
year time horizon.23 In the Murray et al. global model, sus-
tained mass vaccination with 66% coverage of uninfected indi-
viduals for a POI vaccine prevented fewer cases (10.5m-37.0m
cases averted with 20-80% vaccine efﬁcacy over a 17 year time
horizon) than a POD vaccine with mass campaigns scaling up
to 80% coverage over 10 years followed by annual neonatal vac-
cination (16.2m-51.6m cases averted); a trend also reﬂected in
the regional estimates presented.12 However, it must be noted
that there are difﬁculties in identifying whether these are equiv-
alent comparisons given the differences in schedule, size and
infection status of population receiving vaccine and coverage.
Several models explored POI or POD vaccines compared to
a POI&D vaccine. As would be expected since it is a combina-
tion of mechanisms, a number of the studies found the POI&D
vaccine to be most effective.4,14 Those ﬁnding more impact on
disease with the POD vaccine than the POI&D vaccine were
likely confounded by favorable targeting of the vaccines to
latently infected individuals in the POD scenario.20,28
v. Time horizon of impact
The WHO/Stop TB global targets aim to reduce TB incidence
rates to 10 cases per 100,000 population per year by 2035, and
less than 1 case per million population per year by 2050, termed
as tuberculosis elimination.3,5 Several of the studies explored
the potential contribution of future TB vaccines to achieving
the Stop TB 2050 target, but all were published prior to release
of the WHO End TB strategy containing the 2035 goals, so
none directly address these targets. In two papers by Dye et al.,
it was shown that pre-infection POI vaccines to interrupt trans-
mission were unlikely to reach elimination, as even with com-
plete transmission interruption in 2015 an incidence of >100/
million/year would still be expected by 2050.4,16 In the Dye
model, a post-infection vaccine giving full and permanent pro-
tection to 14% of the latently infected population per year was
estimated to reduce incidence to 20/million/year by 2050, and
if combined with treatment of active disease, or a pre-infection
vaccine, would achieve elimination by 2050.4 In country-spe-
ciﬁc models, results suggested that a post-infection vaccine (or
mass preventative therapy) could achieve elimination targets in
China and India.4 These models suggest that a post-infection
vaccine, or either vaccine effect type combined with treatment
of active cases, may be capable of reaching the WHO 2050
elimination goals.4 However, similar models for South Africa
and the USA suggested that elimination was not considered
feasible in these settings with novel vaccines.4 Results from
both the Young and Knight models indicated that none of the
scenarios explored would achieve incidence rates lower than
around 10-20/100,000/year by 2050.19,27
vi. Settings
There was clear variability in vaccine epidemiological impact by
setting. Knight et al. demonstrated a larger proportion and
absolute number of cases would be averted by vaccines in low-
income countries than middle-income countries.27 In Japan,
95% coverage of a BCG-like vaccine with 40-80% vaccine efﬁ-
cacy was considered not cost effective as it could only avert 10-
47 cases per 100,000 children vaccinated over a 10-year hori-
zon.30 Whereas with 92% coverage of a 70% POD vaccine in
the Zambian setting, cases averted were much higher at 199
cases per 100,000 vaccinated at birth;31 though it should be
noted that the Zambian model analyzed a longer 30-year time
horizon. Three models explored the cost effectiveness of adding
booster vaccines in South Africa, but outcomes are not compa-
rable with the Japanese and Zambian models.15,22,24 In two
regional models, for each of the vaccine proﬁles explored the
greatest numbers of cases and deaths avoided were in Asia/
Western Paciﬁc, followed by sub-Saharan Africa (see
Table 3).12,21 Much lower absolute numbers of cases were
avoidable in the other regions, with the next largest impact
observed in the Eastern Mediterranean region where cases
averted were around a third of those in sub-Saharan Africa.21
vii. Economic models
A small number of published studies evaluated the economics
of future TB vaccines (n D 7/18),10,15,22,24,27,30,31 with the
majority (n D 6/7) evaluating cost effectiveness of new vaccines
(either future or BCG based) using either static,15,22,30,31 or
dynamic models.24,27 Optimization techniques were also used
to consider costs associated with different control schemes.10
With the exception of one model exploring a very low efﬁcacy
vaccine and one exploring infant vaccination in a low burden
setting,22,30 those evaluating cost effectiveness found new TB
vaccines to be an overwhelmingly cost effective intervention,
whether from the health system24,27 or societal perspec-
tive.15,27,31 More than half of the models included societal costs,
highlighting that much of the economic burden of TB disease
falls on the TB patient due to the long durations of treatment.
The populations considered in these economic models were
either theoretical10 or setting speciﬁc (South Africa,15,22,24 Zam-
bia31 or Japan30) with only one model considering multiple set-
tings (low- and middle-income countries).27 Cost effectiveness
of vaccines was highly dependent on vaccine characteristics
such as efﬁcacy (with lower efﬁcacy linked to higher
costs),7,15,22,24,30 setting-speciﬁc burden of disease,30 and eco-
nomic considerations such as discount rate,22,30,31 and time
horizon.31
It is important to know the minimum acceptable vaccine
efﬁcacy for designing clinical trials and when making imple-
mentation decisions. Two South African Markov model thresh-
old analyses of new vaccine boosters demonstrated that the
booster strategy would be more effective, and either cost neutral
or more expensive if the booster vaccine demonstrated a vac-
cine efﬁcacy of approximately 40% or above.15,22 The Knight
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et al. study provided contour plots demonstrating the vaccine
efﬁcacies and durations of protection for which the vaccines
would have an above-zero price at which the vaccine would be
cost effective.27 All vaccines in the ranges vaccine efﬁcacy 20-
100% and duration of 5 years to lifelong were cost effective,
and even cost saving above 20% vaccine efﬁcacy and 10 years
duration, when delivered to adolescents and adults.27 However,
the neonatal vaccination program was only cost effective at
higher values of these vaccine characteristics, with no cost effec-
tive vaccine price for a region of the plane where vaccine efﬁ-
cacy and/or duration were relatively low.
Studies identiﬁed post-hoc (n D 2)
For completeness, one unpublished study and one study pub-
lished after the review search date were identiﬁed. The study
published in March 2016 explores the impact of spatial ‘hot-
spot’ targeting compared to random allocation of an adult
POD vaccine in Gujarat, India.33 This model did not compare
vaccine effect types or host infection status or age targeting, but
is the ﬁrst to explore spatial targeting of vaccines, and suggests
spatial targeting could increase impact by 17% in the base case
scenario in this setting.33
The unpublished study is an exploration of the epidemiolog-
ical impact of different future TB vaccine proﬁles when targeted
to adolescents (15 year olds) compared to older adults (60 year
olds) in China.34 This model is a dynamic transmission model
incorporating heterogeneous social mixing patterns by age,
age-speciﬁc natural history parameters, and ﬁtted to age-strati-
ﬁed epidemiological data, and will contribute to the literature
on vaccine age targeting and impact of pre- versus post-infec-
tion vaccines.
Quality assessment (n D 23)
Using the adapted quality assessment tool, scores ranged from
11 to 25 out of 28 (Table 4). Two were considered low qual-
ity,19,23 eight of medium quality,4,13,17,18,25,26,28,29 six high qual-
ity,10,11,14,16,20,30 and seven of very high quality.4,12,15,21,22,27,31
The median score was 20/28, equivalent to high quality. As the
tool was not perfectly suited to analytical papers, the sensitivity
of the median score was assessed by excluding analytical
papers, and the overall score did not change. The major gaps
observed were deﬁnitions of the population and intervention,
ﬁtting methodology, uncertainty and sensitivity analyses, data
sources, and conﬂicts of interest and funding. Comprehensive
uncertainty and sensitivity analyses were lacking in many
studies. Further discussion is included in the supplementary
appendix B.
Discussion
Modeling the epidemiological impact of future TB vaccines is a
relatively young but growing ﬁeld, used to inform rational deci-
sion making in portfolio strategy, prioritization of resources,
and global target setting. To date, the literature remains divided
as to whether vaccines effective pre-infection or post-infection
would provide the greatest epidemiological impact. However,
all-age or adolescent/adult targeted prevention of disease
vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. Mass campaigns or boosters
added to routine neonatal vaccination can have profound addi-
tional epidemiological impact. With the exception of one very
low efﬁcacy vaccine and one low burden setting, economic eval-
uations found new TB vaccines to be overwhelmingly cost
effective, particularly when targeted to adolescent/adult age
groups. The variability of impact by setting, age group vacci-
nated, vaccine characteristics and time frame, must be taken
into account in the development and delivery of future
vaccines.
Given the importance of indirect effects in this research
question, the majority of the 23 included studies captured
transmission through development of dynamic models.
Some potential geographical bias was observed, as several
either excluded sub-Saharan Africa or were based upon an
Asia-like epidemic. Although the avoidable burden of dis-
ease may be higher in Asia, the high disease rates and
slower progress toward global targets in the African region
may mean that this region would be in greatest need of
new interventions such as vaccines to meet the WHO 2035
and 2050 targets.3 Epidemiological outcomes were indicative
of considerable heterogeneity by setting, highlighting the
importance of setting-speciﬁc modeling for decision making.
Only four of the models incorporated HIV strata,12,15,27,31
yet globally 12% of all TB cases are HIV co-infected, of
which three-quarters are found in the African Region.3 It is
currently unknown what effect HIV-infection may have on
vaccine efﬁcacy, but it is generally thought that it may be
lower in this population. Therefore, models without HIV
structure may overestimate vaccine impact, and models
including this structure are a useful tool to conduct sensi-
tivity analyses around HIV-related assumptions.
Historically, novel TB vaccine development has focused pri-
marily on vaccination in infancy. However, more recently a
shift in thinking has led to the prioritization of older age groups
in clinical trials and development plans. For prevention of dis-
ease vaccines, this is supported by the modeling literature,
which demonstrates that all-age or adolescent/adult targeted
POD vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. This is epidemiologically con-
sistent given that in many settings adults comprise the majority
of the disease burden and their primarily pulmonary disease is
a greater source ofM.tb transmission than the extra-pulmonary
disease prevalent in children,3 therefore delivery of POD vac-
cines directly to the adult population provides relatively imme-
diate impact, whereas there is usually a lag of 10-20 years
before any impact of long (>10 years) duration of protection
neonatal vaccination can be seen.
From an implementation perspective, neonatal and adoles-
cent vaccines could potentially be incorporated into existing
delivery platforms, but developing a platform for delivery of
adult vaccination could have serious resource implications.
Although this is an important consideration, one model has
demonstrated that adolescent/adult vaccine targeting would be
more cost effective than neonatal vaccination with a POD vac-
cine.27 Alternatively, several models suggest that addition of
one-off mass campaigns for all ages at initiation of routine neo-
natal vaccination could have a profound effect on the
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population-level impact.19,23,28 No models were identiﬁed com-
paring age targeted POI vaccines or combining age targeting
with targeting to post-infection populations. It was also noticed
by the authors that none of the models explored targeted vacci-
nation of older adults or the elderly, which is surprising given
that several high burden countries are undergoing population
aging (e.g., China, Indonesia) and the higher risk of developing
active disease in this age group.
Our ﬁnding that the modeling literature was equivocal as
to whether post-infection4,20,28 or pre-infection19,35 vaccines
would have greatest epidemiological impact is interesting and
may have important implications. Given the complexity of the
studies, it is not possible to conﬁdently identify the study differ-
ences that explain these diverse ﬁndings. However, there are 2
factors that we believe are likely to be most important. Firstly,
the underlying epidemiology of the population and, in particu-
lar, factors affecting the proportion of disease due to primary
disease and rapid progression versus reactivation or relapse, are
likely to be inﬂuential. This was best illustrated in Dye and Wil-
liams,16 in this study the authors increased rates of treatment of
active disease, which resulted in a switch from greater impact
from a pre-infection vaccine to greater impact from a post-
infection vaccine (Dye and Williams, ﬁgure 6 panels a and b –
by comparing new TB cases per million in 2050 in panel a ver-
sus b at increasing treatment rates per TB case). Increasing the
treatment of active disease reduced transmission and the pro-
portion of disease arising from primary infection (versus reacti-
vation). We recreated this by coding up this model (not shown)
showing that, for the same overall disease burden, when a
greater proportion of disease was due to reactivation the post-
infection vaccines were predicted to have the greater impact
across the full range of rates of treatment of active disease
explored. Secondly, the proportion of the population latently
infected will co-determine the number of people that would
beneﬁt from either a pre- or post-infection vaccine. However,
only two of these six models report the infection preva-
lence.16,20 Another factor that could help explain this difference
is that most of the six models compared assume no relapse
from the recovered class, but in the two models assuming
relapse,4,19 it is possible that relapse rates and assumptions as
to whether this group is protected by post-infection vaccina-
tion, could affect the relative impact of pre- versus post-infec-
tion vaccines. Further, although no major differences were
identiﬁed here, time horizon, vaccine efﬁcacy, and duration of
protection assumptions could also potentially inﬂuence pre- vs.
post-infection outcomes. Given the difﬁculties we have had in
identifying the reasons why these models are making conﬂict-
ing predictions, there is a clear need that these assumptions are
reported carefully in future vaccine modeling studies, and if
this question is important for vaccine development planning,
there may be a need for a controlled modeling study focusing
on this question.
From the vaccine development perspective, although a vac-
cine effective both pre- and post-infection would be the ideal
scenario, pipeline candidates with either pre- or post-infection
efﬁcacy could have value, and modeling could be used to assess
their relative value in different settings. Further, if a candidate
could potentially exhibit different efﬁcacy in infected versus
uninfected populations, efﬁcacy estimates from trials could be
confounded by the balance between primary and reactivation
disease in the trial setting. Or worse, if the recruited population
is limited to either infected or uninfected individuals it is con-
ceivable that a candidate’s development could be discontinued
due to poor efﬁcacy in one population without knowing
whether the candidate would have shown better efﬁcacy in the
other group. Therefore, if proven safe and immunogenic in
both infected and uninfected populations, ideally both should
be recruited into clinical trials and the study powered to esti-
mate vaccine efﬁcacy separately for those IGRA or TST positive
versus negative at recruitment to improve generalizability to
other settings. However, this could make trials infeasibly large,
in which case enrolling both uninfected and infected popula-
tions, but powering the trial on the primary endpoint in one
population, and looking for trend, safety and immunogenicity
in the other population as secondary endpoints may be prefera-
ble to using a combined endpoint.
Upon implementation, sustained campaigns speciﬁcally tar-
geting either uninfected (with a pre-infection vaccine) or
latently infected populations (with a post-infection vaccine)
may not be feasible. To identify such populations, TST or
IGRA testing would be required. Such tests come with cost and
organizational implications, and neither are perfect tests for
latency or the absence of infection.36 Blanket vaccination to
ensure the target population is captured would be an alterna-
tive, but empirical data and modeling would be needed to assess
the costs of vaccine wastage, and consideration given to the
ethics of vaccinating individuals unable to derive direct beneﬁt
from vaccination.
Regarding prevention of disease versus prevention of
infection vaccines, although several studies include vaccines
with these different effect types, there tend to be other
simultaneous changes in the vaccine proﬁles or targeting,
such as age or infection status targeting, which confound
the comparison of the impact of these two vaccine types.
However, overall the studies suggest that prevention of dis-
ease vaccines tend to have a quicker and greater epidemio-
logical impact than prevention of infection vaccines over
the time horizons explored.
Theoretically, it is possible that there could be a genetic pre-
disposition responsible for both ability to control M.tb latent
infection and to respond to a vaccine. For a POD vaccine, this
would become apparent in efﬁcacy trials, as there would be no
impact of such a vaccine on the disease endpoint. However, for
POI vaccine studies with an infection endpoint, such a scenario
could reduce infection rates, but have little impact on popula-
tion level burden of disease as the vaccine may not be effective
in those individuals most likely to progress to disease if
infected. None of the POI vaccine models explored the poten-
tial scenario where vaccine efﬁcacy is linked to likelihood to
progress to disease, but this could be an interesting avenue for
future research.
Although the relative impact of vaccine proﬁles to one
another is informative for rational development of portfolio
strategy, the absolute impact of such programs is important for
understanding the potential role of such new technologies in
achieving global targets and for advocacy for investment. Novel
TB vaccines have the potential to provide an important contri-
bution toward achieving the WHO 2035 and 2050 goals. Yet
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given the ambitious nature of the 2050 targets, even novel vac-
cines may require synergistic pairing with other interventions
to achieve elimination in most modeled scenarios. Due to the
sizeable global pool of latent infection, even a complete trans-
mission block may not achieve elimination because of the con-
tinued burden from reactivation disease. Therefore, prevention
of reactivation disease through vaccination or preventative
treatment of latently infected individuals will be essential to
elimination strategy.
Cost must also be considered when planning implementa-
tion of new TB vaccines, therefore health economic models will
be essential. With the exception of one low-efﬁcacy vaccine
study and one low burden setting,22,30 the studies identiﬁed
found new TB vaccines to be an overwhelmingly cost effective
intervention. The results of threshold analyses are highly con-
text dependent. However, in one analysis of low and middle
income settings, vaccines targeted to adolescents and adults
were shown to be cost effective as low as 20% vaccine efﬁcacy
and ﬁve years duration of protection, whereas infant vaccines
required higher efﬁcacies and longer durations to cross this
threshold over the time horizons considered.27
An adapted tool was developed to assess quality and risk of
bias of included studies for the purposes of this review to sys-
tematically assess reporting, methodological and risk of bias
factors. The majority of included papers were scored as
medium or high quality. The major gaps observed highlight for
future studies the importance of thorough reporting and the
conduct of comprehensive uncertainty and sensitivity analyses.
It is hoped that this quality assessment tool will be of broad use
in future systematic reviews assessing epidemiological models
of other interventions and diseases.
The main limitation of this review was the conduct of inde-
pendent sifting and data extraction by a single reviewer. The
authors recognize that sifting by two independent reviewers
remains the gold standard for systematic reviews.6 However,
due to resource constraints this was not possible, but a very low
threshold was applied for directing sifting queries to a second
reviewer. In addition, the review was ﬁrst conducted in 2014 and
then repeated in 2016, therefore duplication of sifting by the
same primary reviewer was expected to reduce the likelihood of
missing relevant literature. It was found that the study quality
assessment tool developed was not as well suited to assessment
of analytical models as several domains were not applicable,
leading to a higher likelihood of scoring ‘medium’ quality.
Several research gaps were identiﬁed in this analysis of the
available literature. The lack of a clear explanation for the polari-
zation of outcomes for pre-infection and post-infection vaccines
is troubling, therefore a model to explore which key determi-
nants within the model impact these outcomes would be an
important addition to the literature. None of the models pre-
sented explicitly explored the potential impact of targeting vac-
cines to older adult or elderly populations. Such a model would
be pertinent for a country such as China, which has high disease
burden, an aging population, and has only been brieﬂy explored
in one sub-model in the literature. Future vaccines could be
important in tackling multi-drug resistance disease through pre-
vention of transmission or disease, yet drug resistance was not
explored in any of the models identiﬁed. Few of the models
included non-random social mixing patterns, and none
considered the potential impact of evolving mixing patterns on
the impact of vaccines. Some studies have explored the epidemi-
ological impact of vaccine age targeting in sub-Saharan Africa;
however, these models were either missing HIV structure, did
not explore reduction of vaccine efﬁcacy in HIV-infected indi-
viduals, only considered vaccination of uninfected populations,
or were static models. Given HIV co-infection and high forces of
M.tb infection are fundamental to the epidemic in many sub-
Saharan African countries, there is a need for a comprehensive
model incorporating these important elements.
Conclusion
Mathematical modeling has been used to understand how the
epidemiological impact of future vaccines could be altered by
vaccine characteristics, vaccine age targeting, and epidemiologi-
cal setting. It has also proved important for exploring the
potential role of new vaccines for achieving the WHO 2050
goal of tuberculosis elimination. Such modeling should be inte-
gral to the development of future TB vaccines, informing ratio-
nal decision making by cross-product bodies, academia,
industry and policy makers for the development, investment
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Can	 achieve	 2035	 goals	 with	 70%	
neonatal	 coverage	 and	 25%	 5-yearly	
mass	 coverage.	 Could	 be	 achieved	
sooner	with	more	frequent	campaigns	or	
higher	coverage.	With	80%	neonatal	and	


























2025-50	 was	 in	 African	 region	 (AFR),	
smallest	 number	 in	 Western	 Pacific	
region	 (WPR).	 Biggest	 difference	
between	 vaccination	 strategies	 was	 in	
WPR	 (81%),	 smallest	 difference	 was	 in	
AFR	(53%).	Estimate	from	graph	approx.	
80m	 cases	 averted	 with	 adolescent	








a	 comprehensive	 and	 comparable	 exploration	 of	 the	 population-level	
epidemiological	impact	of	the	vaccine	characteristics	and	implementation	strategies	










impact	 of	 targeting	 older	 adults	with	 new	 TB	 vaccines,	 and	 the	 China	 TB	 vaccine	




from	 China,	 to	 explore	 the	 future	 dynamics	 of	 the	 TB	 epidemic	 in	 China	 and	 the	
potential	 impact	 of	 varying	 vaccine	 characteristics	 in	 this	 setting	 (Chapter	 3,	
objectives	2a-c).	To	explore	the	impact	of	implementation	strategies,	this	model	is	








The	 exploration	 of	 the	 TB	 vaccine	modelling	 literature	 identified	 adolescents	 and	
adults	as	an	important	age	group	for	vaccine	targeting	and	has	shown	that	prevention	
of	 disease	 vaccines	 are	 likely	 to	 provide	 the	 greatest	 and	most	 rapid	 impact.	 The	




These	 target	 populations	 and	 desired	 outcomes	 must	 then	 be	 translated	 in	 to	
appropriate	 design	 of	 clinical	 trials.	 As	 highlighted	 by	 the	 two	 epidemiological	
research	 needs	 identified	 from	 the	 TB	 Vaccine	 Blueprint	 (see	 Box	 1,	 Chapter	 1),	
mathematical	modelling	 can	 inform	 the	 ideal	 characteristics	 and	 populations,	 but	









inhabitants,	 reported	 adult	 TB	 notification	 rates	 ranging	 between	 0	 and	
2,847/100,000	adults	per	year.59	Similar	variations	were	reported	 in	a	settlement-
level	study	in	the	Gambia,	where	rates	in	settlements	of	4,000-68,000	people	ranged	
from	 48	 to	 239/100,000	 population/year.60	 The	 potential	 for	 such	 large	 local	





population	 characteristics	 of	 interest	 for	 vaccine	 development	 (e.g.	 age	 and	 HIV	









data	 to	 inform	 design	 of	 clinical	 trials	 to	 recruit	 the	 populations	 identified	 in	 the	










TB	 vaccine	 clinical	 trial.	 Measuring	 GPS	 coordinates	 at	 the	 home	 is	 a	 resource-





accuracy	 of	 such	 descriptions	 is	 often	 low.	 This	 was	 demonstrated	 by	 a	 study	
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comparing	 verbal	 descriptions	 in	 the	 clinic	 register	 to	 GPS	 readings	 taken	 at	 the	
home.64	 Two	 study	 staff	 were	 unable	 to	 categorise	 the	 patient’s	 cluster	 (approx.	
1,300	population)	of	residence	from	verbal	descriptions	for	31.8%	and	59.7%	of	the	





























• Most	high	burden	settings	 routinely	 collect	 these	
data	
• Aggregated	 data	 usually	 report	 paediatric	 and	




• Lack	 of	 spatial	 granularity	 as	 clinics	 may	 cover	
broad	 areas,	 and	 in	 low	 income	 settings	without	




















• Often	 collect	 large	 amounts	 of	 demographic	 and	
additional	 risk	 factor	 data	 as	 part	 of	 the	 HDSS	
survey	rounds	
• Usually	sites	with	capacity	to	conduct	clinical	trials	

















• Can	collect	data	 in	 the	 recruitment	population	of	
interest	and	in	locations	able	to	conduct	a	clinical	







• Time	 consuming	 to	 set	 up	 and	 conduct	 study.	






















• Complicated	 logistics	 of	 ensuring	 availability	 of	
field	 staff	 to	 return	 to	 home	 of	 all	 patients	
immediately	 after	 registration,	 or	 difficulties	 of	
following	up	at	a	later	date.	













• Pictographic	 representation	 of	 roads	 and	
















• Assumes	 sufficient	points	of	 interest	 to	orientate	
within	map	
• Requires	 high	 speed	 and	 reliable	 mobile	 data,	








• Mapped	 points	 of	 interest	 identified	 by	 the	
community	 improve	 ease	 of	 use	 of	 maps	 in	 this	
• Only	 maps	 patient	 to	 a	 cluster	 of	 approximately	














patients	 starting	 ART	 treatment	 in	 Blantyre,	
Malawi.	
• Only	 identifies	 residence	 for	 patients	 in	 28	 study	
clusters	





A	 new	approach	 is	 needed	 to	 be	 able	 to	 prospectively	 collect	 place	 of	 residence,	
ideally	integrated	in	the	NTP	to	keep	costs	and	logistical	issues	to	a	minimum.	Several	
tools	 are	 available	 that	 could	 be	 used	 to	 collect	 place	 of	 residence	 at	 time	 of	




















Map	 book	 system,	 but	 the	 scaleability,	 accuracy,	 and	 real	 time	 data	 collection	 of	
electronic	platforms.		
In	 chapter	 5	 of	 this	 thesis,	 I	 describe	 the	 development	 and	 evaluation	 of	 ePAL	
(electronic	PArticipant	Locator)	-	a	new	app	designed	for	rapid,	low	cost	collection	of	
the	 location	 of	 the	 TB	 patient’s	 place	 of	 residence	 as	 an	 integrated	 part	 of	 the	
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National	 Tuberculosis	 Programme.	 In	 Chapter	 5,	 I	 provide	 spatial	 mapping	 of	





In	 this	 chapter,	 I	 have	 described	 the	 public	 health	 need	 for	 new	 TB	 vaccines	 and	
challenges	in	their	development.	From	these	challenges,	two	clear	epidemiological	
research	needs	have	been	identified.	Firstly,	the	need	for	mathematical	modelling	of	
a	 comprehensive	 range	 of	 vaccine	 characteristics	 in	 China,	 in	 addition	 to	 a	
consideration	 of	 the	 impact	 of	 age	 targeting	 of	 vaccination	 to	 adolescents	 versus	
older	 adults,	 to	 inform	 maximisation	 of	 the	 potential	 future	 burden	 of	 pipeline	
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TB	 demographics	 and	 epidemiology	 in	 China.	 Firstly,	 modelled	 epidemiological	
projections	to	2050	without	introduction	of	new	TB	vaccines	are	described	(objective	
2a).	 Using	 this	 calibrated	 epidemiological	 model,	 the	 population-level	




question	 was	 identified	 based	 upon	 research	 gaps	 identified	 from	 the	 literature	
review	in	Chapter	2,	and	through	discussions	with	Willem	Hanekom	at	the	Bill	and	
Melinda	Gates	Foundation	(part-funder	of	the	work	in	this	chapter).	Collaborators	at	
Aeras,	 WHO	 and	 TBVI	 also	 contributed	 to	 scoping	 the	 research	 question	 and	
outcomes.	 The	methodology	was	 developed	 by	myself	with	 input	 from	 Professor	
Richard	 White,	 Dr	 Tom	 Sumner	 and	 Dr	 Gwenan	 Knight.	 I	 collected	 the	 data	 for	
parameterisation	 and	 calibration	 of	 the	model	 from	 secondary	 sources.	 The	 core	
model	structure	was	based	upon	a	model	developed	by	Knight	et	al.,1	but	with	major	
adaptations	 to	 capture	 the	 demographics	 and	 epidemiology	 in	 China	 and	 a	 wide	
variety	 of	 vaccine	 characteristics	 and	 implementation	 strategies,	 including	 ‘leaky’	
mechanisms	of	vaccine	efficacy	against	infection	and	disease,	incorporation	of	social	
mixing	patterns,	and	development	of	model	outcomes	(e.g.	incidence	rate	reduction,	























countries,	 it	 has	 been	 estimated	 that	 by	 2050,	 nearly	 80%	 of	 the	 world’s	 older	
population	will	 be	 living	 in	 less	 developed	 regions.3	 Three	 of	 the	WHO’s	 high	 TB	
burden	countries	already	estimate	at	 least	1	 in	10	of	 their	population	are	aged	at	
least	 65	 years	 (China	 10%,	 Thailand	 10%,	 and	 Russia	 13.6%).2,5	With	 the	 ongoing	
demographic	ageing	occurring	globally,	including	in	many	countries	with	high	burden	
of	TB	disease,	the	results	of	such	modelling	in	China	could	be	indicative	of	possible	






research	 studies	 using	 modelling	 to	 estimate	 the	 potential	 impact	 of	 new	 TB	
vaccines.8	 The	majority	 of	modelling	 papers	 exploring	 potential	 future	 TB	 vaccine	
impact	are	in	global	or	India-like	settings,8	where	the	epidemic	remains	younger	adult	
and	new	infection	driven.	Modelling	in	China’s	epidemiological	setting	is	needed	to	
understand	 the	 characteristics	 required	 to	maximise	 the	 potential	 impact	 of	 new	
vaccines	 in	 this	 setting,	by	 informing	 target	product	profiles,	 clinical	development	
plans,	candidate	stage	gating	and	implementation	strategies.	
There	are	currently	13	candidates	 in	 the	clinical	development	pipeline	 for	new	TB	
vaccines,9	 representing	 a	 variety	 of	 antigens	 delivered	 through	 different	 vaccine	
modalities	(e.g.	whole	cell,	adjuvanted	protein,	viral	vector),	with	the	potential	for	
relatively	 diverse	 vaccine	 characteristics	 and	 indications.10	 However,	 scientific	









possible	 implementation	of	 the	candidate	currently	 in	 trials,	and	of	other	pipeline	
candidates	that	could	potentially	be	developed	in	this	high	burden	country.	
Therefore,	modelling	was	conducted	to	fill	the	most	pressing	research	gap	for	TPP	
development,	 exploring	 vaccine	 efficacy	 against	 infection,	 vaccine	 efficacy	 against	
disease,	duration	of	protection,	and	the	relative	impact	of	pre-	versus	post-infection	





more	detailed	exploration	of	age-targeting	of	 vaccines	 in	 chapter	4.	The	evidence	





2.		a)	 Develop	 a	 mathematical	 model	 calibrated	 to	 epidemiological	 and	
demographic	 temporal	 and	 age	 distribution	 trends	 in	 China,	 accounting	 for	
uncertainty	 in	 natural	 history	 parameters,	 to	 predict	 the	 evolution	 of	 the	 TB	
epidemic	over	the	2050	time	horizon.	










An	 age-structured	 dynamic	 compartmental	 transmission	 model	 (Figure	 3.1)	
described	 by	 a	 series	 of	 difference	 equations	 (section	 3.6.1)	 was	 developed	 and	
calibrated	 to	 epidemiological	 and	 demographic	 data	 from	 China	 to	 estimate	 TB	




Consistent	with	other	models	 in	the	 literature,8	 the	natural	history	of	 tuberculosis	
was	 described	 by	 five	 epidemiological	 states:	 uninfected	 (S),	 latently	 infected	 (L),	
infectious	active	TB	disease	(I),	non-infectious	active	TB	disease	(NI),	and	recovered	
from	active	TB	disease	 (R)	 (Figure	3.1).	 The	uninfected	population	was	defined	as	
those	 never	 infected	 with	Mycobacterium	 tuberculosis,	 latent	 as	 the	 population	
remaining	infected	without	developing	clinical	symptoms,	infectious	disease	as	those	
with	 bacteriologically-positive	 pulmonary	 TB,	 non-infectious	 as	 patients	 with	
bacteriologically-negative	 pulmonary	 TB	 or	 extra-pulmonary	 TB,	 and	 recovered	 as	
those	who	have	either	 received	 successful	 treatment	or	naturally	 recovered	 from	







age-specific	 contact	 patterns	 (" #, % ) 	between	 the	 infectious	 and	 disease-free	
populations	 in	 that	 time	 step,	 and	 the	 probability	 of	 transmission	 per	 respiratory	
contact	 (z).	 Of	 the	 uninfected	 population	 becoming	 infected,	 a	 proportion	 (p)	
experienced	 fast	 progression	 directly	 to	 active	 disease	 and	 the	 remainder	 (1-p)	
entered	the	latent	state.	Latently	 infected	individuals	could	develop	active	disease	
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through	 ‘slow	 progression’	 of	 the	 existing	 infection	 (v)	 or	 ‘fast	 progression’	 upon	
reinfection	(λpx),	where	x	represents	protection	against	development	of	reinfection	
disease	due	to	the	immune	response	to	existing	infection.	For	all	new	active	cases,	
regardless	 of	 whether	 fast	 or	 slow	 progressors,	 a	 proportion	 (f)	 developed	
bacteriologically	 positive	 active	 disease,	 and	 the	 remainder	 (1-f)	 developed	
bacteriologically-negative	‘non-infectious’	disease.	Individuals	with	non-infectious	TB	
could	progress	to	infectious	disease	at	rate	w.		




was	 scaled	 down	 by	 a	 factor	 e,	 as	 detection	 of	 bacteriologically	 negative	 and	
extrapulmonary	disease	is	lower.13,14	Undetected	cases	entered	the	relevant	active	
disease	 state	 and	 became	 prevalent	 cases.	 Prevalent	 cases	 could	 be	 removed	 by	
natural	 cure	 (n)	 to	 the	 recovered	state,	or	 removed	 from	the	system	by	TB	death	




The	 population	 in	 the	 recovered	 state	 could	 be	 reinfected	 at	 rate	 λx	 to	 develop	
primary	 active	 disease	 (p)	 or	 enter	 the	 latent	 pool	 (1-p).	 Relapse	 (r)	 from	 the	
recovered	state	to	return	to	the	active	disease	state	occurred	at	higher	rates	than	the	
latent	population	due	to	the	higher	risk	of	developing	disease	in	this	population.			






vaccination	 was	 represented	 by	 a	 transition	 to	 the	 vaccinated	 stratum	
('(, ')	and	'.).	Vaccine	efficacy	was	modelled	as	“leaky”,	therefore	all	infection	and	
disease	states	were	possible	in	the	vaccinated	stratum,	but	vaccination	altered	the	
relevant	 natural	 history	 parameters	 to	 reduce	 progression	 to	 infection	 and/or	
disease.	 Vaccine	 efficacy	 against	 infection	 (effI)	 was	modelled	 by	multiplying	 the	
infection	parameter	(λ)	by	1-effI.	Vaccine	efficacy	against	disease	(effD)	was	applied	
in	 the	 same	 manner	 to	 development	 of	 disease	 parameters,	 which	 were	 the	
proportion	developing	primary	active	disease	(p),	and	risk	of	reactivation	from	the	
latent	(v)	and	recovered	(r)	classes.	Therapeutic	vaccination	was	not	considered,	so	
transition	 from	 unvaccinated	 to	 vaccinated	 strata	 was	 only	 possible	 for	 the	
susceptible,	 latent	 and	 recovered	 populations	 ('(, ')	and	'. ,	 respectively).	 Theta	













upon	 available	 literature,	 age-stratified	 where	 indicated	 by	 available	 data	 or	
biological	plausibility.	Social	mixing	between	age	strata	was	based	upon	social	mixing	
pattern	data	from	a	study	in	Southern	China.15	Treatment	success	was	based	upon	
historical	 data,	 and	 assumed	 to	 plateau	 beyond	 2011	 due	 to	 high	 success	 rates	
achieved	 (95%).16	 To	minimise	 short-term	 fluctuations	 in	 the	WHO-reported	 case	
detection	ratio	(CDR)	data,17	a	generalised	logistic	function	was	manually	fitted	to	the	
WHO	CDR	estimates	for	1990-2010.17	BCG	delivery	was	assumed	to	remain	constant,	









64	 and	 ≥65years)	 UN	 population	 division	 estimates	 for	 2010	 and	 projections	 for	
2050.18	












run	 for	 one	 million	 randomly	 generated	 parameters	 sets	 and	 the	 likelihood	
calculated.	The	20	highest	likelihood	parameter	sets	were	then	used	as	seeds	for	an	
adaptive	ABC-MCMC.	Sequential	parallel	ABC-MCMC	chains	were	employed,	seeding	
with	 acceptances	 from	 the	previous	 chains	 and	adapting	 the	acceptance	 criterion	
until	a	full	model	fit	to	all	18	data	ranges	was	achieved.	From	the	2,152	model	fits	






























Time	 horizon	 of	 vaccination	
scenarios	
2025-2050	































post-infection	 (P&PI),	 modelled	 as	 vaccine	 ‘take’	 possible	 in	 susceptible,	 latently	
infected	 and	 recovered	 populations.	 As	 secondary	 analyses,	 pre-infection	 (PRI)	
vaccines	effective	only	in	susceptible	populations,	and	post-infection	(PSI)	vaccines	
only	effective	in	latently	infected	and	recovered	populations,	were	modelled.		
Impact	 of	 duration	of	 protection	on	 the	potential	 population-level	 impact	 of	 new	
vaccines	 is	 important	 information	 to	 inform	 the	 TPP.	 Duration	 of	 protection	 was	
assumed	to	be	2,	3,	5,	7,	10,	15,	20,	25	years	or	lifelong.	Duration	of	protection	was	
assumed	to	be	exact,	with	no	Immunosenescent	waning	in	elderly	populations.	
Vaccine	 implementation	 in	 China	 was	 assumed	 from	 2025	 to	 2050.	 Routine	 TB	
vaccination	was	delivered	to	nine	year	olds,	assumed	to	co-deliver	with	HPV	vaccine	
as	 part	 of	 the	 school-based	 vaccination	 platform.	 Although	 HPV	 is	 not	 currently	
implemented	 in	 China,	 WHO	 recommends	 delivery	 to	 ages	 9-13	 years,25	 and	
vaccination	at	the	lower	end	of	this	range	is	anticipated	long-term.26	Mass	campaigns	
vaccinating	 adolescents	 and	 adults	 (>9	 years	 old)	 were	 initiated	 in	 2025,	 and	
modelled	with	a	frequency	of	the	duration	of	protection	or	10	years,	whichever	was	
longer.	Although	this	covers	a	wider	age	group	than	might	be	anticipated	once	the	
vaccine	 is	 available,	 this	 ensures	 the	 peak	 ages	 of	 infection	 and	 disease	 will	 be	
covered	by	this	vaccination	campaign.	A	10-year	interval	between	mass	campaigns	
was	 considered	 the	 most	 feasible,	 informed	 by	 stakeholder	 experience	 of	 other	
campaigns.27,28	
As	 there	 is	 no	 existing	 HPV	 vaccination	 in	 China	 to	 inform	 coverage	 of	 routine	





















burden	 of	 disease,	 other	 care	 and	 prevention	 options	 available,	 and	 cost	 of	 the	
vaccine.	 China’s	 high	 DOTs	 coverage	 and	 treatment	 success	 leaves	 minimal	
opportunities	 for	 reducing	 burden	with	 currently	 available	 alternatives,	 therefore	
even	 relatively	 small	 reductions	 in	 disease	 burden	 through	 vaccine	 programmes	
could	 be	 of	 value.	 Discussion	 with	 stakeholders	 identified	 20-29%	 incidence	 rate	
reduction	in	2050	compared	to	no	new	vaccine	baseline	as	the	absolute	minimum	
level	of	impact	from	a	new	TB	vaccine	that	could	potentially	be	of	interest	(Personal	
communication,	Willem	Hanekom,	15th	December	2016).36	 This	was	 equivalent	 to	
reducing	incidence	from	a	modelled	no	new	vaccine	median	baseline	in	2050	of	34	
cases	per	100,000	population,	down	to	24-27	cases	per	100,000	population.		







between	 VE-POI	 and	 VE-POD,	 examples	were	 also	 given	 at	 the	 extremes	 of	 each	









level	 impact	 is	 the	 goal,	 if	measuring	 just	 one	 of	 these	 endpoints,	 it	 is	 helpful	 to	
understand	any	risks	of	making	stage-gating	decisions	based	upon	a	single	endpoint.	














median	 values	 and	 ranges	 for	 VE-POI	 and	 VE-POD	 required	 to	 achieve	 a	






3. Incidence	 rate	 reduction	 in	 2035	 compared	 to	 no	 new	 vaccine	 baseline	 and	
cumulative	cases	averted	2025-2035		
4. Maximum	achievable	and	 range	of	 incidence	 rate	 reduction	 for	 vaccines	with	
efficacy	POI-	or	POD-only	(as	distinct	from	efficacy	in	both).	













be	 highly	 effective	 but	with	 short	 duration	 of	 protection,	 there	may	 be	 sufficient	
political	 will	 to	 deliver	mass	 campaigns	more	 frequently.	 A	 scenario	 analysis	 was	










59.5)	per	100,000	 in	2025	to	33.8	 (UR:	27.8-37.9)	per	100,000	population	 in	2050	
(Figure	3.3).	During	the	same	period,	mortality	rates	were	predicted	to	decline	from	









































































































































































































































































































































































































































































































































































































































































































































































finding	 that	 China	 was	 demonstrated	 to	 be	 undergoing	 a	 transition	 from	 a	
transmission-driven	to	a	reactivation-driven	epidemic	(Figure	3.10).	In	2000,	28·6%	
(UR:	21·9-32·5)	of	all	cases	were	estimated	to	be	a	result	of	reactivation,	increasing	



















































With	 the	 profiles	 and	 implementation	 assumptions	 explored,	 new	 TB	 vaccines	
implemented	in	2025	reduced	incidence	rates	compared	to	a	no	new	vaccine	baseline	
by	a	maximum	of	79%	(UR:	77-81%)	by	2050,	reducing	incidence	to	7	(UR:	6-8)	cases	












infection	 and	 disease	 could	 achieve	 49%	 (UR:	 47-53%)	 IRR	 (Figure	 3.11,	 top	 right	
panel),	and	with	10	years	duration	of	protection	up	to	79%	(77-81%)	IRR	(Figure	3.11,	
centre	panel).	With	a	duration	of	protection	above	the	maximum	frequency	of	mass	
























all	 possible	 combinations	 that	 could	 potentially	 provide	 this	 level	 of	 impact.	 For	




Exploring	 the	 slightly	 higher	 incidence	 rate	 reduction	 of	 30-39%	 in	 2050,	median	
vaccine	characteristics	for	VE-POI	and	VE-POD	were	both	60%	(Table	3.2,	column	3).	
Comparison	with	 the	medians	 for	 20-29%	 incidence	 rate	 reduction	 demonstrated	
that	 an	 increase	 in	 protection	 against	 disease	 was	 most	 likely	 to	 provide	 the	
additional	impact.	However,	such	impact	is	achievable	even	with	no	vaccine	efficacy	
against	 infection	(lower	limit	of	VE-POI	=	0%),	as	long	as	sufficient	vaccine	efficacy	
against	disease	(60-80%)	 is	achieved.	Conversely,	 if	VE-POI	were	100%,	 it	could	be	
coupled	with	a	VE-POD	of	as	low	as	30%	(lower	limit	of	VE-POD	=	30%,	column	3)	to	















high	 as	 70-79%	 could	 be	 achieved,	 though	 would	 require	 a	 completely	 disease-
blocking	vaccine	(i.e.	VE-POD=100%).	





































VE-POD	 40%	(0-60%)	 60%	(30-80%)	 90%	(60-100%)	 100%	(100-100%)	 n/a	 n/a	
VE-POI	 60%	(0-100%)	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 n/a	 n/a	
10	year	duration	vaccine	(with	10	yearly	mass	campaigns)	
VE-POD	 10%	(0-30%)	 30%	(0-40%)	 40%	(20-50%)	 60%	(40-70%)	 80%	(60-80%)	 100%	(100-100%)	































































protection		 5	years	 10	years	 Consult	heat	maps	for	full	results.	
	
The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (20-29%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	





























The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (50-59%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	































The	 medians	 of	 VE-POI	 and	 VE-POD	 are	
indicative	 of	 the	 minimum	 profile	 considered	
highly	 likely	 to	 provide	 the	minimum	 required	
epidemiological	 impact	 (70-79%	TB	 IRR)	at	 the	
given	duration	of	protection.	Ranges	should	be	
interpreted	with	caution,	as	an	interaction	exists	
between	 these	 characteristics,	 therefore	 the	
minimums	of	 each	 range	 combined	would	not	
provide	sufficient	impact.	This	level	of	impact	is	
not	 possible	 with	 a	 5-year	 duration	 vaccine.	














of	 rate	 reduction	 and	 trends	 (Figure	 3.12).	 The	 MRRs	 for	 2-5	 years	 duration	 of	






























9.1m)	 cases	 and	 56,000	 (UR:	 30,000-100,000)	 to	 185,000	 (UR:	 101,000-333,000)	
deaths	 during	 2025-2050.	 For	 a	 10	 year	 protection	 vaccine,	 if	 VE-POI	 were	 then	
increased	to	80%,	an	additional	0.2	million	cases	would	be	averted;	whereas	if	instead	
VE-POD	were	increased	to	80%,	an	additional	1.7	million	cases	would	be	averted.		
Additional	 years	 of	 protection	 would	 also	 avoid	 additional	 cases	 and	 deaths.	 For	
example,	for	a	100%	VE-POD	vaccine	the	average	annual	additional	number	of	cases	
averted	 when	 increasing	 duration	 from	 two	 to	 three	 years	 is	 1.5	 million.	 With	
























points.	When	 comparing	 the	 percentage	 incidence	 rate	 reduction	 to	 the	 no	 new	
vaccine	baseline	in	2035,	a	marginally	lower	incidence	rate	reduction	was	estimated	
for	 durations	 of	 five	 years	 and	 above,	 whereas	 a	 higher	 percentage	 reduction	 in	
incidence	rate	was	estimated	in	2035	than	2050	for	the	two	and	three	year	durations	
of	protection.	This	is	due	to	the	timing	of	vaccine	waning	relative	to	the	time	point	at	


























and	 POI-only	 (VE-POD=0%)	 (Figure	 3.17,	 right	 panel),	 highlight	 again	 that	 for	
equivalent	profiles	the	achievable	impact	is	greater	with	a	POD	vaccine	than	POI.	
Assuming	 100%	 efficacy	 against	 disease	 (VE-POD=100%,	 VE-POI=0%),	 the	 10	 year	
duration	 of	 protection	 vaccine	 achieved	 78.4%	 (UR:	 76.6-80.4%)	 incidence	 rate	
reduction,	averting	11.6	(UR:	10.8-12.4)	million	cases	between	2025-2050.	Whereas	

















































60	 0	 2	 2.9	(2.4-3.8)	 0.8	(0.7-0.8)	
60	 0	 3	 4.3	(3.5-5.6)	 1.1	(1.0-1.1)	
60	 0	 5	 11.3	(9.3-14.6)	 1.6	(1.5-1.7)	
60	 0	 7	 17.0	(14.0-21.6)	 2.2	(1.9-2.6)	
60	 0	 10	 18.6	(15.4-23.7)	 2.5	(2.4-2.7)	
0	 60	 2	 5.6	(4.1-7.2)	 2.2	(1.9-2.4)	
0	 60	 3	 8.3	(6.1-10.6)	 3.1	(2.8-3.4)	
0	 60	 5	 31.7	(29.1-34.4)	 4.8	(4.4-5.1)	
0	 60	 7	 51.0	(48.8-53.2)	 6.0	(5.6-6.4)	









impact.	With	 disease	 endpoints	 as	 the	 trial	 outcome,	 70%	 (60-80%)	 VE-POD	was	
estimated	 to	 provide	 confidence	 in	 achieving	 30-39%	 incidence	 rate	 reduction	 in	







The	 highest	 achievable	 incidence	 rate	 reduction	 with	 100%	 efficacious	 vaccines	








disease	 and	 infection	 differ	 greatly	 between	 the	 three	 vaccine	 types.	 The	 post-
infection	 (PSI)	 vaccine	 contours	 are	 almost	 horizontal,	 indicating	 that	 the	 vaccine	
impact	comes	almost	exclusively	from	the	vaccine	efficacy	for	prevention	of	disease	
(Figure	 3.19,	 right	 panel).	 The	 incidence	 rate	 reduction	 outcome	 is	 much	 more	
sensitive	 to	both	 types	of	vaccine	efficacy	 for	a	PRI	vaccine	 (centre	panel),	with	a	
slightly	greater	sensitivity	to	vaccine	efficacy	for	prevention	of	infection.	Due	to	the	

























































































Increasing	 the	 frequency	 of	 mass	 campaigns	 to	 every	 5	 years	 improved	 the	
achievable	 impact	 in	 all	 duration	 scenarios	below	10	 years	duration	of	protection	
(Figure	3.21).	For	the	two-year	duration	of	protection	vaccines,	the	IRR	more	than	




was	 able	 to	 achieve	more	 than	 the	 absolute	minimum	 of	 20-29%	 incidence	 rate	





































VE-POD	 50%	(10-70%)	 70%	(50-90%)	 100%	(80-100%)	 Not	achievable	 Not	achievable	 Not	achievable	
VE-POI	 60%	(0-100%)	 50%	(0-100%)	 60%	(0-100%)	 Not	achievable	 Not	achievable	 Not	achievable	
5	year	duration	vaccine	(with	5	year	mass	campaigns)	
VE-POD	 10%	(0-30%)	 30%	(0-40%)	 40%	(20-50%)	 60%	(40-70%)	 90%	(80-100%)	 100%	(100-100%)	




A	 strategic,	 data-driven	 approach	 to	 the	development	 of	 new	TB	 vaccines	will	 be	
essential	to	ensure	evidence-based	maximisation	of	the	future	impact	of	TB	vaccines,	
by	 developing	 vaccines	 with	 the	 most	 appropriate	 characteristics	 and	 for	 the	
populations	most	in	need.	In	this	research,	I	explored	vaccine	intrinsic	characteristics	
in	the	target	product	profile	(duration	of	protection,	vaccine	efficacy	against	disease,	
and	 vaccine	 efficacy	 against	 infection)	 to	 estimate	 the	 potential	 population-level	







in	 2050,	 and	 impact	 was	 maximised	 when	 mass	 campaign	 frequency	 equalled	
duration	of	protection.		
















Alternatively,	 an	 implementation	 approach	 could	 be	 taken	 if	 longer	 trials	 are	 not	
feasible	 or	 a	 new	 vaccine	 is	 found	 to	 provide	 limited	 duration	 of	 protection.	 By	















of	 the	 population	 protected	 was	 similar.	 From	 an	 epidemiological	 perspective,	
investment	in	longer	duration	vaccines	would	not	necessarily	be	needed;	however,	
cost-effectiveness	 analyses	 would	 be	 required,	 as	 less	 frequent	 mass	 campaigns	
could	lead	to	large	cost	savings.	
During	the	2025-2050	vaccination	period,	most	new	TB	cases	were	attributable	to	
reactivation	 disease,	 many	 of	 which	 were	 likely	 infected	 before	 introduction	 of	
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vaccine.	Hence,	 the	 incidence	 rate	 reduction	achieved	by	P&PI	vaccines	was	most	
sensitive	 to	 vaccine	 efficacy	 for	 prevention	 of	 disease,	 with	 limited	 gains	 from	
increases	 in	 efficacy	 against	 infection.	 Although	 there	 was	 value	 in	 efficacy	 for	
prevention	of	infection,	in	this	setting	greater	population-level	gains	were	achieved	
by	 improving	 vaccine	 efficacy	 for	 preventing	 development	 of	 disease.	 Therefore,	




in	 2050	 by	 79%	 (77-81%)	 compared	 to	 the	 no	 new	 vaccine	 baseline,	 reaching	 an	
incidence	rate	of	7	(UR:	6-8)	per	100,000	population	and	averting	11.6	million	(UR:	
10.2-12.6m)	 cases	 and	 270,000	 (UR:	 145,000-483,000)	 deaths	 by	 2050.	 This	 is	 a	
sizeable	burden	of	disease	averted,	and	would	be	a	significant	contribution	towards	
the	WHO	elimination	goal	(incidence	of	1	case	per	million	population	by	2050),37	as	





rate	 reduction	 and	 cases	 averted	 should	 therefore	 be	 the	 strategic	 goal,	 but	 in	 a	
challenging	 development	 environment,	 identifying	 the	 minimum	 acceptable	
incidence	 rate	 reduction	 can	 inform	 vaccine	 characteristics	 in	 the	 TPP	 minimum	
profile,	and	hopefully	be	a	step	towards	more	efficacious	vaccines	in	the	future.		
Once	the	minimum	acceptable	incidence	rate	reduction	in	2050	has	been	chosen	by	
stakeholders,	 the	 appropriate	 section	 of	 Table	 3.4	 could	 be	 used	 within	 a	 target	
product	profile	or	preferred	product	characteristic	 table.	The	durations	to	achieve	
the	 absolute	 minimum	 impact	 and	 the	 duration	 above	 which	 minimal	 additional	




reduction,	 the	median	 and	 range	 of	 vaccine	 efficacy	 estimates	 for	 prevention	 of	
infection	and	for	prevention	of	disease	were	estimated.	The	median	values	provide	




of	 delivering	 the	 required	 impact.	 These	 are	 wide	 and	must	 be	 interpreted	 with	








there	 is	 a	 risk	 that	 a	 potentially	 suitable	 candidate	 could	 be	 discarded	 if	 VE-POD	
remained	unknown	and	VE-POI	were	 to	 fall	 below	 this	 high	 stage-gate	 threshold.	
Therefore,	in	China	trials	should	either	focus	on	VE-POD	endpoints,	or	include	both	
VE-POI	and	VE-POD	endpoints.	If	a	longer	duration	of	protection	were	expected	with	
a	 given	 vaccine,	 or	 both	 endpoints	 were	 measured	 and	 protection	 in	 both	 were	
anticipated,	lower	vaccine	efficacies	could	provide	sufficient	impact,	and	therefore	
studies	should	be	powered	to	measure	these	lower	efficacies.		
Target	 Product	 Profiles	 may	 be	 used	 for	 informing	 both	 clinical	 trial	 design	 and	
pipeline	 stage	 gating.	 Within	 the	 bounds	 of	 feasibility,	 clinical	 trials	 should	 be	








a	 given	 vaccine.	 The	 estimated	 impact	 can	 be	 benchmarked	 against	 a	 minimum	








the	 same	 improvement	 in	 VE-POI.	 Therefore,	 in	 this	 epidemiological	 setting,	
prioritisation	 of	 P&PI	 candidates	 with	 potential	 for	 prevention	 of	 disease	 activity	
would	be	rational.		
A	 similar	 number	 of	 cases	were	 averted	with	 100%	 vaccine	 efficacy	 against	 both	
infection	and	disease	with	two	years	duration	of	protection,	as	was	estimated	with	
20%	vaccine	efficacy	against	each	and	10	years	duration	of	protection.	Therefore,	it	
is	 possible	 to	 compensate	 for	 lower	 vaccine	 efficacies	 with	 higher	 durations	 of	
protection	and	vice	versa,	but	would	require	potentially	large	compensatory	changes.	
The	additional	gains	from	an	additional	year	of	protection	from	a	vaccine	tend	to	be	












protection	 from	 PSI	 and	 PRI	 vaccines,	 it	 is	 clear	 that	most	 impact	 from	 the	 P&PI	
vaccine	came	from	protection	against	disease	in	those	already	infected,	which	was	
consistent	with	baseline	 epidemiological	model	 outcomes	demonstrating	 that	 the	
majority	of	cases	in	China	were	reactivation	disease.	A	post-infection	vaccine	should	
be	 developed	 following	 a	 similar	 prevention	 of	 disease-focussed	 strategy	 as	 P&PI	
vaccines.	The	pre-infection	vaccine	was	almost	equally	sensitive	to	efficacy	against	
infection	 or	 disease,	 therefore	 clinical	 trials	 could	 benefit	 from	 including	 both	
endpoints	to	gauge	the	full	potential	of	such	vaccines.	
Incidence	rate	reductions	in	2050	were	the	primary	outcome	of	interest	in	this	study.	
However,	 several	 secondary	 outcomes	 helped	 provide	 a	 broader	 picture	 of	 the	
impact	of	the	vaccine	profiles.	Estimated	mortality	rate	reductions	were	similar	to	
the	 incidence	 rate	 reductions,	 with	 the	 exception	 of	 durations	 of	 five	 years	 and	
below,	in	which	mortality	rate	reductions	were	larger.	This	is	a	function	of	timing	of	





to	 the	 fact	 that	 an	 individual	 can	be	protected	 from	 recurring	 incident	 cases,	 but	
death	can	only	be	avoided	once.	A	similar	pattern	was	observed	when	comparing	
incidence	 rate	 reductions	 in	2035	 to	2050.	Mass	 vaccination	occurred	 in	2035,	 so	
unlike	2050	none	of	the	vaccines	had	waned	in	2035	(not	shown).		
Given	 the	 incidence	 rate	 reduction	 is	 sensitive	 to	 the	 relative	 timing	 of	 the	 last	




3.13	and	Figure	3.14	and	 range	 from	around	1.0	million	 (UR:	0.8-1.1m)	cases	and	
21,000	 (UR:	 11,000-38,000)	 deaths	up	 to	 11.6	million	 (UR:	 10.2-12.6m)	 cases	 and	
270,000	(UR:	145,000-483,000)	deaths	during	the	2025-2050	vaccination	period.		
Discussion	with	stakeholders	suggested	that	shorter	five-year	spacing	between	mass	
campaigns	 could	 be	 feasible	 in	 some	 settings.28	 Reducing	 the	 frequency	 of	 mass	
campaigns	 from	 10-yearly	 to	 5-yearly	 more	 than	 doubled	 the	 incidence	 rate	
reduction	achieved	by	2	year	protection	vaccines,	and	also	improved	the	incidence	
rate	 reductions	 achieved	 by	 the	 3-7	 year	 protection	 vaccines.	 Conducting	 mass	
campaigns	 this	 frequently	 over	 the	 long	 term	 could	 potentially	 prove	 incredibly	
costly,	and	a	challenge	to	sustain	momentum	in	the	campaigns,	especially	as	burden	







had	 comprehensively	 explored	 the	 influence	 of	 vaccine	 characteristics	 on	
epidemiological	impact.	Such	research	is	needed	to	help	maximise	vaccine	impact	by	
informing	 Target	 Product	 Profile	 ‘ideal’	 characteristics,	 and	 ensuring	 at	 least	 a	
minimum	required	 level	of	 impact	by	helping	 inform	 ‘minimum’	characteristics.	 In	
addition,	 only	 two	 mathematical	 models	 had	 explored	 vaccine	 impact	 with	 very	




prevention	of	 infection	vaccines.	The	 literature	to-date	was	divided	as	 to	whether	
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available.	 In	 the	 China	 model	 presented	 in	 this	 chapter,	 results	 supported	 the	






2009	 and	 2050.	 The	mass	 vaccination	 coverage	 assumption	 for	 China	 (73%)	 was	
similar	 to	 the	assumption	 in	our	model,	but	 routine	coverage	was	assumed	much	






(53.3%;	 UR:	 50.6-56.1).	 In	 the	 Knight	 study,	 approximately	 8	 million	 cases	 were	




was	 a	 global	 model	 exploring	 the	 importance	 of	 age-specificities	 in	 TB	 vaccine	
modelling.39		
The	Liu	study	compared	neonatal	vaccination	to	neonatal	plus	periodic	mass	all-age	
vaccination	 (‘mixed	 vaccination’)	 in	 China.38	 The	 mass	 revaccination	 frequencies	
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explored	were	mostly	shorter	(3-6	years)	than	were	considered	feasible	in	my	study	
(5-10	years).	Mass	campaign	coverages	were	 lower	 (10-40%)	 in	 the	Liu	 study,	but	
were	 coupled	 with	 very	 high	 routine	 neonatal	 coverage	 (70-95%),	 and	 optimistic	
vaccine	 characteristics	 (100%	 lifetime	 efficacy	 against	 infection)	 and	 timing	 of	
introduction	(2018).	Although	the	neonatal	campaigns	delivered	minimal	impact,	the	
mixed	vaccination	campaigns	initiated	in	2018	were	able	to	achieve	the	2035	WHO	
goal	 of	 an	 incidence	 rate	 of	 less	 than	 10	 cases	 per	million	 population.	 The	 100%	
efficacious	POI	vaccine	in	this	chapter	achieved	only	a	27%	(UR:	23-33%)	reduction	
compared	 to	 the	 no	 vaccine	 scenario	 by	 2035,	 but	 the	 comparatively	 greater	
incidence	reduction	in	the	Liu	study	was	due	to	the	very	optimistic	implementation,	
efficacy,	and	duration	of	protection	assumptions.	In	addition,	the	lack	of	relapse	after	




behaved	as	a	 ‘leaky’	vaccine.	As	will	be	discussed	 in	more	depth	 in	Chapter	4,	the	















to	achieve	a	minimum	acceptable	 level	of	 impact	 to	 inform	TB	vaccine	TPPs,	help	





and	 of	 the	 TB	 epidemic	 in	 China.	 Particularly	 important	 in	 developing	 such	 age	
structured	 projections	 were	 the	 calibration	 to	 age-stratified	 demographic	 and	
epidemiological	data,	through	age	structure	in	the	modelled	parameters,	 including	
age-wise	 contact	 patterns.	 At	 time	 of	 development,	 this	 was	 the	 first	 TB	 vaccine	
model	 to	 incorporate	heterogeneous	mixing	patterns	by	age.	A	 recent	publication	
has	 also	 incorporated	mixing	 patterns,	 but	 used	 European	 data	 for	 global	mixing	
patterns,39	whereas	 in	 this	model	 I	 improve	on	 this	by	using	contact	pattern	data	
specific	to	China.15		
3.5.4 Study	Limitations	
There	 were	 several	 limitations	 to	 this	 study,	 most	 of	 which	 relate	 to	 model	
assumptions	discussed	elsewhere,	but	are	mentioned	again	below.			
The	model	is	calibrated	to	a	series	of	age-stratified	country-level	data.	The	mortality	
rate	 estimates	 for	 China	 are	 relatively	 low	 given	 the	 disease	 rates,	 therefore	 to	
achieve	a	model	fit,	wide	mortality	rate	confidence	interval	targets	for	calibration	and	
a	relatively	low	case	fatality	rate	were	assumed.	This	should	have	minimal	impact	on	
the	 percentage	 mortality	 rate	 reduction,	 but	 means	 estimates	 of	 the	 number	 of	
deaths	averted	is	likely	an	underestimate.	
The	model	 assumes	geographically	homogenous	TB	epidemiology	 in	China,	 yet	 as	
highlighted	by	Gao	et	al.	this	is	known	not	to	be	the	reality.	At	this	stage	in	vaccine	
development,	 the	 regional	 level	 of	 granularity	 is	 not	 required	 for	 vaccine	
Chapter	3:	Epidemiological	impact	of	TB	vaccine	characteristics																	 156	
development	 decision-making	 and	 was	 therefore	 not	 required	 from	 this	 model.	




active	 TB	 remained	 constant	 throughout	 the	 study	 period.	 However,	 given	
socioeconomic	 improvements	 over	 time,	 this	 approach	 might	 underestimate	 the	
progression	rates	in	the	earlier	years	and	overestimate	them	in	to	the	future.		
In	 the	 current	 model	 structure,	 when	 recovered	 populations	 are	 reinfected	 they	
either	 develop	 primary	 disease	 or	 return	 to	 the	 latent	 state.	 Although	 this	 is	 an	
acceptable	assumption,	remaining	in	the	recovered	state	instead	of	returning	to	the	
latent	state	could	be	a	possible	alternative	assumption.	Given	the	reactivation	rates	
in	 recovered	 populations	 are	 generally	 assumed	 higher,	 this	 would	 likely	 lead	 to	




lead	 to	 entering	 the	 recovered	 state.	 Given	 the	majority	 of	 cases	 on	 appropriate	
treatment	 are	 thought	 to	 become	 non-infectious	 by	 two	 weeks	 on	 treatment,	














it	would	be	expected	 that	 the	overarching	 conclusions	presented	here	would	 still	
hold.	A	second	frequency	of	mass	vaccination	is	considered	in	the	scenario	analysis,	
but	others	may	be	possible	once	more	information	about	a	new	candidate’s	duration	
of	 protection	 and	 efficacy	 is	 known.	 As	 demonstrated	 in	 the	 scenario	 analysis,	
frequency	 of	 mass	 vaccination	 can	 have	 a	 substantial	 impact	 on	 the	 achievable	
population-level	impact	of	shorter	duration	vaccines.	
Modelled	 estimates	 of	 the	 median	 vaccine	 efficacy	 assumed	 10-yearly	 mass	
campaigns,	 and	 were	 made	 for	 the	 duration	 allowing	 the	 minimum	 acceptable	
impact	(5	years	protection)	and	the	duration	above	which	minimal	epidemiological	
gains	 were	 made	 (10	 years).	 However,	 if	 more	 frequent	 mass	 campaigns	 were	
considered	beneficial	and	affordable,	lower	vaccine	efficacies	could	be	acceptable,	as	
was	demonstrated	in	the	scenario	analysis.	Also,	if	a	higher	minimum	level	of	impact	




horizons	 can	 potentially	 influence	 the	 relative	 impact	 of	 pre-	 and	 post-infection	











This	 research	 highlights	 the	 need	 for	 careful	 consideration	 of	 the	 criteria	 for	 key	
vaccine	 characteristics	 such	 as	 duration	 of	 protection	 (keeping	 feasible	
implementation	 in	 mind),	 and	 vaccine	 efficacy	 against	 infection	 or	 disease	 when	
developing	TB	vaccine	Target	Product	Profile	and	Clinical	Development	Plans.	
For	 development	 strategists,	 such	 as	 BMGF,	 WHO,	 cross-product	 bodies	 and	
developers,	 a	 key	 implication	 of	 this	 research	 is	 the	 importance	 of	 efficacy	 for	
prevention	of	disease	for	maximising	impact	on	disease	burden	in	China	during	2025-
2050.	 Although	 there	 was	 some	 value	 in	 prevention	 of	 infection,	 vaccine	





Some	higher	 levels	of	 incidence	 rate	 reduction	were	only	achievable	with	at	 least	
some	vaccine	efficacy	against	disease.	Therefore,	an	infection	outcome	would	not	be	
sufficient	to	guarantee	these	higher	levels	of	impact.	If	high	levels	of	incidence	rate	










2-3	years	of	 a	phase	 IIB	 trial.	 For	example,	phase	 II	 clinical	 trials	 could	 include	an	


















computing	time/capacity.	The	time	step	in	the	model	is	given	by	i = #$(&'()'	+,()).' + 1	
for	the	first	time	step	of	the	year	and	i = #$(&'()'	+,()).' + 2	for	the	second	time	step	
of	the	year.		
New-borns	(births)	in	year	k	(B[k])	entered	the	population	as	uninfected	at	the	start	
of	 the	 year.	 Life	 span	 was	 limited	 to	 no	 more	 than	 100	 years.	 Following	 the	
methodology	 of	 Schenzle	 (1984),40	 ageing	 was	 implemented	 in	 the	 model	 on	 an	
annual	basis	by	transitioning	the	population	in	a	given	sub-population	of	age	j,	to	the	
same	sub-population	of	age	j+1	at	the	very	end	of	each	year.	








7 8, 9 = :;<= : >, ? @ A 8, ? + AB 8, 9C 8, ?DEFDGHIDEJ 	
Where	 C 8, ? = 	 K 8, 9 + L 8, 9 + A 8, 9 + MA 8, 9 + N 8, 9 + KB 8, 9 +OEOPQROEOPSFLB 8, 9 + AB 8, 9 + MAT 8, 9 + NB 8, 9 .	
nygrp	was	the	number	of	contact	age	groups,	m	was	the	age	group	of	the	individual	
exposed	 to	 infection	 (including	 age	 j),	 y	was	 age	 group	 of	 contacts,	:[>, ?] 	was	
number	of	respiratory	contacts	of	age	group	m	with	contacts	of	age	group	y,	:;<=	
was	the	calibration	factor	for	model	fitting,	@	was	the	probability	of	transmission	per	









step	of	a	given	year.	 In	the	middle	of	 the	year,	 the	only	transitions	 for	vaccinated	
populations	were	between	states	within	the	vaccinated	stratum.	As	the	vaccine	was	








and	 prevention	 of	 disease	 efficacy	 (effD)	 reduced	 the	 parameters	 for	
reactivation/relapse	from	latency	and	recovered	(v	and	r)	and	proportion	developing	
primary	active	disease	(p)	by	1-effD.	For	vaccines	only	efficacious	when	delivered	pre-
infection	 (PRI),	25	and	26	were	 zero.	 For	 vaccines	 only	 efficacious	when	 delivered	
post-infection	(PSI),	23	was	zero,	therefore	KB 	remained	at	zero.	For	those	vaccines	
efficacious	both	pre-	and	post-infection,	the	vaccine	was	delivered	to	all	groups	that	
did	 not	 have	 active	 disease	 (i.e.	 non-zero	 and	 equal	 numbers	 for	23, 25	and	26 ).	





K 8, 9 	= 	K 8 − 1, 9 −	(] 9 + 7 8 − 1, 9 )K 8 − 1, 9 X^	
Latent	
L 8, 9 	= 	L 8 − 1, 9 + 7 8 − 1, 9 1 − _[9] K 8 − 1, 9 + `N 8 − 1, 9 X^−	 a 9 + 7 8 − 1, 9 _ 9 ` + ][9] L 8 − 1, 9 X^	
New	infectious	active	TB	cases	




bcd_MA 8, 9 = 	7 8 − 1, 9 _ 9 (1− f 9 ) K 8 − 1, 9 + `L 8 − 1, 9 + `N 8 − 1, 9 X^ + 	a 9 (1− f 9 )L 8 − 1, 9 X^ + g 9 (1 − f 9 )N 8 − 1, 9 X^	
Infectious	active	TB	cases	
A 8, 9 = A 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W] bcd_A 8, 9−	 b 9 + ] 9 + ]8[9] A 8 − 1, 9 X^	
Non-infectious	active	TB	cases	
MA 8, 9 = MA 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MA 8, 9−	 b 9 + ] 9 + ]b8 9 + d MA 8 − 1, 9 X^	
Recovered	









LB 8, 9 	= 	 LB 8 − 1, 9+ 1 − cffA 7 8 − 1, 9 1 − 1 − cffi _[9] KB 8 − 1, 9+ `NB 8 − 1, 9 X^−	 1 − cffi a 9 + 1 − cffA 7 8 − 1, 9 × 1 − cffi _ 9 `+ ][9] LB 8 − 1, 9 X^	
New	vaccinated	infectious	active	TB	cases	
bcd_AB 8, 9 = 	 1 − cffA 7 8 − 1, 9 1 − cffi _ 9 f 9 KB 8 − 1, 9+ `LB 8 − 1, 9 + `NB 8 − 1, 9 X^+	 1 − cffi a 9 f 9 LB 8 − 1, 9 X^+ 1 − cffi g 9 f 9 NB 8 − 1, 9 X^ + dMAB 8 − 1, 9 X^	
New	vaccinated	non-infectious	active	TB	cases	
bcd_MAB 8, 9 = 	 1 − cffA 7 8 − 1, 9 1 − cffi _ 9 (1− f 9 ) KB 8 − 1, 9 + `LB 8 − 1, 9 + `NB 8 − 1, 9 X^+	 1 − cffi a 9 (1 − f 9 )LB 8 − 1, 9 X^ + 1 − cffD g 9 (1− f 9 )NB 8 − 1, 9 X^	
Vaccinated	infectious	active	TB	cases	
AB 8, 9 = AB 8 − 1, 9 +	 1 − hiN[W, 9]×hkC[W] bcd_AB 8, 9−	 b 9 + ] 9 + ]8[9] AB 8 − 1, 9 X^	
Vaccinated	non-infectious	active	TB	cases	









If	j=1:	K 8, 1 = m	
If	j≠1:	
K 8, 9 	= 	K 8 − 1, 9 − 1 − ] 9 − 1 + 7 8 − 1, 9 − 1 K 8 − 1, 9 X^− 23 W, 9 K 8 − 1, 9 − 1 + X[W, 9] 1 − 23 W, 9 )KB 8 − 1, 9 − 1 	
Latent	
L 8, 9 	= L 8 − 1, 9 − 1+ 	7 8 − 1, 9 − 1 1 − _ 9 − 1 K 8 − 1, 9 − 1 + `N 8 − 1, 9 X^− (a 9 − 1 + 7 8 − 1, 9 − 1 _ 9 − 1 ` + ] 9 − 1 )L 8 − 1, 9 − 1 X^− 25 W, 9 L 8 − 1, 9 − 1 + X[W, 9] 1 − 25 W, 9 )LB 8 − 1, 9 − 1 	
New	infectious	active	TB	cases	




bcd_MA[8, 9] = 	7 8 − 1, 9 − 1 _ 9 − 1 (1− f 9 − 1 ) K 8 − 1, 9 − 1 + `L 8 − 1, 9 − 1 + `N 8 − 1, 9 − 1 X^+ 	a 9 − 1 (1 − f 9 − 1 )L 8 − 1, 9 − 1 X^ + g 9 − 1 (1− f 9 − 1 )N 8 − 1, 9 − 1 X^	
Infectious	active	TB	cases	
A 8, 9 = A 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W] bcd_A 8, 9−	 b 9 − 1 + ] 9 − 1 + ]8[9 − 1] A 8 − 1, 9 − 1 X^+ X[W, 9]AB 8 − 1, 9 − 1 	
Non-infectious	active	TB	cases	
MA 8, 9 = MA 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MA 8, 9−	 b 9 − 1 + ] 9 − 1 + ]b8 9 − 1 + d MA 8 − 1, 9 − 1 X^+ X[W, 9]MAB 8 − 1, 9 − 1 	
Recovered	
N 8, 9 = N 8 − 1, 9 − 1 + 	b 9 − 1 A 8 − 1, 9 − 1 + MA 8 − 1, 9 − 1 X^+	 hiN[W, 9]×hkC[W] bcd_A 8, 9 + c×bcd_MA 8, 9−	 g 9 − 1 + 7 8 − 1, 9 − 1 ` + ] 9 − 1 N 8 − 1, 9 − 1 X^− 26 W, 9 N 8 − 1, 9 − 1 + X[W, 9] 1 − 26 W, 9 )NB 8 − 1, 9 − 1 	
Vaccinated	(first	time	step	of	the	year)	
Vaccinated	susceptibles	




LB 8, 9 	= 	 LB 8 − 1, 9 − 1+ 1 − cffA 7 8 − 1, 9 − 1 1 − 1 − cffi _[9− 1] KB 8 − 1, 9 − 1 + `NB 8 − 1, 9 − 1 X^−	 1 − cffi a 9 − 1+ 1 − cffA 7 8 − 1, 9 − 1 )× 1 − cffi _ 9 − 1 ` + ][9 − 1] LB 8− 1, 9 − 1 X^ + 25 W, 9 L 8 − 1, 9 − 1− X[W, 9] 1 − 25 W, 9 )LB 8 − 1, 9 − 1 	
New	vaccinated	infectious	active	TB	cases	
bcd_AB 8, 9 = 	 1 − cffA 7 8 − 1, 9 − 1 1 − cffi _ 9 − 1 f 9− 1 KB 8 − 1, 9 − 1 + `LB 8 − 1, 9 − 1 + `NB 8 − 1, 9 − 1 X^+	 1 − cffi a 9 − 1 f 9 − 1 LB 8 − 1, 9 − 1 X^+ 1 − cffi g 9 − 1 f 9 − 1 NB 8 − 1, 9 − 1 X^+ dMAB 8 − 1, 9 − 1 X^	
New	vaccinated	non-infectious	active	TB	cases	
bcd_MAB 8, 9 = 	 1 − cffA 7 8 − 1, 9 − 1 1 − cffi _ 9 − 1 (1− f 9 − 1 ) KB 8 − 1, 9 − 1 + `LB 8 − 1, 9 − 1+ `NB 8 − 1, 9 − 1 X^ +	 1 − cffi a 9 − 1 (1− f 9 − 1 )LB 8 − 1, 9 − 1 X^ + 1 − cffi g 9 − 1 (1− f 9 − 1 )NB 8 − 1, 9 − 1 X^	
Vaccinated	infectious	active	TB	cases	




MAB 8, 9 = MAB 8 − 1, 9 − 1 +	 1 − hiN[W, 9]×hkC[W]×c bcd_MAB 8, 9−	 b 9 − 1 + ] 9 − 1 + ]b8 9 − 1 + d MAB 8 − 1, 9 − 1 X^− X[W, 9]MAB 8 − 1, 9 − 1 	
Vaccinated	recovered	













active	 disease	 due	 to	 latent	 infection	 (x)	 and	 conversion	 from	 non-infectious	 to	
infectious	 active	 case	 (w).	 These	were	modelled	with	 the	 same	 value	 for	 all	 ages	
based	on	estimates	from	the	literature.	The	ranges	sampled	from	during	calibration	
were	in-line	with	values	applied	in	Knight	et	al.	and	historical	literature.1,13,41		




differences	 were	 calibrated	 separately	 for	 each	 age	 group.	 These	 included	 the	
proportion	 progressing	 directly	 to	 active	 disease	 (p),	 proportion	 developing	
infectious	disease	(f),	risk	of	reactivation	of	latent	infection	or	relapse	of	recovered	
disease	 (v	 and	 r),	 risk	 of	 natural	 cure	 from	 active	 disease	 (n)	 and	 an	 age-wise	




Where	 available,	 parameter	 ranges	 for	 calibration	 were	 based	 upon	 available	





the	 upper	 bound	 of	 immunosenescence	 in	 old	 age	 (Richard	 Aspinall,	 oral	





values	 of	 the	 HIV-positive	 parameters	 (see	 Table	 3.7).	 Immune	 senescence	 is	 a	
gradual	 process,	 therefore	 to	 smooth	 the	 transition	 between	 adult	 and	 elderly	
parameters	for	v,	r,	and	n,	55-64	year	olds	were	programmed	to	take	the	mean	of	the	
15-54	years	and	elderly	calibrated	values.		
In	model	 calibration,	 the	 age-specific	 values	 for	 a	 given	parameter	were	 sampled	
independently.	Where	data	or	biological	plausibility	were	suggestive	of	an	age-wise	
relationship	between	parameters,	constraints	were	set	to	ensure	only	parameter	sets	
adhering	 to	 those	 relationships	were	 retained.	 For	 example,	 given	 TB	mortality	 is	
higher	 at	 the	 age	 extremes,43	 parameter	 sets	were	 only	 retained	 if	 the	 child	 and	
elderly	TB	mortality	calibration	factors	(uiscaleC	and	uiscaleE)	were	greater	than	or	
equal	to	the	adult	parameter	(uiscaleA).		




disease,45	 many	 present	 atypically	 with	 minimal	 pulmonary	 symptoms.45,46	 In	
addition,	 an	 increasing	 proportion	 of	 extrapulmonary	 disease	 is	 observed	 with	
increasing	age	in	this	population.43,47		
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The	 proportion	 of	 the	 population	 directly	 developing	 primary	 disease	 (p)	 and	











Two	 fitting	 factors	 (rmortTB	 and	 uiscale)	 were	 employed	 for	 calibration	 of	 TB	
mortality	in	infectious	and	non-infectious	disease	(ui	and	uni).	First	TB	mortality	was	





basis	 for	 the	 demographic	 structure	 of	 the	modelled	 population.	 The	model	 was	
initiated	 in	1900,	with	 initiation	population	 size	 (p0)	 set	 as	part	of	 the	 calibration	
process	(see	3.6.3.1).	The	‘burn	in’	period	(1900-1999)	ahead	of	the	period	of	interest	
(2000-2050)	 ensured	 the	populations	 in	 the	 calibration	 (2000-2010)	 and	outcome	
(2025-2050)	 periods	 had	 appropriate	 levels	 of	 historical	 exposure	 to	 produce	
relevant	age-wise	rates	of	infection	and	disease.		
Demographic	data	were	obtained	 from	the	UN	population	division	2012	revision.4	
The	 initial	 model	 birth	 rate	 was	 calculated	 by	 dividing	 UN	 average	 annual	 birth	
estimates	for	1975-1980	by	the	UN	reported	1980	population	of	China.4	The	initial	
Chapter	3:	Epidemiological	impact	of	TB	vaccine	characteristics																	 172	
birth	 rate	was	 implemented	 from	 initiation	 to	1989.	To	account	 for	 the	 impact	of	
China’s	 one-child	 policy,	 a	 lower	 birth	 rate	 (based	 upon	 2010	 estimates)	 was	
implemented	from	1990-2009.	Although	the	one-child	policy	was	introduced	in	1979,	
data	 indicate	policy	 implementation	was	not	 instantaneous,	as	birth	 rates	did	not	
begin	to	decline	until	1989/1990,	therefore	the	lower	birth	rates	were	implemented	


















Parameter	 Symbol	 Description	 Prior	proposal	range	and	constraints	 References	 Parameter	 range	




death	 B[k]	 Number	 of	 births	 in	year	k	
Birth	rate	calculated	from	UN	fertility	and	
population	 estimates	 and	 applied	 to	
modelled	population.	1980s	birth	rate	pre-












Death	 rate	 calculated	 from	 UN	 life	
expectancy	estimates	by	age	for	China	and	










































































Constraint:	Parameter	 set	only	 retained	 if	








































v[	 j≥65]	=	0.0001	 -	 0.04	 (adult,	 and	up	 to	
lower	bound	of	HIV-positives)	
	
Constraint:	Parameter	 set	only	 retained	 if	


























elderly	 study,	 range	 from	 adult	 and	 HIV-
positive	ranges)	
	
Constraint:	Parameter	 set	only	 retained	 if	
adult	parameter	selected	was	greater	than	
or	equal	to	elderly	parameter.	





























































Constraint:	 Parameter	 set	 only	 retained	 if	 child	 and	 elderly	
















Constraint:	Parameter	 set	only	 retained	 if	
adult	parameter	selected	was	greater	than	
or	equal	to	elderly	parameter.	





























Previous	 TB	 vaccine	models	 have	 assumed	 homogenous	 random	mixing	 patterns	
within	 modelled	 populations,1,41,52,59	 but	 such	 homogenous	 mixing	 does	 not	







The	Read	 study	estimated	 the	 total	 and	average	daily	number	of	 contacts	by	age	
strata	(0-5,	6-19,	20-64	and	≥	65years)	from	contact	diaries,	in	a	study	enrolling	1821	
participants	 from	 southern	 China.15	 Contacts	 were	 defined	 as	 face-to-face	




64	 years	 age	 group	 (Figure	 3.22,	 left).15	 Importantly,	 the	 total	 number	 of	 daily	





the	term	! ", $ .	This	is	a	matrix	of	the	average	number	of	contacts	per	person	per	
day	between	an	individual	in	the	participant	group	(m)	and	individuals	in	a	contact	
age	group	(y)	(cym)	(Figure	3.22).	In	the	calibration	process,	this	matrix	is	multiplied	
by	 a	 scaling	 factor	 (ncal).	 Reporting	or	 participation	biases	 in	 the	 study	produced	
asymmetry	in	the	number	of	contacts	between	pairs	of	age	groups	in	the	reported	
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contact	matrix	 (Figure	3.22,	 left).15	 Symmetry	was	achieved	using	 the	methods	of	
Baguelin	 et	 al.,60	 by	 estimating	 the	 total	 number	 of	 contacts	 from	 all	 subjects	 in	
participant	age	group	m	with	contact	age	group	y,	and	for	the	age	groups	reversed,	
taking	an	average	of	the	two,	and	converting	back	to	a	contact	rate	by	dividing	the	
number	of	 contacts	by	 the	 size	of	 the	participant	age	group	 (equation	below	and	
Figure	3.22,	right):	
%&'	 = *+ (-&' ∗ /') +	(-'& ∗ /&) /'				
where	-&'	is	average	number	of	contacts	of	participants	in	group	m	with	people	in	
group	y,	-'&	is		average	number	of	contacts	of	participants	in	group	y	with	people	in	




by	 the	 proportion	 of	 the	 contact	 population	 that	 are	 infected	 2 3,45[3,4] .	 These	 are	
summed	over	the	contact	age	groups	to	give	Mtb	transmission	risk	(force	of	infection)	















rate	 (CDR)	 may	 be	 lower	 in	 elderly	 populations	 than	 adults,	 due	 to	 diagnostic	
difficulties	and	reduced	access	to	care.61	Age-wise	differences	were	reflected	in	the	
model	by	exploring	age-specific	CDR	calibration	factors	for	<55	years	and	the	elderly,	
with	 parameter	 sets	 retained	 only	 if	 adult	 CDR	was	 at	 least	 equal	 to	 the	 elderly	
parameter.	An	older	adult	calibration	factor	was	calculated	as	the	mean	of	the	adult	
and	 elderly	 factors.	 These	 older	 adult	 parameters	 were	 to	 allow	 a	more	 gradual	
parameter	transition	in	to	old	age.		
Although	case	detection	estimates	 fluctuated	over	 time,	 the	data	 suggest	a	 large,	




















given	the	high	 levels	of	treatment	success	 (95%)	reported	 in	recent	years,16,17	and	
that	 only	 3.6%	of	 the	 197	 countries	 studied	 in	 Knight	 et	 al.	 report	 a	 higher	 2011	


































CDRscale[j	 ≥	 55,	 <65]	 =	
0.09	–	0.28	
	























A	 two-stage	 calibration	 process	 was	 employed,	 with	 the	 first	 stage	 a	 manual	
calibration	to	age-stratified	UN	population	projections	for	2010	and	2050,18	and	the	





model	 was	 adjusted	 to	 align	 with	 the	 overall	 population	 size	 and	 four	 age	
stratifications	(0-14	years,	15-54	years,	55-64	years	and	³65	years)	at	these	two	time	
points.	Uncertainty	ranges	were	only	available	for	0-14	years	and	15-54	years,	as	UN	














All	 1,359,822	 n/a	 n/a	
0-14	 246,707	 n/a	 n/a	
15-54	 863,710	 n/a	 n/a	
55-64	 135,859	 n/a	 n/a	
65+	 113,546	 n/a	 n/a	
2050	
All	 1,384,976	 1,208,829	 1,579,558	
0-14	 204,187	 124,968	 300,552	
15-54	 623,982	 527,054	 722,200	
55-64	 225,492	 n/a	 n/a	




adjustment	 of	 the	 population	 size	 at	model	 initiation	 (p0)	 and	 a	 fitting	 factor	 for	
mortality	 rates	 (rmort).	 The	 fitted	 values,	 which	 gave	 the	 best	 overall	 fit	 to	 the	
selected	calibration	data	were	1,267,142	million	 for	p0	and	 -0.6	 for	 rmort.	Model	
demographic	fits	are	shown	in	Figure	3.7.	
3.6.3.2 Epidemiological	calibration	targets	
Estimates	 and	 confidence	 intervals	 around	 age-stratified	 prevalence	 of	
bacteriologically-positive	 pulmonary	 TB	 disease	 were	 obtained	 from	 national	
prevalence	surveys	conducted	in	2000	and	2010,	reported	in	Wang	et	al.	 (2014).19	
Data	 from	 the	 1990	 survey	 were	 not	 used,	 as	 the	 diagnostic	 protocol	 was	 less	
sensitive,	and	age-stratified	data	were	not	reported.	Although	all-TB	prevalence	rates	
were	 available,	 clinically	 diagnosed	 TB	 included	 in	 these	 estimates	 was	 likely	 an	
overestimate	of	true	prevalence	due	to	over	diagnosis	based	on	clinical	signs,	and	did	
not	align	well	with	the	disease	states	in	the	model.	Therefore,	calibration	was	to	the	
biologically-positive	 prevalence	 data,	 as	 these	 most	 closely	 represented	 the	
infectious	disease	state	in	the	model	(I).	
Disease	Surveillance	Point	data,	considered	nationally	representative,	were	used	to	






uncertainty	 ranges	 for	 calibration	were	 based	 upon	 estimates	 of	 under	 reporting	
from	other	 data	 sources.	 Causes	 of	misclassification	 of	 TB	 deaths	 include	HIV	 co-
infection	and	malnourishment,	and	occur	more	frequently	in	deaths	at	home	or	in	
rural	 areas.	Wang	 et	 al.	 and	 Yang	 et	 al.	 estimated	 TB	mortality	mis-classification	
(underestimation)	 in	 China,	 particularly	 due	 to	 miscoding	 as	 pneumonia,62	 at	
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approximately	50%.63,64	Therefore	the	upper	range	of	the	calibration	ranges	was	set	





therefore	 age-specific	 notification	 rates	 of	 all	 TB	 (including	 smear	 positive,	 smear	
negative,	 and	 extra-pulmonary	 TB)	were	 employed	 for	model	 fitting.20	Up	 to	 20%	
over-reporting	 of	 notifications	may	 occur	 due	 to	 the	 use	 of	 clinical	 algorithms	 as	
opposed	 to	 biological	 testing	 for	 diagnosis.	 Up	 to	 20%	 under-reporting	 was	
estimated,	 as	 it	 was	 assumed	 that	 the	 reported	 data	 only	 captured	 public	 (CDC)	
notifications,	which	constitute	80%	of	cases,	and	also	cases	that	are	asymptomatic	or	
do	 not	 exhibit	 standard	 symptoms	 may	 be	 missed.65,66	 Therefore,	 confidence	
intervals	 for	 calibration	 were	 +/-20%	 of	 the	 WHO-reported	 notification	 point	
estimates.17	
To	ensure	an	appropriate	case	detection	rate	in	the	fitting	process,	the	model	was	






















was	 implemented.	 One	 million	 parameter	 sets	 were	 randomly	 selected	 from	
literature-informed	 prior	 ranges	 and	 run	 through	 the	 ‘no	 new	 vaccine’	 baseline	
model.	Such	a	large	number	of	parameter	sets	ensured	thorough	exploration	of	the	
parameter	space.	Variances	were	estimated	for	the	calibration	data,	assuming	the	





calibration	 ranges	 of	 all	 18	 epidemiological	 data	 points	 (Table	 3.10).	



























All	 63.9	 51.1	 76.7	
0-14	 2.7	 2.2	 3.2	
15-54	 64.6	 51.7	 77.5	
55-64	 104.4	 83.5	 125.2	




All	 3.37	 1.69	 5.06	
0-14	 0.29	 0.15	 0.44	
15-59	 1.91	 0.96	 2.87	






³15	 178	 163	 195	
15-29	 92	 72	 116	
30-59	 155	 126	 189	
60+	 596	 510	 698	
2010	
³15	 116	 101	 132	
15-29	 59	 40	 86	
30-59	 99	 77	 129	
60+	 346	 294	 407	
All	age	TB	incidence	rate	





likely	date	of	 implementation	of	 a	new	vaccine.	Modelled	 characteristics	of	novel	
vaccines	have	previously	been	categorised	within	four	dimensions:	the	host	infection	










in	never-infected	 individuals	 (!" > 0, !& = 0, !( = 0).	 Post-infection	 (PSI)	 vaccines	
were	assumed	efficacious	when	delivered	to	either	latently	infected	populations	or	
those	who	 had	 recovered	 from	 active	 disease	 (!" = 0, !& > 0, !( > 0).	 A	 vaccine	
effective	pre-	and	post	infection	(P&PI),	producing	immunity	in	all	except	those	with	
active	 disease	 (!" > 0, !& > 0, !( > 0 ),	 was	 modelled	 to	 estimate	 the	 greatest	
preventative	 vaccine	 impact	 given	 the	 efficacy	 and	 other	 vaccine	 parameters.		















PRI	 Yes	 No	 No	 No	
PSI	 No	 Yes	 No	 Yes	




reduced	 the	 infection	 parameter,	 and	 prevention	 of	 disease	 vaccine	 reduced	 the	
parameters	 for	 development	 of	 disease	 (proportion	 developing	 primary	 active	
disease,	 and	 risk	 of	 reactivation	 from	 latent	 and	 recovered	 classes).	 Modelled	
vaccines	 did	 not	 affect	 infectiousness	 of	 disease,	 severity	 of	 disease,	 case	 fatality	
ratio,	likelihood	of	natural	cure,	or	case	detection.	
As	 the	 research	question	 aimed	 to	 explore	 the	 impact	 of	 a	 comprehensive	 set	 of	
vaccine	efficacies,	the	full	range	of	vaccine	efficacies	from	0%	to	100%,	in	10%	steps,	







longer,69	 it	 is	possible	that	these	 longer	durations	of	protection	would	be	possible	




The	 model	 that	 the	 basic	 structure	 was	 developed	 from	modelled	 all-or-nothing	
prevention	 of	 disease	 vaccines,1	 meaning	 that	 the	 proportion	 moved	 to	 the	
vaccinated	 stratum	was	vaccine	efficacy	 scaled	by	 coverage	 (‘effective	 coverage’),	
with	 the	 vaccinated	 stratum	 100%	 protected	 against	 disease.	 The	 different	
assumption	modeled	here	was	of	 ‘leaky’	vaccine	efficacy,	 in	which	 the	proportion	





latent	 (v)	and	recovered	classes	 (r).	 In	 this	 leaky	protection	model,	 the	vaccinated	




to	 have	 greater	 impact	 than	 leaky	 vaccines.70	 Therefore,	 to	 ensure	 conservative	
estimates	in	this	model,	which	is	important	when	estimating	the	potential	achievable	
impact	 of	 a	 vaccine,	 a	 leaky	 vaccine	 was	 more	 appropriate.70	 Secondly,	 from	 a	
technical	 perspective,	 all-or-nothing	 vaccination	 could	 not	 be	 used	 to	 model	 a	
vaccine	with	simultaneous	efficacy	against	infection	and	disease,	as	is	the	research	










vaccination	 platform,	 mass	 vaccination	 of	 adolescents	 and	 adults	 was	 to	 ensure	






(87%).30,31	 Coverage	 of	 mass	 vaccination	 was	 modelled	 at	 70%,	 based	 upon	








In	 recent	modelling	 to	 inform	TB	antimicrobial	 TPPs,	 given	 there	was	an	effective	









estimates	 of	 the	 values	 of	 the	 duration	 and	 vaccine	 efficacies	 for	 prevention	 of	
infection	and	disease	characteristics	required	to	achieve	pre-defined	levels	of	impact	
were	 required.	 Given	 the	 interdependence	 of	 these	 three	 characteristics,	 two	
durations	of	protection	were	identified	(see	3.3.5),	and	median	values	and	ranges	for	
the	prevention	of	 infection	and	disease	characteristics	required	to	achieve	a	given	
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Accordingly,	 vaccine	 implementation	 in	 Chapter	 3	 was	 modelled	 as	 routine	
vaccination	of	9	year	olds	alongside	HPV	vaccination,	with	periodic	mass	vaccination	
of	adolescents/adults.	This	takes	advantage	of	a	 likely	future	vaccination	platform,	






the	 age	 distribution	 of	 TB	 in	 China	 between	 2000	 and	 2050.	 In	 2000,	most	 cases	
occurred	in	the	15-64	year	old	age	group	(75.8%;	UR:	71.3-81.0);	whereas	by	2050,	
74.5%	(UR:	70.2-78.6)	were	estimated	to	occur	in	the	elderly	(≥65	years	old).	This	was	













and	 there	 are	 no	 candidates	 recruiting	 the	 elderly.	 Older	 age	 groups	 tend	 to	 be	
excluded	due	to	uncertainty	with	regards	to	safety	and	immunogenicity.	However,	
the	robust	efficacy	achieved	zoster	vaccines	in	older	adults	and	the	elderly	provides	
precedent	 for	 considering	 TB	 vaccine	 development	 in	 older	 age	 groups.10,11	
Therefore,	 results	 of	 this	 study	 are	 of	 importance	 for	 informing	 recruitment	






Aim	 1:	 Generate	 mathematical	 models	 of	 age-stratified	 demography	 and	 TB	












To	 explore	 age	 targeting,	 in	 the	 following	 research	 adolescent	 vaccines	 were	
routinely	delivered	to	15	year	olds,	and	older	adult	vaccines	to	60	year	olds,	with	a	
one-off	3-year	mass	campaign	of	ages	16-19	and	61-64	year	olds.	Selection	of	these	
vaccination	 ages	 took	 into	 consideration	 the	 high	 burden	 age	 groups	 observed	 in	
Chapter	 3,	 logistical	 feasibility	 of	 delivery,	 the	 adolescent	 age	 group	 of	 current	
strategic	 focus,	 and	 safety	 considerations	 for	 the	older	 age	group.	 To	explore	 the	






















expert	 opinion,	 these	were	 considered	 a	 likely	 and	 an	 optimistic	 scenario	 for	 the	
duration	 of	 protection,	 and	 allowed	 exploration	 of	 the	 impact	 of	 targeted	
vaccination.	In	Chapter	3,	waning	occurred	exactly	at	the	duration	of	protection	for	
all	individuals	and	was	not	altered	by	the	age	of	the	vaccinated	individual.	This	was	
improved	 to	more	 closely	 reflect	biological	 variation	 in	 this	 chapter,	 by	modelling	
waning	at	the	population	level	as	normally	distributed	around	the	mean	duration	of	
protection,	with	a	 standard	deviation	of	10%	of	 the	mean.	 Secondly,	 in	older	 age	
groups	it	is	biologically	plausible	that	immunosenescence	could	lead	to	more	rapid	
waning	 of	 protection.	 To	 avoid	 bias	 towards	 older	 adult	 vaccination,	
immunosenescent	waning	was	represented	by	accelerated	waning	in	the	population	











































Paper	 2:	 New	 tuberculosis	 vaccines	 –	 the	 impact	 of	 age	 targeted	 vaccination	 in	
China	and	implications	for	vaccine	development	
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I	substantially	modified	the	model	with	guidance	from	Prof.	Richard	White,	Dr	Tom	
Sumner	 and	 Dr	 Gwenan	 Knight,	 including	 development	 of	 age	 structure	 and	
parameterisation,	 calibration	 to	 age	 stratified	 epidemiological	 (prevalence,	
notifications,	 mortality	 and	 incidence)	 and	 demographic	 calibration	 targets,	 age	
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(15-19	 years)	 or	 older	 adults	 (60-64	 years)	 and	 varying	 vaccine	 characteristics,	 to	
inform	strategic	vaccine	development.	
Methods:	A	Mycobacterium	tuberculosis	transmission	model	was	calibrated	to	age-
stratified	 demographic	 and	 epidemiological	 data	 from	 China.	 Vaccine	
implementation	(age	targeting	and	coverage)	and	characteristics	(efficacy,	duration	







profiles	 delivered	 to	 older	 adults	 had	 higher	 population-level	 impact,	 and	 lower	
number	 needed	 to	 vaccinate	 per	 case	 or	 death	 averted,	 than	 if	 delivered	 to	
adolescents.	 Vaccinating	 older	 adults	 with	 post-infection	 vaccines	 provided	
























new	 TB	 vaccines	 targeted	 to	 older	 adults,	 and	 to	 compare	 this	 approach	 to	 the	
current	 strategic	 focus	 on	 adolescent	 vaccination.	 This	 data-driven	 model	 is	
calibrated	to	age-stratified	data	from	the	WHO,	UN	population	division,	and	empirical	
studies	 for	 demographics,	 prevalence,	mortality,	 notification	 and	 incidence	 rates,	
including	capturing	temporal	trends,	and	incorporates	empirical	data	on	non-random	
age	mixing.	This	study	is	the	first	to	show	that	older	adult	vaccination	with	new	TB	






ageing,	 reactivation-driven	 TB	 epidemics	 such	 as	 in	 China.	 In	 these	 settings,	 an	
efficacious	post-infection	vaccine	delivered	to	older	adults	will	be	critical	to	maximise	




Despite	 progress	 in	 tuberculosis	 (TB)	 prevention	 and	 care	 during	 the	 last	 two	





possible	 from	 further	 investment	 in	 existing	 tools	 alone	 are	 unlikely	 to	 reach	 the	
World	 Health	 Organization	 (WHO)	 2025,	 2035	 and	 2050	 TB	 goals	 in	 China.14-18	







framework	 to	 explore	 the	 potential	 future	 impact	 of	 vaccine	 characteristics	 and	
implementation	 strategies	 to	 inform	TPP	development.	 Impact	 achieved	 varies	by	
epidemiological	 and	demographic	 setting,5,6	 therefore	 country-specific	models	 are	
needed	for	appropriate	vaccine	selection	and	implementation	planning	such	as	age	
targeting.	A	prophylactic	TB	vaccine	candidate	is	in	Phase	III	clinical	trials	in	China	at	
time	of	writing,9	 therefore	modelling	 to	elucidate	 the	potential	 impact	of	new	TB	
vaccines	and	implementation	strategies	in	China	is	urgently	needed.	
Traditional	vaccine	development	pathways	 focussed	on	 infant	vaccination,	 though	
recently	the	field	has	experienced	a	paradigm	shift	towards	adolescents	and	adults,20	
supported	by	insights	from	mathematical	modelling.2,5	However,	older	adult	(60-64	
years)	 and	 elderly	 (≥65	 years)	 populations	 remain	 neglected	 in	 TB	 vaccine	








the	elderly.6	Dynamics	of	 TB	disease	and	demographics	are	 intimately	 linked,	 and	
influence	the	impact	of	age-targeted	interventions.5	Only	two	studies	have	modelled	
new	 TB	 vaccines	 in	 China,4,23	 and	 neither	 accounted	 for	 age	 specificities	 in	
epidemiology	or	demographics.	Further,	in	these	studies,	vaccination	was	either	at	
birth	or	all-ages,	and	vaccine	characteristics	modelled	were	unclear	or	unrealistic	(e.g.	
100%	 vaccine	 efficacy).4,23	 Although	 not	 exploring	 vaccines,	 a	 modelling	 study	 in	
China	 showed	 that	 existing	 TB	 interventions	 alone	 would	 not	 reach	 WHO	 2035	












calibrated	 to	 China’s	 TB	 epidemic	 was	 developed	 in	 R,24	 based	 upon	 the	 model	
developed	by	Knight	et	al.	(2014).2	A	summary	follows.	See	supplementary	materials	
for	full	details.	
The	 model	 represents	 five	 infection	 states:	 uninfected,	 latent	 infection,	
bacteriologically-positive	 active	 TB	 disease,	 bacteriologically-negative	 active	 TB	
disease,	 and	 recovered	 from	 active	 TB	 disease	 populations.	 Transitions	 between	




states	 comprised	 both	 unvaccinated	 and	 vaccinated	 strata.	 Age	 was	 modelled	 in	
single	 years	 from	0-100.	Main	 age	 categories	 for	 parameters	 and	outcomes	were	




Table	 S1,	were	 identified	based	upon	available	data.	HIV	has	been	 identified	as	 a	
proxy	for	elderly	immunosenescence,25	therefore	for	parameters	without	available	
elderly	data,	priors	were	based	upon	data	from	HIV	populations.	Temporal	evolution	
of	 the	 age	 distribution	 of	 infection	 and	 disease	 was	 captured	 historically	 and	
prospectively	by	calibration	to	age-stratified	epidemiological	and	demographic	data	
using	 age-specific	 natural	 history	 parameters	 and	 contact	 patterns.	 To	 provide	 a	
more	 gradual	 older-age	 transition	 in	 reactivation,	 relapse,	 natural	 cure	 and	 case	
detection	parameters,	55-64	year	old	parameters	were	estimated	as	the	mean	of	the	
adult	and	elderly	calibrated	values.	Heterogeneity	in	age-wise	contact	patterns	were	






A	 two-stage	 calibration	 process	 was	 employed,	 with	 the	 first	 stage	 a	 manual	
calibration	to	UN	2010	and	2050	age-stratified	demographic	data	and	projections,29	




the	 model	 was	 calibrated	 to	 18	 epidemiological	 data	 ranges:	 China’s	
bacteriologically-positive	prevalence	rates	(≥15,	15-29,	30-59	and	≥60	years)	in	2000	
and	2010,12	2010	notification	rates	(all-age,	0-14,	15-54,	55-64,	and	≥65	years),32	2010	
mortality	 rates	 (all-age,	 0-14,	 15-59	 and	 ≥60	 years),33	 and	 2010	 all-age	 incidence	
rate.28	After	ranking	by	 likelihood,	the	20	highest	from	one	million	parameter	sets	
randomly	selected	from	uniform	priors	were	used	as	seeds	for	the	adaptive	rejection	











annual	 M.tb	 infections	 was	 estimated	 using	 methods	 described	 previously.34	
















in	 the	specified	host	 infection	status	groups.	Therefore,	 the	proportion	effectively	
immunised	in	a	given	year	was	the	product	of	coverage	in	hosts	with	the	specified	
infection	status,	and	vaccine	efficacy.		
Vaccine	 efficacy	 (VE)	 was	 modelled	 as	 40%,	 60%	 and	 80%	 protective	 against	
development	of	TB	disease	 (‘prevention	of	disease’).	Vaccination	was	modelled	as	
‘take’	(all-or-nothing)	protection.	Vaccine	protection	in	four	host	infection	statuses	
was	 explored:	 1)	 uninfected	 individuals	 (pre-infection:	 PRI),	 2)	 latently	 infected	
individuals	(post-infection,	latency-only:	PSI-L),	3)	individuals	either	latently	infected	
or	 recovered	 from	active	disease	 (post-infection:	PSI-L&R),	or	4)	 individuals	either	






state.	 To	 account	 for	 immunosenescence,	 an	 additional	 2%	 annual	 waning	 was	
assumed	 for	 elderly	 populations,	 and	 was	 varied	 between	 0-5%	 in	 sensitivity	
analyses.	
All	 combinations	 of	 these	 characteristics	 and	 implementation	 strategies	 were	










The	 study	 sponsor	 (Aeras),	 a	 non-profit	 Product	 Development	 Partnership,	











≥70	 year	olds	 (Supplementary	 Figure	 S10).	Although	not	 calibrated	 to	 these	data,	
modelled	 age-stratified	 infection	 prevalence	 aligned	 closely	 with	 published	
Quantiferon	data.1	At	vaccine	introduction,	2·2%	(UR:	1·7-2·8)	of	15-19	year	olds	and	




in	2000,	 to	74·5%	 (UR:	70·2-78·6)	 in	 the	elderly	 (≥65	years)	 in	2050	 (Figure	1B).	A	
concurrent	age	 shift	was	observed	 in	 the	 source	of	new	 infections	 (Figure	1C	and	







In	 the	 baseline	 scenario,	 the	 all-age	 TB	 disease	 incidence	 rate	 was	 projected	 to	
decline	from	56·2/100,000	population/year	(UR:	51·4-60·0)	in	2025	to	33·7/100,000	
population/year	 (UR:	 27·6-38·8)	 in	 2050,	 and	 the	mortality	 rate	 from	2·0/100,000	







All	 vaccine	 profiles	 explored	 provided	 greater	 population-level	 impact	 when	
delivered	to	older	adults	than	adolescents	(Figure	2).	The	relative	differences	were	
demonstrated	 by	 the	 ‘intermediate’	 vaccine	 profile	 (Table	 1),	 where	 the	 median	
population	level	incidence	rate	reduction	by	older	adult	vaccination	ranged	from	1.9-	
to	 157.5-times	 greater	 than	 observed	with	 adolescent	 vaccination,	 depending	 on	






was:	 vaccines	 effective	 pre-infection	 (PRI),	 post-infection	 in	 latency	 (PSI-L),	 post	
infection	in	individuals	either	latently	infected	or	recovered	from	active	disease	(PSI-
L&R),	 and	 pre-	 and	 post-infection	 (P&PI).	 Vaccination	 of	 older	 adults	 with	 post-





The	 relative	 incidence	 rate	 reduction	 by	 older	 adult	 compared	 to	 adolescent	




Inducing	 vaccine	 protection	 in	 both	 latent	 and	 recovered	 populations	 (PSI-L&R)	
provided	markedly	greater	 impact	 than	protection	only	 in	 latency	 (PSI-L)	 (Figure	2	
and	 Supplementary	 Figure	 14).	 This	 was	 especially	 important	 in	 older	 adult	
populations,	 where	 latency-only	 vaccines	 (PSI-L)	 provided	 44%	 (UR:	 20-89%)	 less	
impact	than	PSI-L&R	vaccines	(Figure	2).		
As	expected,	 increased	vaccine	efficacy,	duration	of	protection	or	 coverage	 led	 to	
greater	incidence	rate	reductions	(Figure	2).	The	cumulative	NNV	per	case	or	death	










cases	 were	 averted	 (Figure	 2	 and	 Supplementary	 Table	 S4).	 The	 lowest	 impact	
vaccines	explored	averted	as	few	as	2,000	cases	during	2025-2050.	









per	 case	 or	 death	 averted,	 when	 delivered	 to	 older	 adults	 (60-64	 years)	 than	
adolescents	 (15-19	 years).	 With	 the	 most	 effective	 vaccine	 profile	 and	 coverage	
explored,	up	to	3·0	million	cases	were	averted	between	2025-2050.	By	2050,	the	no	
new	vaccine	baseline	results	suggest	that	around	75·1%	of	incident	TB	cases	would	









Even	 though	 immunosenescence	 disadvantaged	 older	 adult	 vaccination,	 targeting	
older	 adults	 consistently	 provided	 greater	 epidemiological	 impact	 than	 targeting	
adolescents,	regardless	of	the	vaccine	characteristics	explored.	Although	older	adult	
campaigns	 delivered	 more	 vaccines	 than	 adolescent	 campaigns	 for	 the	 same	





likely	 to	 provide	 at	 least	 equivalent,	 if	 not	 greater,	 impact	 than	 adolescent	
vaccination.	
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The	 relative	 impact	 of	 pre-infection	 versus	 post-infection	 vaccines	 varied	 in	
adolescent	and	older	adult	populations.	Vaccination	of	older	adults	achieved	higher	
population-level	 impact	 with	 post-infection	 vaccines,	 whereas	 higher	 impact	 was	
achieved	 in	 adolescents	 by	 pre-infection	 vaccines;	 explained	 by	 the	 substantially	
higher	prevalence	of	latent	infection	in	older	adults.	Pre-infection	vaccines	provided	





delivered	 to	 older	 adults,	 indicating	 vaccines	 also	 effective	 against	 relapse	 after	







towards	 WHO	 2050	 goals.	 Even	 greater	 impact	 could	 be	 achieved	 with	 less	
conservative	 delivery	 strategies	 (e.g.	 one	 off	mass	 vaccination	 to	 all	 adults),	 or	 if	
higher	efficacy	or	duration	of	protection	were	achieved.	Our	model	demonstrates	




represented	 this	 uncertainty	 by	 sampling	 from	 elderly	 parameter	 priors	 spanning	
HIV-negative	 and	 HIV-positive	 adult	 ranges	 in	 the	 calibration	 process.	 Given	
population	 ageing,	 the	 assumption	 that	 the	 contact	 matrix	 remained	 constant	
throughout	the	study	period	may	provide	conservative	impact	estimates.	The	vaccine	
was	 assumed	 to	 provide	 “all-or-nothing”	 protection,	 but	 the	 alternative	 “leaky”	
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assumption	could	reduce	impact	estimates.35	Due	to	high	current	treatment	success	
and	case	detection	estimates,	these	were	assumed	to	plateau.	 If	 improvements	 in	
current	 care	 measures	 were	 achieved,	 or	 better	 diagnostics	 or	 treatments	
introduced,	the	impact	achieved	by	vaccines	could	potentially	be	reduced.	However,	




extend	 beyond	 2050,	 therefore	 relative	 vaccine	 impact	 may	 change	 over	 longer	
horizons.6	 Better	 vaccines	 (e.g.	 lifelong	 protection)	 or	 coverage	 could	 improve	
impact,23	 but	 were	 not	 considered	 likely	 scenarios	 by	 experts.	 Infant	 vaccination	
could	be	explored,	but	 impact	would	be	very	 low	over	this	time	horizon	given	the	
declining	 force	 of	 infection	 in	 China.2,5	 To	 answer	 the	 research	 question,	 we	
deliberately	restricted	mass	campaigns	to	narrow	age	ranges	(15-19	and	60-64	years).	




to	older	age	groups,	and	 to	provide	a	comparison	of	 this	approach	 to	 the	current	
strategic	 focus	 on	 adolescent	 vaccination.20	 This	 required	 age-specific	 model	
parameterization	and	calibration,	and	is	the	first	China	TB	model	to	calibrate	to	age-
stratified	mortality	 and	 notification	 rates	 and	 include	 data-informed	 non-random	
mixing	 by	 age.	 Our	 results	 are	 consistent	 with	 the	 conclusions	 of	 the	 Dye	 study	
regarding	the	importance	of	post-infection	vaccines	in	China,23	but	provide	a	critical	
clarification:	that	population-level	impact	with	such	vaccines	is	contingent	on	delivery	










an	 efficacious	 post-infection	 vaccine	 delivered	 to	 older	 adults	 will	 be	 critical	 to	
maximise	population-level	impact	and	would	provide	a	crucial	contribution	towards	
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Pre−Infection (PRI) Post−Infection in Latency (PSI−L)
Pre− and Post−Infection (P&PI)Post−Infection in Latency and Recovered (PSI−LR)
Adolescent Older Adult Adolescent Older Adult










































































































































































































































































































































































































































































































model	was	 a	 further	 development	 of	 the	model	 described	 in	 Chapter	 3,	 to	 avoid	
excessive	repetition	of	methods	and	baseline	model	fitting	results,	sections	from	the	
paper	 supplement	 that	 repeat	methodology	 or	 results	 described	 previously	 have	
been	replaced	with	signposting	to	the	relevant	sections	in	Chapter	3.		
4.3.1 Model	structure	






































between	 sufficient	 granularity	 and	 computing	 time/capacity.	 The	 time	 step	 in	 the	






was	 data-informed,	 but	 limited	 to	 no	 more	 than	 100	 years.	 Following	 the	
methodology	 of	 Schenzle	 (1984),36	 ageing	 was	 implemented	 in	 the	 model	 on	 an	
annual	basis	by	transitioning	the	population	in	a	given	sub-population	of	age	j,	to	the	
same	sub-population	of	age	j+1	at	the	end	of	each	year.	
Transmission	 : *, ; = <=>? <[A, B]D E *, BF[*, B]3GH3I2J3GK  
where	F *, B = L *, ; + M *, ; + E *, ; + NE *, ; + O *, ;+LP *, ; + MP *, ; + OP *, ;QGQR1SQGQRTH 	and	nygrp	was	
the	number	of	contact	age	groups,	m	was	the	age	group	of	the	individual	exposed	to	
infection	 (including	 age	 j),	 y	was	 age	 group	 of	 contacts,	<[A, B] 	was	 number	 of	
respiratory	 contacts	 of	 age	 group	m	 with	 contacts	 of	 age	 group	 y,	<=>? 	was	 the	















Uninfected	(Susceptible)	L *, ; = 	L * − 1, ; − V ; + : * − 1, ; L * − 1, ; WX	
Latent	M *, ; = M * − 1, ; + : * − 1, ; 1 − Y ; (L * − 1, ; + ZO * − 1, ; )WX	− [ ; + : * − 1, ; Y[;]Z + V[;] M * − 1, ; )WX	
New	infectious	active	TB	cases	\]^_E *, ; = : * − 1, ; Y ; ` ; L * − 1, ; + ZM * − 1, ; + 	ZO * − 1, ; WX	+	[ ; ` ; M * − 1, ; WX + 	a ; ` ; O * − 1, ; WX + ^NE * − 1, ; WX	
New	non-infectious	active	TB	cases	\]^_NE *, ; = : * − 1, ; Y[;] 1 − `[;] L * − 1, ; + ZM * − 1, ;+ 	ZO * − 1, ; WX	+	[ ; 1 − `[;] M * − 1, ; WX + a ; (1 − `[;])O * − 1, ; WX	
Infectious	active	TB	cases	E *, ; = E * − 1, ; + 1 − bcO d, ; ×bfF d \]^_E *, ; 	− \ ; + V ; + VT[;] E * − 1, ; WX	
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Non-infectious	active	TB	cases	NE *, ; = NE * − 1, ; + 1 − ]	×bcO d, ; ×bfF d \]^_NE *, ; 	
	 − \ ; + V[;] + VHT[;] + ^ NE * − 1, ; WX	
Recovered	O *, ; = O * − 1, ; + \ ; E * − 1, ; + NE * − 1, ; WX	+(bcO d, ; ×bfF d ) \]^_E *, ; + ]	\]^_NE *, ; 	−(a ; + : * − 1, ; Z + V[;])O[* − 1, ;]WX	
Vaccinated		
Vaccinated	uninfected	(susceptible)	LP *, ; = LP * − 1, ; − :[* − 1, ;]LP * − 1, ; WX	
	−V[;]LP * − 1, ; WX	
Vaccinated	latent	MP *, ; = MP * − 1, ; + : * − 1, ; (LP * − 1, ; + ZOP * − 1, ; )WX	
	 −V[;]MP * − 1, ; WX	
Vaccinated	recovered	OP *, ; = OP * − 1, ; − Z:[* − 1, ;]OP * − 1, ; WX	






If	j=1:	L *, 1 = g	
If	j≠1:	L *, ; = 	L * − 1, ; − 1 − V ; − 1 + : * − 1, ; − 1 L * − 1, ; − 1 WX	
	 −!" d, ; L * − 1, ; − 1 	+W d, ; 1 − !" d, ; LP * − 1, ; − 1 	
Latent	M *, ; = M * − 1, ; − 1 + : * − 1, ; − 1 1 − Y ; − 1 (L * − 1, ; − 1+ ZO * − 1, ; − 1 )WX	− [ ; − 1 + : * − 1, ; − 1 Y[; − 1]Z + V[; − 1] M * − 1, ; − 1 )WX	−!$ d, ; M * − 1, ; − 1 		+W d, ; 1 − !$ d, ; MP * − 1, ; − 1 	
New	infectious	active	TB	cases	\]^_E *, ; = : * − 1, ; − 1 Y ; − 1 ` ; − 1 L * − 1, ; − 1 + ZM * − 1, ; − 1+ 	ZO * − 1, ; − 1 WX	+	[ ; − 1 ` ; − 1 M * − 1, ; − 1 WX	+	a ; − 1 ` ; − 1 O * − 1, ; − 1 WX + ^NE * − 1, ; − 1 WX		
New	non-infectious	active	TB	cases	\]^_NE *, ; = : * − 1, ; − 1 Y ; − 1 1 − `[; − 1] L * − 1, ; − 1+ ZM * − 1, ; − 1 + 	ZO * − 1, ; − 1 WX	+	[ ; − 1 1 − `[; − 1] M * − 1, ; − 1 WX + a ; − 1 (1 − `[;− 1])O * − 1, ; − 1 WX	
Infectious	active	TB	cases	E *, ; = E * − 1, ; − 1 + 1 − bcO d, ; ×bfF d \]^_E *, ; 	
	 − \ ; − 1 + V ; − 1 + VT[; − 1] E * − 1, ; − 1 WX	
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Non-infectious	active	TB	cases	NE *, ; = NE * − 1, ; − 1 + 1 − ]	×bcO d, ; ×bfF d \]^_NE *, ; 	
	 − \ ; − 1 + V[; − 1] + VHT[; − 1] + ^ NE * − 1, ; − 1 WX	
Recovered	O *, ; = O * − 1, ; − 1 + \ ; − 1 E * − 1, ; − 1 + NE * − 1, ; − 1 WX	+(bcO d, ; ×bfF d ) \]^h T,Q + ]	×	\]^_NE *, ; WX	−(a ; − 1 + : * − 1, ; − 1 Z + V[; − 1])O[* − 1, ; − 1]WX	−!) d, ; O * − 1, ; − 1 		+W d, ; 1 − !) d, ; OP * − 1, ; − 1 	
Vaccinated			
Vaccinated	uninfected	(susceptible)	LP *, ; = LP * − 1, ; − 1 + !" d, ; L * − 1, ; − 1 	
	 −(:[* − 1, ; − 1]+	V[; − 1])LP * − 1, ; − 1 WX	
	 −W[d, ;] 1 − !" d, ; LP * − 1, ; − 1 	
Vaccinated	latent		MP *, ; = MP * − 1, ; − 1 + !$ d, ; M * − 1, ; − 1 	+	: * − 1, ; − 1 (LP * − 1, ; − 1 + ZOP * − 1, ; − 1 )WX	
	 −	V[; − 1]MP * − 1, ; − 1 WX − W[d, ;] 1 − !$ d, ; MP * − 1, ; − 1 	
Vaccinated	recovered	OP *, ; = OP * − 1, ; − 1 + !) d, ; O * − 1, ; − 1 − Z:[* − 1, ;− 1]OP * − 1, ; − 1 WX	
	 −V[; − 1]OP * − 1, ; − 1 WX − W[d, ;] 1 − !) d, ; OP * − 1, ; − 1 		 	
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4.3.3 Model	parameters,	data	sources	and	calibration	
Justification	 of	 selection	 and	 sources	 for	 natural	 history,	 demographic,	 social	 and	
control	parameters	have	been	described	previously	in	Chapter	3.	
Natural	 history	 parameter	 range	 justifications	 are	 summarised	 in	 Chapter	 3,	 and	
natural	history	parameter	prior	ranges,	referred	to	as	Supplementary	Table	S1	in	the	
manuscript,	 are	 described	 in	 the	 same	 section.	 Demographic	 parameters	 are	
described	in	Chapter	3,	as	are	data	to	inform	heterogeneous	social	mixing	patterns	
by	 age	 and	existing	 control	measures.	As	 the	 focus	of	 this	 research	question	was	
related	 to	 age-targeted	 vaccination,	 the	 age	 stratification	 in	 natural	 history	




2010	 and	 2050,29	 and	 the	 second	 stage	 an	 adaptive	 rejection	 ABC	MCMC-based	
method	 using	 a	 modified	 easyABC	 package	 to	 calibrate	 to	 18	 China-specific	
epidemiological	data	ranges.	To	represent	age-structured	TB	epidemiology	in	China,	
the	 model	 was	 calibrated	 to	 eighteen	 epidemiological	 data	 points	 and	 their	









previous	 work.	 Vaccine	 implementation	 assumptions	 include	 age	 targeting	 of	
vaccination,	 year	 of	 implementation	 and	 coverage.	 The	 subset	 of	 vaccine	
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characteristics	 modelled	 was	 informed	 by	 the	 results	 presented	 in	 Chapter	 3.	
Modelled	 vaccine	 characteristics	 included	 the	 host	 infection	 status	 required	 for	







was	 implemented	 2025-2027.	 The	 equivalent	 older	 adult	 campaign	 vaccinated	 60	
year	olds	routinely,	and	61-64	year	olds	in	the	3-year	catch	up	campaign.	
Adolescent	 vaccination	 was	 of	 interest	 given	 many	 current	 clinical	 trials,	 target	
product	profiles	and	vaccine	development	strategies	focus	on	vaccination	in	this	age	
group.	 Previous	 modelling	 has	 shown	 that	 vaccinating	 adolescents	 and/or	 adults	
would	provide	greater	and	more	 cost	effective	 impact	 than	vaccinating	 in	 infancy	
over	the	2024/25-2050	time	horizon.2,5	In	many	countries	a	rapid	increase	in	TB	rates	
occurs	during	adolescence,	therefore	vaccination	of	this	age	group	would	hopefully	
provide	protection	during	 the	period	during	which	 infection	and	disease	 rates	are	
known	to	be	high.	With	a	lifelong	protective	vaccine,	vaccination	of	adolescents	could	
eventually	 be	 age	 de-escalated	 in	 to	 infancy,	 but	 given	 the	 immediate	 need	 for	






studies.1,22	 The	 decision	 to	 vaccinate	 specifically	 60-64	 year	 olds	 took	 in	 to	








as	vaccination	before	 immunosenescence	 increases	 the	 likelihood	of	a	 robust	and	
sustained	immune	response	to	vaccines	(Richard	Aspinall,	oral	communication,	5th	
June	2015).	This	 is	 supported	by	results	of	Zostavax	 trials	against	herpes	zoster	 in	
older	adults,	where	vaccine	efficacy	 in	60-69	year	olds	(64%,	95%	CI:	56-71%)	was	
similar	to	50-59	year	olds	(70%,	95%	CI:	54-81%),	but	much	higher	than	in	70-79	year	
olds	 (41%,	 95%	 CI:	 28-52%)	 and	 ≥80	 years	 (18%,	 95%	 CI:	 -29	 to	 48%).38	




communication,	 5th	 June	 2015).38	 Therefore,	 vaccination	 of	 60-64	 year	 olds	 was	
explored	as	a	possible	alternative	target	population	for	new	TB	vaccines	in	China.		
4.3.4.2 Implementation:	Timing	and	coverage	




up	was	assumed	to	be	 immediate	 in	 routine	vaccination	 (15	or	60	year	olds),	and	
catch	up	campaigns	in	16-19	year	olds	or	61-64	year	olds	were	assumed	to	occur	over	




vaccine	 acceptance	 study	 in	 China,	 and	 coverage	 achieved	 with	 HPV	 vaccines	
delivered	in	schools	in	South	Africa.	The	gross	secondary	school	enrolment	ratio	in	




















whereas	 for	 some	 viral	 vectored	 MV85A	 vaccines	 immune	 priming	 by	 previous	
exposure	was	found	to	 improve	the	antigen-specific	 immune	response.	Therefore,	
the	 efficacy	 of	 a	 given	 candidate	 may	 be	 reliant	 upon	 whether	 the	 vaccinated	
individual	 is	M.tb-naïve,	 currently	 latently	 infected	 or	 ever-infected.	 Clinical	 trials	
tend	to	enrol	either	uninfected	46	or	infected	7,47	populations,	assessed	by	IGRA	or	
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PPD,	 depending	 upon	 the	 anticipated	 pre-requisites	 for	 an	 immune	 response	
according	to	the	antigens	included	in	the	vaccine.		
Four	infection	status	combinations	were	modelled	(Table	S2).	Pre-infection	vaccines	
were	 assumed	 to	 prevent	 development	 of	 active	 disease	 only	 in	 never-infected	
individuals	(!" > 0, !$ = 0, !) = 0).	Two	types	of	post-infection	(PSI)	vaccines	were	
modelled,	the	first	(PSI-L)	was	only	effective	in	those	currently	latently	infected	with	
M.tb	 (!" = 0, !$ > 0, !) = 0 ),	 including	 those	 who	 had	 recovered	 but	 were	 re-
infected	 and	 enter	 the	 latent	 state.	 	 The	 second	 (PSI-L&R)	 was	 efficacious	 when	
delivered	to	either	latently	infected	populations	or	those	who	had	recovered	from	
active	 disease	 (!" = 0, !$ > 0, !) > 0).	 Finally,	 a	 vaccine	 effective	 pre-	 and	 post	












PRI	 Yes	 No	 No	 No	
PSI-L	 No	 Yes	 No	 No	
PSI-L&R	 No	 Yes	 No	 Yes	
P&PI	 Yes	 Yes	 No	 Yes	
	
4.3.4.4 Characteristics:	Effect	type	
Vaccines	 with	 a	 prevention	 of	 disease	 (POD)	 effect	 type	 were	 modelled.	 This	
















Vaccine	 efficacies	 of	 40%,	 60%	and	80%	were	modelled.	Although	examples	 exist	
exploring	the	extremes	of	vaccine	efficacy	(17.6-100%),	the	majority	of	TB	vaccine	
models	in	the	literature	explore	a	VE	range	of	40-80%.6	Given	current	challenges	in	
developing	 a	 highly	 effective	 TB	 vaccine,	 the	 upper	 bound	 of	 vaccine	 efficacy	
considered	technically	feasible	was	80%.		
















the	 literature	 assumed	 10	 year	 or	 lifelong	 immunity.6	 Based	 upon	 expert	
consultation,	 lifelong	 immunity	 was	 considered	 unlikely	 with	 early	 candidates,	
therefore	10	and	20	years	of	protection	were	modelled.	
A	 sigmoid-shaped	 waning	 profile	 was	 assumed,	 therefore	 waning	 was	 normally	
distributed	around	a	mean	of	10	or	20	years	protection	with	a	standard	deviation	of	
1	 or	 2	 years,	 respectively.	 Waning	 was	 exact,	 meaning	 that	 those	 individuals	
experiencing	 waning	 leave	 the	 vaccinated	 category	 and	 return	 to	 the	 equivalent	
unvaccinated	state.		




















for	 those	 aged	 j	 in	
year	k	
	
Annual	 routine	 vaccination	 of	 30%	 and	 70%	
explored,	 age	 targeted	 to	 15	 or	 60	 year	 olds.	 In	
addition,	three-year	catch	up	campaign	for	16-19	
year	olds	or	61-64	year	olds,	with	above	coverages	



































Average	waning	 of	 protection	 at	 10	 or	 20	 years,	
normally	 distributed	 around	 the	 mean	 with	













The	model	 was	 first	 run	 allowing	 transmission	 from	 all	 infected	 populations	 as	 a	
baseline.	It	was	then	re-run	four	times	for	each	year	of	interest,	blocking	transmission	
from	 infected	 individuals	 in	 one	 age	 group	 per	 run	 by	 reducing	 the	 infectious	
individuals	 in	 that	 age	 group	 to	 zero.	 The	 total	 number	 of	 new	 infections	 was	
estimated	in	the	year	of	interest	for	each	of	these	runs.	The	percentage	reduction	in	
new	infections	compared	to	the	baseline	was	calculated,	giving	an	estimate	of	the	




period	 of	 time	 (2025-2050)	 as	 opposed	 to	 annually,	 the	 reported	measure	 is	 the	
cumulative	NNV	per	case	or	death	averted	for	the	period	2025-2050.	It	is	calculated	
by	dividing	 the	 total	number	of	vaccines	delivered	during	 that	period	by	 the	 total	
number	of	cases	or	deaths	averted	during	the	same	period.	Programmatically,	this	
measure	 could	 be	 seen	 as	 an	 indicator	 of	 impact	 achieved	 per	 vaccine	 resource	
expended,	therefore	minimising	the	NNV	is	desirable.		
4.3.6 Additional	results	and	discussion	
4.3.6.1 Epidemiological	 outcomes:	 Burden	 of	 disease	 and	 contribution	 to	
transmission	in	vaccinated	age	groups	
At	time	of	vaccine	introduction	(2025),	1·5%	(UR:	1·3-1·7)	of	cases	occurred	in	the	15-





22)	of	cases	were	projected	 to	occur	 in	 the	15-24	and	60-69	year-old	age	groups,	
respectively.	 This	 highlights	 the	 potentially	 avoidable	 burden	 of	 disease,	 which	 is	
clearly	higher	in	the	older	age	group.	







































































































































































The	model	was	 not	 calibrated	 to	 the	 Gao	 et	 al.	 prevalence	 of	 infection	 data,1	 as	
although	the	four	locations	selected	for	the	study	were	considered	representative	of	
the	social	and	epidemiological	diversity	across	China,	the	study	did	not	use	random	
selection	of	 sites	or	participants	 from	a	nationally-representative	 sampling	 frame;	
therefore	the	generalisability	to	our	country-level	model	was	uncertain.		
A	 comparison	 to	 these	 data,	 however,	 found	 that	 the	 modelled	 age-stratified	
prevalence	 of	 infection	matched	 the	 published	Quantiferon	 (QFN)	 data	 very	well	
(Figure	S10).	In	our	model,	the	overall	prevalence	of	infection	was	15.3%	(UR:	13.8-
17.0%),	ranging	from	1.3%	(1.2-1.4%)	in	children	aged	5-9	years,	up	to	36.9%	(32.9-
40.3%)	 in	 ≥70	 years	 old.	 In	 the	 Gao	 study,	 prevalence	 of	 infection	 measured	 by	
Quantiferon	was	19%,	ranging	from	3%	in	children	5-9	years	to	32%	in	≥70	years	old.	
The	model	appeared	to	slightly	overestimate	infection	prevalence	in	the	>70	years	
group,	 but	 data	 suggest	 that	 QFN	 and	 TST	 tests	 are	 slightly	 less	 sensitive	 in	 the	
elderly.48	TST-estimated	prevalence	was	higher	than	QFN	estimates	for	all	except	one	
age	 group	 due	 to	 lower	 test	 specificity.	 Alignment	 of	 model	 outcomes	 with	 the	
empirical	Quantiferon	data	set	speaks	to	the	validity	of	this	epidemiological	model.	
Prevalence	 of	 latent	 TB	 at	 vaccine	 introduction	 in	 2025	 showed	 a	 similar	 age	
distribution	to	2013	(Figure	S11),	but	a	slightly	lower	overall	prevalence	of	13·6%	(UR:	
11·0-16·4%)	due	 to	declining	 transmission	 rates.	Prevalence	of	 infection	was	1·8%	
(UR:	 1·4-2·2%)	 in	 10-19	 year	 olds,	which	 includes	 the	 adolescent	 15-19	 years	 age	
group	receiving	the	vaccine,	and	26·6%	(UR:	21·6-31·6%)	in	60-69	year	olds,	which	
includes	the	older	adult	60-64	year	old	vaccinated	group.	Prevalence	of	infection	is	









































































4.3.6.4 Vaccination	 outcomes:	 Comparison	 of	 post-infection	 vaccine	 effect	 types	
(PSI-L	vs	PSI-L&R)	
Two	types	of	post-infection	(PSI)	vaccine	were	compared:	a	vaccine	effective	only	in	






Whereas	 uncertainty	 ranges	 on	 the	 PSI-L&R	 results	 were	 relatively	 narrow,	



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As	 the	 model	 was	 fitted	 to	 age-wise	 notification	 and	 prevalence	 rates,	 and	 the	
majority	of	elderly	disease	was	reactivation	disease,	these	reactivation	parameters	





for	 these	 two	mutually	 compensatory	parameters	and	 therefore	wide	uncertainty	
ranges	around	the	proportion	coming	from	latency	or	recovered	populations.	Given	







Wide	 uncertainty	 ranges	were	 observed	 in	 both	 adolescent	 and	 older	 adult	 PSI-L	
vaccine	 scenarios.	However,	 uncertainty	was	proportionally	 greater	 in	 older	 adult	
vaccination	due	to	the	larger	burden	of	reactivation	disease	in	older	age	groups	and	
the	broader	priors	for	older	adult	and	elderly	reactivation	parameters.	In	addition,	
the	 contribution	 of	 reactivation	 from	 the	 recovered	 population	 in	 adolescents	 is	




consistently	 substantially	 higher	 impact,	 indicating	 that	 in	 vaccine	development	 it	
may	be	important	to	explore	whether	a	vaccine	is	safe	and	effective	in	both	those	
latently	infected	and	recovered	from	disease.	
The	 wide	 intervals	 on	 the	 PSI-L	 results	 also	 affect	 the	 comparison	 with	 the	 pre-
infection	vaccines.	Although	median	 impact	estimates	were	much	higher	 for	post-
infection	 latency-only	 than	 pre-infection	 vaccines,	 overlap	 of	 estimate	 ranges	
indicated	some	uncertainty	as	to	the	difference	in	impact	between	these	vaccines.	
For	 example,	 the	 latency-only	 post-infection	 vaccine	 with	 “intermediate”	 profile	
provided	 to	 older	 adults	 reduced	 2050	 incidence	 rates	 by	 6·1%	 (UR:	 1·3-8·7%)	
compared	 to	 baseline,	 indicating	 some	 uncertainty	 as	 to	 whether	 a	 latency-only	
vaccine	would	have	greater	impact	than	the	equivalent	pre-infection	vaccine	(3·3%,	
UR:2·3-5·3%).	
4.3.6.5 Vaccination	 outcomes:	 Reduction	 in	 2050	 TB	 mortality	 rate	 in	 vaccine	
scenarios	compared	to	the	no	new	vaccine	baseline	
The	reduction	in	population-level	TB	mortality	rate	in	2050	compared	to	the	no	new	








in	 incidence	 rate	 than	 the	 percentage	 reduction	 in	 mortality	 rate,	 whereas	 the	
opposite	was	observed	in	older	adult	vaccination.	This	is	a	function	of	the	relative	TB	
mortality	 rate	 in	 the	 population	 directly	 protected	 by	 the	 vaccine.	 The	 model	 is	
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parameterised	 such	 that	TB	death	 rates	 in	 the	elderly	 (≥65	years)	 are	equal	 to	or	
higher	than	in	adolescents	and	adults.	As	older	adult	vaccines	providing	10	or	20	years	
duration	of	protection	protect	up	to	the	age	of	69	or	79	years,	respectively,	higher	
case	 fatality	 rates	 in	 the	elderly	period	 (≥65	years)	meant	 that	more	deaths	were	



































































































































































Pre−Infection (PRI) Post−Infection in Latency (PSI−L)
Pre− and Post−Infection (P&PI)Post−Infection in Latency and Recovered (PSI−LR)
Adolescent Older Adult Adolescent Older Adult



















averted,	 estimated	 at	 110,000	 (UR:	 85,000-151,000)	 to	 3.0	million	 (UR:	 2.5-3.5m)	
cases	and	2,790	(1,400-6,410)	to	73,730	(37,700-146,410)	deaths	through	older	adult	
vaccination	campaigns.		
The	 lowest	 achievable	 cumulative	 NNVs	 per	 case	 averted	 2025-2050	 with	 the	
adolescent	and	older	adult	vaccines	explored	were	590	(501-688)	and	120	(103-141),	
respectively,	reaching	as	high	as	59,070	(43,503-77,369)	to	1,505	(1,104-1,944)	with	
the	 least	 effective	 vaccines	 explored.	 Cumulative	 NNV	 per	 death	 averted	 for	




number	 of	 vaccinated	 individuals	 to	 avert	 one	 case	 compared	 to	 older	 adult	
vaccination	 (Table	 1,	 main	 article).	 The	 impact	 of	 adolescent	 versus	 older	 adult	
vaccination	differed	most	for	PSI-L&R	vaccines;	for	the	‘intermediate’	vaccine	profile,	
91	times	more	adolescents	would	need	to	be	vaccinated	than	older	adults	to	avert	
the	 same	 number	 of	 cases,	 and	 200	 times	 more	 adolescents	 would	 need	 to	 be	
vaccinated	 to	 avert	 the	 same	number	of	deaths.	 The	most	 similar	 impact	profiles	
were	pre-infection	vaccines,	for	which	only	1.3	and	2.7	times	more	adolescent	than	





vaccination.	 Given	 substantially	 fewer	 vaccines	 are	 required	 per	 case	 or	 death	
averted	 for	 older	 adult	 vaccination,	 assuming	 the	 number	 and	 size	 of	 doses	 for	
protection	 is	 the	 same	 as	 for	 adolescents,	 the	 impact	 per	 vaccine	 dose	would	 be	

















The	 increase	 in	NNV	with	higher	coverage	 levels	was	due	to	a	combination	of	 the	
vaccination	time	horizon	and	the	changing	disease	burden	over	that	period.	Higher	
coverage	 reduces	disease	 rates	more	 rapidly	 initially	 after	 introduction,	 so	over	 a	
short	 horizon	 the	 large	 additional	 number	 of	 vaccines	 for	 higher	 coverage	 averts	
many	more	cases.	However,	in	the	latter	part	of	the	vaccination	period,	the	higher	
coverage	 levels	 had	 already	 brought	 down	 burden	 of	 disease	 to	 such	 levels	 that	




longer	 periods	 the	 cumulative	 number	 of	 vaccines	 delivered	 for	 70%	 coverage	 is	
much	 higher	 than	with	 30%	 coverage,	 but	 because	 the	 incremental	 gain	 is	much	
lower	in	the	later	years	while	the	same	high	level	of	vaccination	is	maintained,	the	
cumulative	 NNV	 over	 this	 period	 is	 higher	 with	 70%	 coverage	 than	 with	 30%	
coverage.	 Therefore,	 although	NNV	 is	marginally	 higher	with	 the	 higher	 coverage	








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vaccine	efficacy	was	 assumed	 to	be	 invariable	by	 age	of	 administration.	 This	was	
considered	acceptable	given	the	age	of	routine	older	adult	vaccination	(60	years)	was	
selected	to	precede	the	main	onset	of	immunosenescence,49	and	given	that	zoster	
vaccine	 trials	 have	 provided	 proof	 of	 concept	 for	 achieving	 robust	 efficacy	 and	




the	 experience	with	 elderly	 vaccination	 against	 influenza,50	 vaccine	 efficacy	 could	
conceivably	be	lower	in	this	older	population.	Therefore,	an	exploration	of	whether	









for	 older	 adults	 10	 years	 was	 assumed,	 with	 the	 added	 disadvantage	 of	
immunosenescence	from	the	age	of	65	years.	Coverage	was	also	assumed	as	70%	in	



































































Comparing	 the	 adolescent	 ‘high’	 to	 older	 adult	 ‘low’	 vaccine	 and	 coverage,	 older	
adult	 vaccination	 averted	 more	 cases	 and	 required	 fewer	 vaccinations	 per	 case	
averted	for	both	post-infection	vaccines.	Therefore,	even	if	trials	were	to	show	that	
a	 post-infection	 vaccine	 were	 much	 less	 efficacious	 and	 durable	 and	 anticipated	
achievable	coverage	were	much	lower	in	older	adults	than	adolescents,	older	adult	
vaccination	would	 likely	 still	 provide	 greater	 impact	 than	 vaccinating	 adolescents.	
Therefore,	for	vaccines	with	the	potential	for	post-infection	efficacy,	ensuring	trials	
are	designed	to	examine	safety	and	efficacy	in	these	older	age	groups	is	essential.	
When	 comparing	 identical	 vaccine	 efficacies	 and	durations,	 pre-infection	 vaccines	
provided	greater	impact	with	older	adult	vaccination,	though	the	age-wise	difference	
is	 much	 smaller	 than	 was	 observed	 post-infection	 vaccines.	 Therefore,	 when	
comparison	was	made	between	the	‘high’	adolescent	and	‘low’	older	adult	vaccine	




To	explore	 this	 further,	 sensitivity	 to	 reductions	 in	 individual	characteristics	 in	 the	








coverage,	 though	 the	 NNV	 per	 case	 averted	 was	 still	 lower	 with	 older	 adult	
vaccination.	 If	 both	 coverage	 and	 efficacy	 were	 reduced	 simultaneously	 in	 older	
adults,	adolescent	vaccination	became	preferable.	Therefore,	if	clinical	trials	were	to	
demonstrate	 substantially	 lower	 efficacy	 and/or	 duration	 of	 protection	 in	 older	
adults,	or	feasibility	assessments	were	suggestive	of	low	coverage	in	this	older	age	
group,	further	modelling	would	be	required	to	assess	whether	adolescent	vaccination	






scenario	 (70%	 coverage)	 in	 adolescents	 required	 almost	 double	 the	 number	 of	
vaccines	 needed	 for	 30%	 coverage	 of	 older	 adults,	 therefore	 the	 NNV	 per	 case	
averted	was	much	lower	for	older	adult	vaccination.	Therefore,	with	a	P&PI	vaccine,	
even	with	 the	 pessimistic	 assumption	 of	 halving	 vaccine	 efficacy	 and	 duration	 of	
protection	 for	older	adults	 compared	 to	adolescent	vaccination,	assuming	vaccine	
waning	of	2%	due	 to	 immunosenescence	after	 the	age	of	65	years,	and	assuming	
much	 lower	 coverage	 (30%	 instead	 of	 70%),	 older	 adult	 vaccination	 would	 still	
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older	adults	 in	clinical	 trials,	 to	 investigate	efficacy	and	allow	for	 the	possibility	of	
registration	in	this	epidemiologically	important	age	group.	This	additional	discussion	
further	 strengthens	 this	 recommendation.	 For	 post-infection	 or	 pre-	 and	 post-





















older	adult	 vaccination	policy	 reduced	 incidence	 rates	by	13.8%	 (UR:	12.9-15.2%),	
averting	1.64	million	cases	(UR:	1.40-1.89).		
Although	the	mass	versus	age-targeted	implementation	scenarios	are	compared,	age	
of	 vaccination	 was	 not	 the	 only	 contributory	 factor	 to	 impact	 differences.	 For	
example,	 routine	 coverage	 was	 10%	 higher	 in	 Chapter	 3,	 and	 protection	 was	
modelled	 as	 all-or-nothing	 instead	 of	 ‘leaky’	 in	 this	 chapter.	 Therefore,	 although	
results	provide	a	comparison	of	 targeted	versus	mass	campaigns,	 these	additional	
distinctions	must	be	considered.			











practicality	 of	 such	 large-scale	 production.	 China	 is	 the	 world’s	 largest	 vaccine	
producer,	manufacturing	in	total	more	than	one	billion	vaccine	doses	per	annum,51	
so	 country-level	 capacity	would	 be	 anticipated	 to	 be	 able	 to	meet	 such	 demand.	
Achievability	 also	 relies	 on	 TB	 remaining	 a	 public	 health	priority	 in	 China	 and	 the	
availability	of	funding	for	vaccine	production	and	delivery.	
Assuming	these	do	not	become	limiting	issues,	broad	mass	vaccination	of	adolescents	
and	 adults	 would	 bring	 about	 a	 bigger	 reduction	 in	 2050	 incidence	 rates	 than	
targeted	campaigns	of	15	or	60	year	olds,	therefore	would	be	the	ideal	scenario	to	
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maximise	 vaccine	 impact	 if	 resources	 were	 not	 limited.	 However,	 the	 supply,	
logistical	and	cost	implications	of	vaccinating	the	entire	population	aged	≥10	years	
every	decade,	in	addition	to	routine	vaccination	of	9	year	olds,	would	be	substantial.	
Therefore,	 although	 the	 results	 of	 Chapter	 3	 support	 such	 wide-scope	 mass	
campaigns	 where	 feasible,	 the	 results	 of	 this	 chapter	 demonstrate	 that	 targeted	




Previous	 mathematical	 modelling	 research	 has	 demonstrated	 that	 vaccination	 of	
adolescents,	or	adolescents	and	adults,	would	be	expected	to	provide	greater	impact	
and	cost	effectiveness	than	neonatal	vaccination.2,4,5	Neonatal	vaccination	with	new	
TB	vaccines	has	been	predicted	 to	provide	 limited	 impact	 in	China,	even	with	 the	
optimistic	assumption	of	100%	efficacy	against	infection	with	lifelong	protection	and	





neonatal	 vaccination	 to	 neonatal	 plus	 periodic	 mass	 all-age	 vaccination	 (‘mixed	
vaccination’).	Over	a	17-year	time	frame,	7.63x108	doses	were	delivered	in	the	key	
mixed	vaccination	 scenario.4	 In	 this	 chapter,	 the	number	of	 vaccines	 ranged	1.36-
3.78x108,	but	were	delivered	to	a	narrower	age	group	and	over	a	longer	time	frame	
(26	years).	In	the	Liu	study,	the	time	to	achieving	the	2035	WHO	goal	was	halved,	yet	
the	 number	 of	 vaccinations	 delivered	 did	 not	 double,	 by	 implementing	 the	 25%	
coverage	‘mixed’	vaccination	strategy	compared	to	neonatal	vaccination.	Therefore,	
mass	 or	 adult	 campaigns	 appear	 to	 deliver	 more	 impact	 per	 vaccination	 than	
neonatal	vaccination.	However,	 the	number	needed	to	vaccinate	per	case	averted	
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this	 chapter,	 and	 were	 achieved	 in	 my	 research	 through	 significant	 age-specific	
structure,	parameterisation	and	calibration.		
Empirical	studies	have	demonstrated	the	importance	of	recurrent	TB,	with	one	study	
in	 China	 indicating	 that	 populations	 recovered	 from	 a	 previous	 TB	 episode	
experienced	disease	rates	of	more	than	18	times	the	observed	rate	 in	the	general	
population.52	Modelling	recurrence	is	an	important	natural	history	transition,	and	in	
my	 research	 accounted	 for	 approximately	 20-70%	 of	 all	 reactivation	 disease.	 The	
range	 on	 this	 estimate	 is	wide	 due	 to	 the	 lack	 of	 appropriate	 calibration	 data	 to	
apportion	 cases	 between	progression	 from	 latent	 and	 recovered	populations,	 but	
even	 the	 lower	 end	 of	 the	 modelled	 estimate	 of	 recurrence	 demonstrates	 an	
important	contribution.	Vaccine	protection	of	the	population	recovered	from	disease	
provided	 substantial	 additional	 impact	 beyond	 that	 achievable	 by	 protecting	 only	
latent	 populations.	 In	 the	 Liu	 et	 al.	 study,	 recurrent	 disease	 was	 not	 modelled.4	
Therefore,	 to	calibrate	to	notification	data,	 transmission	or	progression	to	disease	
rates	may	have	been	overestimated,	and	 the	 future	burden	of	TB	may	have	been	
underestimated	 without	 the	 contribution	 of	 recurrence.	 If	 transmission	 was	
overestimated,	the	estimated	impact	of	such	a	prevention	of	infection	vaccine	may	
be	too	high,	and	predictions	of	achieving	2035	goals	would	be	optimistic.	Inclusion	of	
the	 recovered	 population	 is	 clearly	 important	 for	 predicting	 the	 future	 of	 China’s	
epidemic	and	potential	impact	of	future	vaccines,	thus	the	inclusion	of	relapse	and	
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reinfection	 following	 recovery	 is	 an	 important	 element	of	 the	 research	presented	
here.	
Another	 recently	 published	 TB	 vaccine	 study	 (Arregui	 et	 al.,	 2017),5	 explored	 the	
influence	of	age	specificity	in	model	parameterisation	and	fitting	on	the	estimated	










2025-2050	 (extracted	 from	 Figure	 S16),5	 and	 the	 similar	 adolescent	 vaccination	
scenario	in	this	thesis	averted	0.5	million	(UR:	0.4-0.6m)	cases	in	China	over	the	same	
period.	Due	to	model	and	vaccine	differences,	 this	comparison	 is	 interpreted	with	
caution.		
Interestingly,	 in	 the	 Arregui	 WPR	 model,	 sensitivity	 analyses	 removing	 the	 age	
specificity	in	the	demography	and	epidemiology	of	the	model	increased	the	number	
of	cases	averted	by	adolescent	vaccination.5	Therefore,	without	age-specificity	in	the	
model,	 the	 impact	 of	 adolescent	 vaccines	 and	 the	 difference	 between	 infant	 and	
adolescent	vaccines	was	overestimated.	In	the	light	of	results	presented	in	Chapters	
3	 and	 4	 of	 this	 thesis,	 it	 is	 hypothesised	 that	 this	 difference	 derives	 from	 over-
allocation	of	cases	and	transmission	to	younger	age	groups	by	heterogeneous	contact	





age-stratified	 data	 and	 contact	 patterns	 ensured	 that	 the	 distribution	 of	 disease	
burden	was	reflective	of	age-structured	epidemiology	and	demography.	Importantly,	
in	 the	model	 presented	 here,	 such	 age-structured	models	 are	 valuable	 for	 more	
accurately	 estimating	 the	 future	 burden	 of	 disease,	 the	 impact	 of	 age-targeted	
vaccination,	and	most	importantly	for	identifying	the	ages	that	should	be	targeted	to	
provide	the	greatest	population-level	impact.	









absolute	 estimates	 of	 vaccine	 impact,	 strengthen	 the	 conclusion	 that	 older	 adult	
vaccination	 with	 post-infection	 vaccines	 would	 provide	 greater	 impact	 than	








100	 years	 of	 age,	 and	 explored	 vaccines	 delivered	 to	 older	 adults	 capable	 of	
protecting	into	the	elderly	period.	
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Although	 contact	 patterns	were	 not	 the	most	 influential	 age-related	 factor,	 their	
inclusion	 has	 been	demonstrated	 to	 change	 vaccine	 impact	 estimates.5	Given	 the	
greatest	change	was	observed	in	older	age	groups	when	switching	from	homogenous	





at	 the	 country	 level,	 nor	 does	 it	 account	 for	 the	 influence	 of	 social	 and	 cultural	
aspects.	 Therefore,	 using	 country-specific	 data,	 as	 was	 the	 case	 in	 the	 study	
presented	 in	 this	 thesis,	 ensured	 contact	 patterns	 were	 representative	 of	 the	
modelled	population.	
The	Arregui	study	demonstrated	that	epidemiological,	demographic	and	social	age	
dependencies	 substantially	 changed	 vaccine	 impact	 estimates,	 supporting	 the	
importance	of	the	substantial	age	structure	and	calibration	in	the	model	presented	
in	this	thesis.	The	Arregui	study	explored	just	one	vaccine	profile	targeted	to	infants	
or	 adolescents,	 whereas	 this	 thesis	 provides	 the	 research	 needed	 to	 inform	 TPP	
decision	 making	 through	 an	 in-depth	 exploration	 of	 vaccine	 profiles	 and	
consideration	of	vaccination	of	older	adult	populations.	
4.4 Conclusion	
The	 research	 presented	 in	 this	 chapter	 investigated	 the	 impact	 of	 age-targeted	
vaccination	 programmes	 on	 population-level	 TB	 epidemiology	 (objective	 3).	 The	
results	 clearly	 demonstrated	 that,	 with	 all	 vaccine	 characteristics	 explored,	 older	
adult	vaccination	delivered	greater	impact	than	adolescent	vaccination.	Older	adult	




adolescent/adult	 over	 infant	 vaccination	 to	 maximise	 impact.2,4,5	 This	 research	
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was	 delivered	 to	 adolescents.	 Although	 pre-infection	 vaccines	 provided	 relatively	
similar	 levels	 of	 impact	 when	 vaccinating	 either	 age	 group,	 the	 impact	 was	
substantially	lower	than	that	achievable	with	vaccination	of	older	adults	with	a	post-
infection	vaccine.	In	this	setting,	a	vaccine	efficacious	post-infection	or	pre-	and	post-
infection	 delivered	 to	 older	 adults	 will	 be	 critical	 to	 maximise	 population-level	




than	 pre-infection	 vaccines.	 Therefore,	 the	 research	 presented	 here	 provides	 a	
critical	 clarification:	 that	 maximising	 population-level	 impact	 with	 post-infection	
vaccines	is	contingent	on	delivery	to	older	age	groups.	
When	 planning	 vaccination	 programmes,	 there	may	 be	 other	 considerations	 that	
would	 influence	 the	 decision	 regarding	 age	 of	 vaccination,	 such	 as	 the	 resources	
required	 or	 the	 accessibility	 of	 the	 populations.	 School-based	 platforms	 would	
provide	relatively	easy	access	to	adolescents,	whereas	strengthening	the	 influenza	
vaccine	platform	for	vaccination	of	60	year	olds	may	require	more	investment	and	






to	 vaccinate	 (NNV)	 per	 case	 averted	was	 consistently	 lower	 than	 for	 adolescents,	
demonstrating	 that	 the	 increased	 impact	 far	 outweighs	 the	 additional	 vaccines	
required.	NNV	is	a	useful	measure	of	the	balance	between	resource	use	and	benefit,	
and	by	this	measure	clearly	demonstrates	that	older	adult	vaccination	remains	the	
most	 efficient	 use	 of	 resources	 as	 well	 as	 providing	 greatest	 impact.	 However,	
differences	may	exist	in	the	costs	of	vaccine	delivery	between	these	two	age	groups	











this	study	 is	 the	first	 to	show	that	older	adult	vaccination	with	new	TB	vaccines	 is	
likely	to	be	critical	for	maximising	impact	in	settings	such	as	China,	and	strengthens	
the	 conclusions	 from	 previous	 studies	 suggesting	 that	 vaccines	 effective	 post-








included	 the	 dearth	 of	 elderly	 natural	 history	 data,	 the	 assumption	 that	 contact	
patterns	 do	 not	 change	 over	 time	 and	 that	 no	 new	 interventions	 would	 be	
introduced.	 These	 could	 be	 explored	 in	 further	 epidemiological	 and	 modelling	





modelling	 could	 be	 used	 to	 further	 optimise	 the	 older	 adult	 vaccination	 age,	 and	
explore	different	mass	campaign	options.	






III,	 to	ensure	 that	 sufficient	participants	have	been	exposed	 to	 the	 investigational	
product	 to	demonstrate	safety	and	 immunogenicity	 to	the	regulators.	Clinical	 trial	
outcomes	should	ideally	be	disease	endpoints.	Studies	would	ideally	enrol	both	pre-	
and	 post-infection	 populations	 of	 sufficient	 sample	 size	 to	 allow	 stratification	 of	
efficacy	estimates	by	infection	status.	However,	the	required	sample	size	would	likely	
be	 infeasible,	 so	 at	 a	minimum	 trials	 should	 recruit	 post-infection	 populations	 to	












disease,	 efficacy	 pre-	 and/or	 post-infection	 and	 duration	 of	 protection,	which	 are	
needed	 to	 inform	 vaccine	 Target	 Product	 Profiles.	 Several	 studies	 compared	
prevention	 of	 infection	 to	 prevention	 of	 disease	 vaccines,	 and	 consistently	 found	
prevention	of	disease	vaccines	to	provide	greater	impact	and	more	rapidly;	however,	
results	were	confounded	by	simultaneous	changes	 to	vaccine	delivery,	 so	 findings	








modelled	populations.	This	 lack	of	 in-depth	modelling	of	new	TB	vaccines	 in	China	
was	 a	 significant	 gap	 in	 the	 literature	 given	 its	 priority	 as	 a	 high	 burden	 country,	
ageing	population,	and	upcoming	phase	III	TB	vaccine	clinical	trial	results.	
These	research	gaps	were	addressed	in	Chapters	3	and	4,	 in	which	I	developed	an	
M.tb	 transmission	 model	 calibrated	 to	 age-stratified	 demographic	 and	
epidemiological	data	from	China,	and	applied	this	model	as	a	case	study	to	explore	
the	absolute	and	relative	epidemiological	impact	of	different	vaccine	characteristics	
and	 implementation	 strategies	 identified	 as	 research	 gaps	 in	 Chapter	 2.	 Results	
suggest	 that,	 in	 this	 setting,	 efficacy	 for	 prevention	 of	 disease	would	 provide	 the	





baseline	 in	 2050.	 The	 median	 characteristics	 for	 efficacy	 against	 infection	 and	
disease,	and	duration	of	protection	were	estimated	to	inform	the	minimum	and	ideal	
characteristics	in	TB	vaccine	target	product	profiles.		
The	 results	 of	 the	 second	 modelling	 study	 exploring	 vaccine	 implementation	
indicated	 that	 current	 development	 plans	 focussing	 on	 adolescents	 may	 have	
minimal	impact	on	the	burden	of	TB	in	China.	Even	at	much	lower	coverage,	older	












implications	 for	 current	 vaccine	 development	 strategy	 and	 planning	 vaccine	
platforms	for	implementation.	These	include	the	need	for	development	and	testing	
of	 candidates	 to	 explore	 efficacy	 against	 disease,	 particularly	 in	 post-infection	
populations,	 the	 inclusion	 of	 older	 adults	 in	 clinical	 trials,	 and	 planning	 delivery	
strategies	for	this	age	group.	These	recommendations	advocate	for	the	importance	
of	 including	 the	 above	 endpoints	 and	 populations	 in	 TB	 vaccine	 development,	
particularly	 those	currently	neglected	 in	many	development	strategies;	but	should	
not	be	 interpreted	as	 requiring	 the	exclusion	of	 infection	endpoints,	pre-infection	
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populations,	 or	 younger	 trial	 populations,	 as	 they	 may	 provide	 some	 additional	
benefit	if	sufficient	resources	are	available	to	include	them.		
Target	 product	 profiles,	 ideally	 informed	 by	mathematical	modelling	 as	 described	
above,	are	 translated	 in	 to	clinical	development	plans	 (CDPs)	designed	 to	develop	
appropriate	 candidates	 ready	 for	 delivery	 to	 identified	 target	 populations.	 As	




with	 known	 sufficient	 TB	 burden	 for	 vaccine	 trials.54	 Country	 and	 regional	 level	
programmatic	 tuberculosis	 data,	 and	 prevalence	 surveys	 where	 available,	 can	 be	





recruitment	 through	 identification	 of	 geographical	 hotspots	 in	 the	 intended	
recruitment	populations	(e.g.	HIV-negative	populations	or	specific	age	groups).		Given	
the	lack	of	sufficiently	granular	available	data,	and	the	expense	of	large	prospective	
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This	chapter	fulfilled	objective	4	of	the	thesis:	
a)	 Develop	 and	 implement	 a	 novel,	 low	 resource,	 rapidly	 implementable	 and	














Translation	 of	 tuberculosis	 (TB)	 vaccine	 Target	 Product	 Profiles	 (TPPs)	 into	
implementable	clinical	trials	requires	local	epidemiological	data	to	inform	trial	design	
and	 recruitment.	 Available	 prevalence	 and	 incidence	 studies,	 and	 country-	 and	
regionally-aggregated	 National	 Tuberculosis	 Programme	 (NTP)	 data	 can	 assist	
shortlisting	of	sites	with	sufficiently	high	TB	rates	to	conduct	a	clinical	trial.	However,	
as	 highlighted	by	 the	 TB	Vaccine	Blueprint	 epidemiological	 research	needs	 (Box	1	
Chapter	 1),	 following	 these	 preliminary	 regional-level	 assessments,	 local	 data	
stratified	 by	 likely	 recruitment	 characteristics	 and	 trial	 outcomes	 are	 required.	
Surprisingly	few	trial-ready	research	sites	have	sufficiently	granular	data	available	to	
inform	identification	of	high	TB	risk	recruitment	populations	and	to	assist	estimation	
of	 sample	 sizes	 that	 balance	 cost	 and	 risk.1	 Appropriate	 epidemiological	 data	 are	
essential	to	ensure	that	sufficient	participants	are	recruited	in	to	the	study	to	accrue	
an	adequate	number	of	endpoints	over	a	reasonable	timeframe.	




adults	 were	 identified	 as	 an	 age	 group	 of	 interest	 for	 vaccine	 implementation	
targeting.	 This	 may	 vary	 by	 epidemiological	 setting,	 but	 knowledge	 of	 burden	 of	
disease	 and	 identification	 of	 geographical	 disease	 hotspots	 by	 age	 could	 support	
development	of	studies	in	a	given	setting.	Efficacy	trials	often	exclude	HIV-positive	









three	 countries	 in	 the	 M72	 phase	 IIB	 trial).2	 Therefore,	 inexpensive	 and	 rapidly	
implementable	alternative	methods	are	needed	to	collect	sufficient	data	to	design	
late-phase	clinical	trials.	
Existing	 alternatives	 and	 their	 strengths	 and	 limitations	 are	 discussed	 in	 detail	 in	





can	 be	 extracted	 from	 NTP	 records	 to	 achieve	 clinic-level	 granularity,	 but	 clinic	
catchment	areas	may	be	large	(e.g.	100,000	population	in	India)	and	many	areas	of	
high	 TB	 burden	 are	 in	 low-income,	 urban	 settings	 that	may	 be	missing	municipal	





by	 travelling	 directly	 home	with	 the	 patient,	 or	 recruiting	 them	 at	 the	 clinic	 and	
arranging	 a	 later	 follow	 up	 visit	 at	 the	 home.	 However,	 the	 former	 requires	
substantial	 human	 resourcing	 and	 logistics,	 whereas	 the	 latter	 may	 experience	
substantial	 loss	 to	 follow	 up	 given	 the	 challenges	 of	 contacting	 and	 finding	 the	
participants.		
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To	 remove	 the	 need	 for	 home	 visits	 in	 an	 HIV	 testing	 cluster-randomised	 trial	 in	
Malawi,	 a	 map	 book	 system	 for	 clinic-based	 capture	 of	 cluster	 residency	 was	
developed.4,5	The	map	book	consisted	of	a	series	of	paper	maps	marked	with	points	
of	 interest	 (POIs)	 and	 the	 cluster	 boundaries	 from	 the	 parent	 study	 to	 allow	
identification	 of	 study	 cluster.	 An	 evaluation	 of	 the	 tool	 in	 40	 participants	 by	






for	 the	design	of	a	new	tool,	an	electronic	 tablet-based	application	 (app)	 to	more	
accurately	identify	a	patient’s	place	of	residence	when	registering	for	TB	treatment.	
The	map	book	was	developed	in	Blantyre,	Malawi,	an	urban,	high	TB	burden	setting,	
lacking	 the	municipal	address	 system	needed	 for	 identification	of	patient	place	of	
residence.	Malawi	has	one	of	the	top-20	fastest	growing	urban	populations	globally,6	





TB	 cases	 provided	 the	 ideal	 setting	 for	 development	 and	 implementation	 of	 an	




spatial	 mapping	 app	 in	 Blantyre,	 Malawi,	 with	 the	 aim	 of	 mapping	 the	 place	 of	
















local	 study	 leads,	 and	 Frank	 Chipaka	 and	 George	 Sinjani	 provided	 project	
management	support.	RCH,	LC	and	PM	developed	the	research	question.	RCH,	LC,	
RW,	PM	and	EW	conceptualised	and	designed	 the	 study.	AM	developed	 the	ePAL	
software.	 Data	 and	 POI	 management	 was	 conducted	 by	 WS	 and	 RCH.	 MLW	
server/data	management	was	supported	by	Lingstone	Chiume,	David	Matiya,	Vincent	
Phiri	 and	 McEwan	 Khundi.	 RCH	 and	 EW	 conducted	 data	 cleaning	 and	 analysis.	
Production	of	monthly	reports	was	conducted	by	RCH	until	May	2015,	beyond	which	






































Methods:	 High-resolution	 satellite	 maps	 were	 annotated	 with	 points	 of	 interest	
(POIs)	captured	by	community	health	workers	and	loaded	onto	electronic	tablets	for	
use	with	 a	 bespoke	 ‘electronic	 PArticipant	 Locator’	 application	 (ePAL	 app;	 Tripod	
Software,	 Salford)	 combining	 touch-screen	 Global	 Positioning	 System	 (GPS)	
coordinate	capture	with	an	electronic	tuberculosis	register.	Following	training,	ePAL	
was	 used	 by	 tuberculosis	 officers	 from	 11	 primary	 care	 clinics	 for	 collection	 of	
demographics,	 health	 status	 and	 coordinates	of	place	of	 residence	 for	 consenting	
adults	 (≥18	 years)	 initiating	 TB	 treatment.	 Case	 capture	 and	 data	 quality	 were	











of	 residence	of	patients	presenting	at	TB	clinics	 in	areas	 lacking	 formal	addresses.	














and	 rate-limiting.1	 This	 reflects	 the	 combination	 of	 the	 suboptimal	 and	 costly	




trial	 recruitment,	assist	 sample	size	minimisation,	and	help	de-risk	 study	endpoint	
accrual.1	Public	health	programmes	could	also	benefit	from	such	data	for	design	and	
targeting	 of	 local	 TB	 prevention	 and	 care	 programmes.	 However,	 the	 prohibitive	
factors	affecting	clinical	trials	often	also	preclude	formal	prospective	cohort	studies	
to	 inform	clinical	 trial	 design	and	 site	 selection	ahead	of	 trial	 initiation.	 They	also	





inform	planning.	Methods	of	 recording	patient	place	of	 residence	 in	NTP	registers	
often	lack	the	clarity	and	reproducibility	required	to	support	disaggregation.4,10,11	
Africa	 and	Asia	 are	 urbanising	 rapidly	 (>1%	per	 year).6	 Inadequate	 town	 planning	
capacity	has	left	more	than	half	of	city	streets	in	sub	Saharan	Africa	without	a	formal	
















annotated	with	points	of	 interest	 (POIs)	 for	 identification	of	place	of	 residence	 in	
urban	settings.	 In	this	study,	a	paper-based	“map	book”	was	used	by	DHO	staff	to	
assist	patients	in	identifying	whether	they	were	resident	in	one	of	28	research	study	
catchment	 areas	 (~1,300	 adults)	 in	 Blantyre,	 Malawi.4	 The	 study	 found	 excellent	
agreement	between	cluster-residency	defined	in	the	clinic	using	the	“map	book”	and	
cluster	residency	obtained	through	home-visits	(97.5%,	n=40).4		



















density	 informal	 residential	 settlements	 and	 an	 estimated	 population	 of	
approximately	750,000	in	2016.	All	11	TB	registration	centres	that	served	Blantyre	
City	participated	in	the	study,	including	two	public	and	three	private	hospitals,	and	























maps.	 Following	 several	 iterations,	 features	 of	 the	 app	 to	 facilitate	 prompt	 and	




RAM,	 16GB	 eMMC)	 were	 used	 for	 the	 implementation	 study.	 	 Data	 entry	 was	
facilitated	through	use	of	simple	instructions	in	a	choice	of	English	or	Chichewa,	and	
large	 buttons	 for	 data	 entry.	 Verbal	 consent	 and	 checks	 against	 inclusion	 and	









Following	 a	 one-day	 training	 session	 for	 all	 44	 TB	 officers	 and	 nurses	 working	 in	
Blantyre’s	TB	clinics,	implementation	of	the	ePAL	app	began	in	November	2014.	Each	

























one	 of	 three	 high-density	 neighbourhoods	 of	 Blantyre	 (Figure	 5.2),	 described	
elsewhere.5	Evaluation	in	these	settlements	tested	accuracy	in	the	highest	density,	
and	 therefore	most	 challenging,	 areas	 in	which	 to	 ascertain	 location	 of	 residence	
using	ePAL.	GPS	coordinates	collected	at	the	participant’s	place	of	residence	were	
used	 to	 evaluate	 the	 spatial	 accuracy	 of	 the	 ePAL-collected	 coordinates.	 A	 study	
research	assistant	was	guided	to	the	residence	by	the	participant,	and	collected	an	






Statistical	analyses	were	conducted	 in	Stata	 (version	13.1)	and	R	 (version	3.3.1).15	
Descriptive	analyses	of	the	recruitment	population	for	the	main	study	were	reported	
for	 the	12	months	of	 the	study.	For	the	evaluation	cohort,	 the	 ‘spDists’	command	
within	the	‘sp’	R	package	was	used	to	calculate	the	distance	in	metres	between	the	
ePAL	 and	 evaluation	 GPS	 spatial	 point	 for	 each	 participant	 using	 the	 great	 circle	
distance	method	(WGS84	ellipsoid).	ePAL	accuracy	was	assessed	by	the	median	and	












University	 of	 Malawi	 College	 of	 Medicine	 (COMREC)	 and	 the	 London	 School	 of	
Hygiene	 and	 Tropical	Medicine	 (LEO).	 All	 participants	 in	 the	main	 study	 provided	














need	for	additional	electronic	 tablets	 in	 the	busiest	clinics.	1,899	 (98.7%)	of	1,924	
eligible	 adults	 agreed	 to	 participate,	 with	 the	main	 reasons	 for	 non-participation	
being	not	wishing	to	participate	in	research	(n=12),	time	pressure	(n=3),	not	wanting	








Participants	 were	 mostly	 male	 (n=1,167,	 61.4%),	 and	 mean	 age	 was	 37.9	 years.	
Sputum	smear	microscopy	results	were	available	for	56.9%	(n=1,080)	of	participants,	
of	 whom	 58.8%	 (n=636)	 were	 smear	 positive.	 Overall,	 43%	 of	 patients	 had	
microbiologically	 confirmed	 disease	 (microscopy,	 Xpert	 or	 culture)	 at	 time	 of	
registration	for	TB	care.	The	majority	were	classified	as	previously	untreated	‘new’	
TB	cases	(n=1,661,	87.5%),	with	5.6%	relapse,	6.3%	‘other’,	and	<1%	were	treatment	





ePAL	 (Figure	 5.3),	 of	 which	 1,229	 reported	 residence	 in	 urban	 Blantyre.	Monthly	
estimates	of	coordinate	capture	for	those	self-reporting	residency	in	Blantyre	ranged	
77%	 (95%	 CI:	 68-85%)	 to	 95%	 (95%	 CI:	 89-98%).	 Two	 percent	 of	 those	 reporting	
residence	 outside	 of	 urban	 Blantyre	 had	 ePAL	 coordinates	 falling	 within	 urban	



















evaluation	 area	 provided	 written	 consent	 to	 participate.	 Follow	 up	 of	 these	




(Interquartile	 range	 (IQR):	 35m-317m).	 The	minimum	estimated	distance	was	4m,	
and	 the	greatest	was	11.6km,	with	 the	participant	having	GPS-recorded	 residency	











of	 a	 difference	 in	 the	 evaluation	 distance	 distributions	 between	 health	 centres	





and	 evaluation	 GPS	 coordinates.	 None	 of	 20	 possible	 explanatory	 variables	 were	
significantly	 associated	 with	 large	 displacement,	 including	 study	 month.	 A	
Spearman’s	 rank	 test	 for	 correlation	 between	month	 and	 distance	was	 also	 non-
significant	(p=0.13).		
In	 the	 larger	monitoring	data	set	 for	 the	 full	12	months	of	 the	study,	a	significant	
relationship	 between	 large	 errors	 (>1km)	 and	 patient-level	 factors,	 notably	 HIV	
status,	raised	the	question	of	whether	some	patients	had	deliberately	misinformed	
TB	officers	about	the	true	location	of	their	household,	motivated	by	TB	and/or	HIV	
stigma.	 Informal	 interview	 during	 home	 visits	 identified	 various	 patient-level	
explanations,	for	instance	staying	with	relatives	for	diagnosis.		However,	these	data	
were	not	fully	systematically	captured.	
Median	 time	 lag	 between	 ePAL	 entry	 and	 evaluation	 data	 upload	 (latest	 possible	
follow	up	date)	was	26	days	(IQR:	14-37	days).	The	Spearman’s	correlation	between	
the	 evaluation	 distance	 and	 data	 collection	 lag	 estimate	 was	 0.12	 (p=0.17),	









PArticipant	 Locator),	was	 developed,	 implemented	 and	 evaluated	 in	 collaboration	
with	the	National	TB	Programme	and	District	Health	Office	in	Blantyre,	Malawi,	was	
that	 this	 provided	 a	 rapidly	 implementable	 and	 sustainable	 approach	 to	 remote	
capture	of	place	of	residence	for	patients	with	no	formal	address	system.		
Monthly	 feedback	 meetings	 supported	 troubleshooting	 and	 near	 complete	 case-
capture	 within	 a	 few	 months	 of	 implementation.	 	 Real-time	 collection	 of	 GPS	
coordinates	was	sufficiently	accurate	for	most	patients	to	support	real-time	spatial	
analysis	of	disease	burden,	and	interventions	such	as	household	contact	screening.		
Home	visits	showed	substantial	errors	 in	household	 identification	 for	about	1	 in	7	
patients,	 however,	 reflecting	 issues	 such	 as	multiple	 places	 of	 residence,	 but	 also	
likely	deliberate	misidentification	by	some	patients.	Data	generated	by	ePAL	has	high	











meetings	 with	 the	 TB	 officers.	 This	 may	 have	 also	 contributed	 to	 very	 high	
participation	rates.	The	app	interface	and	training	were	designed	for	ease	of	use	by	
individuals	without	experience	of	electronic	data	collection.	Error	rates	were	low	for	
single-entry	 electronic	 data	 capture.	 Implementation	 was	 rapid	 and	maintenance	
was	relatively	low	in	cost	and	staff	time.		
This	tool	can	be	adapted	for	use	in	different	settings,	with	the	main	investment	for	




One	 full	 time	 field	 staff	 member	 was	 employed	 for	 ongoing	 monitoring	 and	
evaluation	 visits,	 which	 is	 likely	 to	 be	 essential	 for	 maintaining	 as	 well	 as	
understanding	accuracy	and	case-capture.	Our	use	of	tablets	instead	of	computers	
kept	 hardware	 costs	 for	 electronic	 data	 capture	 low,	 and	 avoided	 reliance	 on	
unstable	sources	of	electricity	and	internet.	With	the	support	of	the	District	Health	




ePAL-based	 data	 collection	 was	 successfully	 incorporated	 in	 to	 the	 National	
Tuberculosis	Programme	through	this	integration	in	to	routine	patient	registration.	





accuracy	 diminished	over	 time.	 Results	 of	 the	 study,	 including	 health	 centre-level	
reports,	were	provided	to	the	NTP	and	TB	officers	on	a	monthly	basis.	
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We	 estimate	median	 distance	 between	 the	 ePAL	 coordinates	 and	 GPS-measured	
coordinates	 to	 be	 84m	 (IQR:	 35-317m).	 The	 median	 would	 correspond	 to	
approximately	6	to	8	dwellings	from	the	patient’s	residence	 in	the	highest	density	
areas,	but	as	close	as	the	adjacent	structure	in	low-density	suburbs.	The	accuracy	of	
GPS	 measurements	 at	 the	 home	 was	 maximised	 by	 taking	 averaged	 waypoints,	
reducing	the	inherent	inaccuracy	of	measurement	to	a	few	metres,	although	this	will	
have	been	increased	by	cloud	cover,	rain,	and	proximity	to	buildings.		Home-visit	and	
ePAL	GPS	 readings	 used	 slightly	 different	 reference	 points	 (from	 the	 front	 of	 the	
building	 at	 home-visit,	 but	 centre	 of	 the	 building	 image	 on	 the	 satellite	 maps),	
introducing	 unavoidable	 ‘inaccuracy’	 even	when	 fully	 correct.	 The	 evaluation	was	












such	 large	 differences	 were	 mostly	 due	 to	 relocation,	 for	 instance	 temporary	
residence	with	a	relative	to	seek	TB	care,	and	also	as	a	result	of	heavy	rainfalls	and	





The	 main	 limitation	 was	 the	 difficulty	 of	 conducting	 home	 visits	 in	 high	 density	
informal	settlement	areas,	which	followed	verbal	description	given	to	TB	officers	and	
recorded	in	the	paper	NTP	register	(the	standard	approach	before	ePAL).	Use	of	ePAL	
coordinates	 was	 avoided	 to	 prevent	 observer	 bias.	 	 Tracking	 down	 the	 correct	
households	 proved	 very	 time-consuming,	 leading	 to	 some	 long	 delays	 between	
registration	 and	 home	 visit	 (IQR:	 14-37,	 maximum	 182),	 and	 was	 completely	
unsuccessful	 in	 50	 (29.2%)	 of	 patients	 registering	 in	 the	 four-month	 evaluation	

















































































0	≤	m	<	20	 16	 13.2%	(7.8-20.5)	 16	
13.2%	
(7.8-20.5)	
20	≤	m	<50	 27	 22.3%	(15.2-30.8)	 43	
35.5%	
(27.0-44.8)	
50	≤	m	<	100	 24	 19.8%	(13.1-28.0)	 67	
55.3%	
(46.0-64.4)	
100	≤	m	<	200	 18	 14.8%		(9.1-22.5)	 85	
70.2%	
(61.2-78.2)	
200	≤	m	<	500	 12	 9.9%	(5.2-16.7)	 97	
80.2%	
(71.9-86.9)	
500	≤	m	<	1000	 7	 5.8%	(2.4-11.6)	 104	
86.0%	
(78.5-91.6)	
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the	 POI	 labels	 on	 and	 off.	 This	 is	 of	 use	 if	 a	












































Chichewa	 in	 the	 settings	 section	of	 the	app.	TB	
centre	is	selected	in	the	settings	to	allow	correct	
auto-generation	 of	 the	 ePAL	 participant	
reference	 (as	 this	 starts	 with	 the	 centre	 code).	
Initials	 of	 new	 data	 collectors	 to	 appear	 as	




Top	 left:	 ePAL	 map	 fully	 zoomed	 out	 (zoom	 12)	
demonstrating	POI	search	function.	Red	boundaries	





green	 =	 shop,	 blue	 =	 place	 of	 worship,	 purple	 =	
bridges	 and	 public	 structures,	 white	 =	 plots	 and	
other).	
	
Bottom	 left:	 ePAL	 map	 at	 full	 zoom	 (level	 19)	
demonstrating	 the	 high	 density	 of	 structures	 and	
high	coverage	of	POIs.	When	a	place	of	residence	is	
selected	by	the	user,	the	red	pointer	labelled	“Me”	














field	 tested.	 Eighteen	 randomly	 selected	 adults	 attending	 a	 market	 place	 in	 the	
annotated	area	were	invited	to	participate.	Those	verbally	consenting	to	participate	
were	 asked	 to	 identify	 and	 mark	 their	 place	 of	 residence	 on	 a	 printed	 map	 (six	
participants	for	each	POI	density),	then	accompanied	by	a	field	worker	to	their	place	















Inherent	 inaccuracies	 in	 GPS	 receivers	 and	 methods	 of	 GPS	 collection	 affect	 the	




receivers	 are	 estimated	 as	 “typically	 accurate	 to	 within	 10	meters”.17	 Combined,	
these	 two	 contribute	 to	 an	 overall	 GPS	 reader	 error	 of	 approximately	 10m.	




Study	 design	 and	 standard	 operating	 procedures	 endeavoured	 to	minimise	 these	
errors.	Firstly,	to	maximise	accuracy	of	the	GPS	measurements,	waypoint	averaging	
was	employed.	This	functionality	takes	a	measurement	every	second	until	the	sample	
size	 is	 large	enough	 that	 the	estimate	of	 the	mean	remains	stable	with	additional	
sampling	 (defined	 on	 the	 handset	 as	 “100%	 confidence”).	 This	 process	 takes	 3-5	




In	 the	clinic,	ePAL	users	 selected	 the	centre	of	 the	participant’s	dwelling	as	doors	
were	not	visible	on	the	maps.	Therefore,	 the	GPS	data	collection	method	ensured	
adequate	 signal	 strength,	but	 contributed	 to	a	 consistent	offset	of	 several	metres	
from	the	location	of	the	dwelling	if	correctly	identified	on	ePAL.	

















and	 data	 analysis	 for	 monthly	 monitoring	 was	 conducted	 in	 Stata,	 version	 13.1	
(StataCorp	LP,	College	Station,	Texas).		










the	 ‘raster’	 package	 ‘pointDistance’	 command,	 ‘geosphere’	 package	 ‘distm’	
command,	and	the	‘sp’	package	‘spDists’	command.	The	difference	between	these	
	Chapter	5:	electronic	PArticipant	Locator	app	 334	







the	 key	 monitoring	 aspects	 was	 appropriate	 capture	 of	 coordinates.	 The	 overall	
coordinate	capture	of	those	reporting	urban	Blantyre	residence	was	89%.	Monthly	
point	 estimates	 of	 the	 proportion	with	 available	 coordinates	 ranged	 77%	 to	 95%	
(Table	5.4).	Through	monitoring	and	feedback	to	the	TB	officers	at	monthly	meetings,	
coordinate	capture	was	maintained	at	high	levels.	










































Exact	 time	 between	 clinic	 registration	 and	 evaluation	 follow	 up	 visit	 was	 not	
recorded.	 However,	 date	 of	 upload	 of	 evaluation	 visit	 data	 was	 available,	 so	 lag	
between	 date	 of	 collection	 and	 latest	 possible	 follow	 up	 date	 was	 estimated.	 As	
discussed	in	section	5.2,	mean	lag	between	ePAL	entry	and	latest	possible	follow	up	
was	 26	 days	 (IQR:	 14-37	 days),	 ranging	 from	 2	 days	 to	 182	 days	 (Figure	 5.7).	















































































the	 study	were	 invited	 to	participate	 in	 the	evaluation	visit	 at	 the	home.	Consent	
rates	 for	evaluation	visits	were	very	high,	and	 if	100%	 follow	up	were	achievable,	

























In	 moving	 forward	 with	 ePAL	 after	 the	 12-month	 study	 period,	 evaluation	
transitioned	to	monitoring	visits.	These	followed	the	same	format	as	evaluation	visits,	
but	were	conducted	for	5%	of	registrations	(at	 least	1	per	centre	per	month).	The	
written	 consent	 and	 evaluation	 questions	 were	 removed	 from	 the	 app	 as	 the	
evaluation	 period	 had	 finished.	A	 small	 number	 of	 key	 risk	 factor	 questions	were	
moved	into	the	case	report	form.		
Ethics	approval	has	been	sought	and	granted	for	de-escalating	the	enrolment	age	for	
ePAL	 data	 collection	 as	 part	 of	 the	 “Hit	 TB	 Hard”	 study	 to	 include	 children.	 For	






















in	Blantyre	 are	 city	 residents.	 Results	of	 the	ePAL	 study	demonstrate	 that	 a	 large	
proportion	(27%,	n=	514)	of	those	registering	in	Blantyre	are	rural	Blantyre	or	out-of-
district	residents.	A	TB	vaccine	trial	with	a	sample	size	based	upon	NTP	data	would	











As	can	be	seen	 in	Figure	5.9A	above,	the	majority	of	 incident	TB	cases	 in	Blantyre	
were	focussed	in	central	and	central-west	areas	of	the	city.	This	high	concentration	







vaccine	 trial	 recruitment.	 However,	 several	 additional	 areas	 are	 highlighted	 once	





For	ongoing	clinical	 trials,	 the	exact	definition	of	 ‘disease’	varies	between	studies,	
with	 some	measuring	effect	against	purely	microbiologically	 confirmed	endpoints,	
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and	others	 using	broader	 clinically-defined	endpoints.2,19	 The	 results	 in	 Figure	 5.9	
would	 most	 likely	 be	 directly	 relevant	 for	 studies	 measuring	 clinically	 defined	
endpoints.	Some	studies	limit	the	outcome	to	pulmonary	disease,	therefore	mapping	
exclusively	of	pulmonary	disease	may	be	more	 informative.	 Sixty	percent	of	 ePAL	







This	would	not	 be	 an	 accurate	 estimate	of	 the	disease	 rates	 and,	 potentially,	 the	
location	 of	 patients	 in	 studies	 where	 outcomes	 are	 limited	 to	 microbiologically	
confirmed	disease.	In	this	study	only	43%	of	patients	had	microbiologically	confirmed	
disease	at	time	of	registration.	In	the	subset	of	patients	resident	in	urban	Blantyre	
with	 coordinates	 available,	 48%	 were	 microbiologically	 positive	 at	 time	 of	
registration.	 Therefore,	 exploring	 the	 distribution	 and	 rates	 of	 microbiologically	







One	 limitation	of	 this	 approach	 is	 the	delay	 in	 culture	 results	becoming	available.	
Planned	future	analyses	include	merging	the	ePAL	database	with	culture	results	from	
the	 parent	 study	 (Hit	 TB	Hard),	 to	 include	 patients	with	 culture	 results	 becoming	
available	after	the	treatment	initiation	visit.	






age	 ranges	 (e.g.	 13-15	 years).	Map	A	 in	 Figure	5.12	demonstrates	 the	anticipated	
rates	in	18-25	years	olds	as	an	example	of	the	distribution	that	could	be	expected	in	
more	 limited	young	adult	age	groups.	The	age	for	 inclusion	 in	ePAL	has	now	been	
























when	 the	 primary	 outcome	 is	 limited	 to	 microbiologically-positive	 pulmonary	
disease.	 In	 these	 first	 two	 figures	 all	 participants	 are	 included,	whereas	 in	 Figure	
5.14C	 it	 was	 assumed	 that	 recruitment	 criteria	 would	 exclude	 HIV	 positive	
populations.	Enumeration-area	 level	HIV	prevalence	was	not	available	 to	estimate	














underpowered.	 Importantly,	 several	 enumeration	 areas	 marked	 with	 a	 *	 were	
particularly	affected	by	the	change	in	outcome	or	recruitment	criteria.	These	areas	
may	 be	 suitable	 for	 a	 trial	 with	 a	 broad	 outcome	 measure	 and	 recruitment	
population,	but	become	unsuitable	if	the	trial	design	is	more	restrictive.	
These	analyses	serve	as	an	example	of	mapping	to	inform	trial	design	with	the	ePAL	







innovation	 in	 approaches	 to	 proof	 of	 concept	 studies.	 One	 such	 innovation	 is	
conducting	 prevention	 of	 relapse	 (POR)	 studies	 for	 phase	 IIB	 proof	 of	 concept	 of	
efficacy	before	progressing	to	phase	 III	POD	studies.	POR	 is	effectively	a	subset	of	






















vaccines	 effective	 post	 infection	 will	 be	 important	 to	 maximise	 vaccine	 impact.	
Therefore,	 recruitment	 of	 latently	 infected	 populations	 in	 TB	 vaccine	 trials	 for	
demonstration	of	safety,	and	ideally	efficacy,	will	be	essential.	Testing	for	latency	is	
generally	 either	 an	 inclusion	 criterion	 or	 part	 of	 initial	 participant	 assessments	 to	
ensure	infection	status	is	known	at	time	of	vaccination.	The	M72	and	M.vaccae	TB	


















of	 burden	of	 TB	disease	 in	 high	burden	urban	 settings	without	municipal	 address	
systems.	 Additional	 questions	with	 regards	 to	 demographic	 or	 risk	 factors	 can	 be	
included	 in	 the	 eCRF	 to	 allow	 stratification	 of	 the	 data	 by	 potential	 recruitment	
characteristics.	
One	of	 the	main	 limitations	of	ePAL	 for	 the	estimation	of	notification	 rates	 is	 the	
availability,	quality	and	relevance	of	the	denominator	data.	In	Blantyre,	census	data	
were	 readily	 available	 to	 allow	 estimation	 of	 notification	 rates	 by	 census	





using	 these	 denominators	 may	 be	 over-estimated.	 An	 enumeration	 study	 has	
recently	been	conducted	in	Blantyre	to	improve	these	estimates,	so	planned	future	






alternatively	 progress	 in	 the	 use	 of	 satellite	 imagery	 for	 population	 enumeration	
could	allow	the	high-resolution	satellite	maps	to	be	used	for	enumeration.21	
As	 mentioned	 in	 section	 5.5.3,	 ePAL	 would	 have	 limited	 utility	 in	 informing	


















In	 a	 typhoid	 study	 led	 by	 Franziska	 Olgemoeller	 and	 Nick	 Feasey,	 ePAL	 has	 been	
























denominator,	 and	 conducting	 observed	 versus	 expected	 analyses	 to	 identify	
statistically	significant	TB	hotspots.	 In	addition,	several	TB	vaccines	 in	 the	pipeline	
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context	 of	 existing	 research	 and	 the	 current	 TB	 vaccine	 pipeline.	 I	 provide	
recommendations	for	development	of	TB	vaccines	from	the	perspective	of	vaccine	











product	 profiles	 (TPPs).	 Available	 data	 to	 inform	 clinical	 trial	 design	 often	 lacks	
granularity,	 and	 prospective	 data	 collection	 tends	 to	 be	 expensive	 and	 time	
consuming.	 Through	 the	 research	 presented	 in	 this	 thesis	 I	 aimed	 to	 inform	 the	
development	of	appropriate	TB	vaccines	and	target	populations	to	maximise	future	
population-level	impact,	and	help	selection	of	trial	sites	and	recruitment	populations	
to	 accelerate	 vaccine	 development.	 This	 was	 achieved,	 firstly,	 through	 the	

































calibrated	 transmission	 model	 of	 TB	 epidemiology	 in	 China,	 followed	 by	 the	
incorporation	of	new	TB	vaccines	to	explore	the	epidemiological	impact	of	different	
combinations	 of	 efficacy	 against	 infection	 and	 disease,	 pre-	 versus	 post-infection	
vaccines,	 and	 varied	 durations	 of	 protection	 and	 frequencies	 of	mass	 vaccination	
campaigns.	Population-level	impact	of	these	vaccines	implemented	over	2025-50	was	

















This	was	achieved	 through	 the	development,	 implementation	and	evaluation	of	 a	
novel	 app	 (ePAL)	 integrated	 in	 to	 the	 NTP	 in	 Blantyre,	 Malawi,	 for	 clinic-based	
identification	 of	 place	 of	 residence	 of	 patients	 registering	 for	 TB	 care.	Using	 data	



























effective	 with	 post-infection	 vaccines.	 However,	 when	 comparing	 identical	
vaccines,	 older	 adult	 vaccination	 provided	 consistently	 greater	 impact,	 so	 to	










- Shorter	 durations	 of	 protection	 could	 be	 compensated	 for	 by	 increasing	 the	
frequency	of	mass	campaigns	(e.g.	5-yearly).	




- In	 China,	 to	 achieve	 20-29%	 incidence	 rate	 reduction	 in	 2050	 with	 5	 years	
duration	 of	 protection	 and	 10-yearly	 mass	 campaigns,	 the	 required	 median	
vaccine	efficacies	were:	prevention	of	disease	(VE-POD)	40%	(range:	0-60%)	and	











adolescent	 vaccination,	 even	 if	much	 lower	 coverage	were	 achieved	 in	 older	
adult	vaccination.	
- Post-infection	 vaccines	 provided	 substantial	 impact	 when	 delivered	 to	 older	
adults,	 whereas	 impact	 was	 negligible	 when	 this	 vaccine	 was	 delivered	 to	
adolescents.	Although	pre-infection	vaccines	provided	relatively	similar	levels	of	
impact	when	vaccinating	either	age	group,	the	 impact	was	substantially	 lower	
than	 that	 achievable	 with	 vaccination	 of	 older	 adults	 with	 a	 post-infection	
vaccine.	
- Recommendations	 for	 post-infection	 vaccines	 were	 robust	 to	 substantial	
reductions	in	efficacy	and	duration	of	protection	in	older	adults,	whereas	for	pre-
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infection	 vaccines	 the	 preference	 for	 older	 adult	 vaccination	 could	 be	
diminished.	




- With	 the	 adolescent/adult	 delivery	 strategy,	 the	maximum	possible	 incidence	
rate	reduction	in	2050	was	79%	(UR:	77%-81%)	reducing	incidence	to	7	(UR:	6-8)	
cases	per	100,000	population.	This	was	achieved	with	100%	protection	against	






to	 adolescents,	 or	 3.0	 million	 (UR:	 2.5-3.5m)	 cases	 through	 older	 adult	
vaccination	campaigns.		





























The	 systematic	 review	 publication	 included	 in	 Chapter	 2	 is	 the	 first	 and	 only	
publication	 in	 the	 literature	 to	 bring	 together	 the	 available	 literature	 on	
mathematical	 modelling	 of	 the	 epidemiological	 impact	 of	 new	 TB	 vaccines.	 This	
research	provides	 a	 comprehensive	 summary	of	 the	 available	 literature,	 and	 is	 of	
significance	for	informing	TB	vaccine	development	as	it	provides	summaries	of	the	
research	available	to	inform	several	key	aspects	of	TB	vaccine	TPPs.	The	article	also	




In	 the	 mathematical	 modelling	 research	 in	 this	 thesis,	 I	 developed	 a	 highly	 age-






incorporated	social	 contact	patterns.1	This	 study	confirmed	the	 importance	of	 the	
inclusion	of	social	contact	patterns	and	age	stratification	in	TB	transmission	models,	
and	demonstrated	this	in	the	context	of	TB	vaccines,	which	validates	the	decisions	
made	 in	 my	 research	 to	 create	 such	 a	 highly	 age-stratified	 model	 incorporating	
heterogeneous	 mixing.	 The	 Arregui	 publication	 is	 a	 top-level	 assessment	 of	 the	
impact	 of	 a	 single	 vaccine	 type	 at	 the	 regional	 level,	 and	 uses	 European	 mixing	
patterns	scaled	to	regional	demographics	to	inform	social	mixing.1	My	research	takes	
this	a	step	further,	modelling	a	comprehensive	range	of	vaccine	characteristics	at	the	
country	 level,	 parameterising	 with	 a	 country-specific	 contact	 matrix.	 The	 use	 of	
country	 specific	 data	was	 considered	 important,	 as	 this	 accounts	 not	 just	 for	 the	
impact	of	demographics	on	contact	patterns,	but	also	includes	any	social	influences	
on	contact	patterns.	
This	 research	 was	 the	 first	 to	 explore	 the	 potential	 impact	 of	 new	 TB	 vaccines	
targeted	to	older	age	groups,	and	to	provide	a	comparison	of	this	approach	to	the	
current	 strategic	 focus	 on	 adolescent	 vaccination.	 This	 required	 the	 age-specific	
model	parameterisation	and	calibration	mentioned	above,	and	is	the	first	China	TB	
model	 to	 include	 calibration	 to	 age-stratified	mortality	 and	notification	 rates.	 The	










and	 post-infection).	 Such	 a	 comprehensive	 exploration	 of	 vaccine	 characteristics	
provides	a	detailed	analysis	of	the	impact	individually	and	in	tandem	of	the	different	
characteristics,	 and	 also	 ensures	 that	 once	 trial	 results	 become	 available	 that	
modelling	results	are	available	for	the	relevant	characteristics.	
This	modelling	has	been	developed	in	the	context	of	only	two	other	China	TB	vaccine	
modelling	 studies,	 one	 of	 which	was	 only	 published	 in	 2017.2,3	 	 Neither	 of	 these	
existing	 publications	 accounted	 for	 age	 specificities	 in	 epidemiology	 or	
demographics.	Further,	in	these	studies,	vaccination	was	either	at	birth	or	all-ages,	
and	vaccine	characteristics	modelled	were	unclear	or	unrealistic	(e.g.	100%	vaccine	



















locally-relevant	 POIs	 in	 the	 initial	 development,	 and	 ongoing	 feedback	 and	
improvement	of	the	app	and	data	collection	through	regular	meetings	with	the	TB	







ePAL	 development	 and	 implementation	 was	 rapid,	 with	 POI	 collection	 for	 local	
adaptation	 of	 the	 app,	 training	 of	 data	 collectors,	 implementation,	 and	 a	 run-in	
period	for	refining	the	app	and	field	usage	achieved	in	less	than	five	months.	With	
lessons	learned	from	this	study,	future	sites	 implementing	ePAL	could	achieve	this	







The	main	 limitation	of	 the	systematic	 review	was	 the	single-reviewer	approach	 to	
literature	sifting.	Risks	from	this	approach	were	minimised	as	the	sifting	was	repeated	














retaining	 reinfected	 recovered	 populations	 in	 the	 recovered	 state.	 Such	 a	 change	
would	not	have	an	effect	on	the	direction	of	impact	or	conclusions	of	this	research.	
It	would	be	anticipated	to	marginally	increase	the	number	and	proportion	of	cases	
arising	 from	 the	 recovered	population	and	would	 likely	 strengthen	 the	conclusion	





death,	 death	 from	 other	 causes,	 or	 natural	 cure.	 A	 more	 realistic	 approach	 to	





if	 such	 data	 were	 available,	 the	 model	 could	 be	 re-structured	 to	 allow	 a	 certain	
proportion	of	case	detection	to	occur	within	6	months	of	onset,	and	the	remainder	
to	 occur	 over	 time,	with	 the	 rate	 of	 detection	 linked	 to	 disease	 progression.	 This	
would	be	achieved	by	developing	a	series	of	disease	states	representing	progression	
of	untreated	disease,	and	each	state	would	be	associated	with	a	case	detection	ratio.	








progressing,	 but	 was	 considered	 too	 uncertain	 to	 be	 able	 to	 include	 other	 new	
interventions	 in	 this	 research.	 The	 introduction	of	new	diagnostics	 and	 treatment	
regimens	could	potentially	alter	the	course	of	the	epidemic.	If	this	were	to	occur,	the	
estimations	 of	 absolute	 impact	 of	 new	 TB	 vaccines	 could	 potentially	 be	 an	
overestimate.	 The	 relative	 impact	 of	 the	 different	 vaccine	 types	 would	 not	 be	
anticipated	to	be	affected.	Perhaps	with	the	exception	of	a	highly	safe	and	effective	
treatment	for	clearance	of	latent	infection,	which	if	safe	in	the	elderly	could	impact	
the	 relative	 impact	 of	 the	 different	 vaccine	 types.	 Due	 to	 high	 current	 treatment	
success	and	case	detection	estimates	 in	China,	 these	were	assumed	 to	plateau.	 If	





represented	 this	 uncertainty	 by	 sampling	 from	 elderly	 parameter	 priors	 spanning	
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HIV-negative	and	HIV-positive	adult	ranges	in	the	calibration	process.	The	extreme	
end	 of	 the	 HIV	 ranges	 may	 not	 be	 reflective	 of	 immunesenescence,	 but	 fitting	
methods	 allowed	 sampling	 from	 this	 range	 to	 allow	 for	 the	 potential	 impact	 of	
immunosenescence.	 Immunosenescent	 waning	 of	 vaccine	 efficacy	 was	 also	 an	
unknown,	so	was	assumed	2%	per	year	waning	in	the	elderly	population	in	the	main	
analysis,	 and	 explored	 up	 to	 5%	 in	 sensitivity	 analyses.	 Results	 were	 robust	 to	
immunosenecent	sensitivity	analyses.	
Given	population	ageing,	the	assumption	that	the	contact	matrix	remained	constant	
throughout	 the	 study	 period	 may	 provide	 conservative	 impact	 estimates.	 Larger	
older	adult	and	elderly	populations	in	the	future	could	increase	the	transmission	from	
these	age	groups.	This	could	be	modelled	in	future	sensitivity	analyses,	though	could	
only	 account	 for	 demographic	 changes,	 changes	 caused	 by	 societal	 differences	
cannot	be	predicted. 
The	vaccination	 campaigns	modelled	were	 considered	 feasible	based	upon	expert	
opinion	 and	 implementation	 of	 other	 vaccines	 in	 China	 and	 elsewhere.	 In	 reality,	
success	of	campaigns	will	be	reliant	on	the	vaccine	developed,	the	prioritisation	of	TB	
as	 a	 public	 health	 problem,	 and	 the	 availability	 of	 facilities	 or	 funding	 to	 develop	
facilities	 for	 the	 large-scale	 manufacture	 of	 TB	 vaccines.	 At	 the	 global	 level,	
adolescent	 and	 adult	 vaccination	 with	 just	 20%	 coverage	 has	 been	 estimated	 to	
require	 seven	 dedicated	 manufacturers,4	 therefore	 the	 70%	 coverage	 mass	
campaigns	modelled	here	may	be	feasible	for	a	country	with	as	much	manufacturing	
capacity	as	China,5	but	may	not	be	feasible	from	a	global	perspective.	This	research	















versus	 previously	 treated	 TB	 notification	 data	was	 considered,	 but	 the	 data	were	








the	 relative	 impact	 of	 vaccine	 types.	 Pre-infection	 vaccines,	 for	 example,	 tend	 to	
perform	better	over	longer	time	horizons.8	However,	beyond	2050	there	would	be	
too	much	uncertainty	in	the	model.	Full	benefit	of	vaccines	delivered	pre-2050	would	
extend	 beyond	 2050,	 therefore	 relative	 vaccine	 impact	 may	 change	 over	 longer	
horizons.8	 Results	 presented	 from	 the	models	 were	 specific	 to	 the	 2025-50	 time	
horizon.	
The	results	presented	in	the	thesis	are	representative	of	the	Chinese	epidemic,	which	














follow	 up	 visits.	 Use	 of	 ePAL	 coordinates	 was	 avoided	 to	 prevent	 observer	 bias.		
Tracking	down	the	correct	households	proved	very	time-consuming,	leading	to	some	
long	delays	between	registration	and	the	home	visit.	While	this	highlights	the	need	
for	 alternatives	 such	 as	 ePAL,	 and	 analyses	 indicated	 no	 significant	 bias	 in	 ePAL	
accuracy	with	 delayed	 follow	up,	 it	 is	 possible	 that	 incomplete	 capture	may	have	
biased	 our	 estimates	 of	 ePAL	 accuracy	 if,	 for	 instance,	 deliberately	 incorrect	
information	 had	 been	 provided	 or	 patients	 living	 in	 more	 distant	 locations	 were	
harder	to	track	down	for	follow	up	visits.		
Fourteen	 percent	 of	 evaluation	 visits	 were	 >1km	 from	 the	 place	 of	 residence	
registered	in	ePAL.	Analyses	suggest	this	may	be	associated	with	factors	relevant	to	





of	 this	 issue.	 Shortening	 the	 time	 between	 registration	 and	 follow	 up	 could	 help	
reduce	 the	number	 relocating,	but	 given	 relocation	or	multiple	 addresses	may	be	
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the	 greatest	 reduction	 in	 disease	 burden,	 and	 2)	 a	 better	 understanding	 of	 local	
epidemiology	 to	 inform	 the	 selection	 of	 trial	 sites,	 recruitment	 populations	 and	
design	clinical	trials.		
The	 existing	mathematical	modelling	 evidence	 to	 inform	 TB	 vaccine	 development	
strategy	 had	 not	 previously	 been	 summarised.	 To	 identify	 available	 literature	 for	
informing	the	first	research	need,	in	the	first	section	of	this	thesis	I	conducted	the	
first	 ever	 systematic	 review	 of	 the	 available	 mathematical	 modelling	 literature	
exploring	 the	epidemiological	 impact	of	new	TB	vaccines.	This	 review	provides	TB	
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vaccine	 developers	 a	 comprehensive	 summary	 of	 the	 range	 of	 available	
epidemiological	modelling	data	to	inform	vaccine	development	decisions.	This	review	
identified	several	substantial	research	gaps	for	 informing	TB	vaccine	development.	
These	 included	 the	 impact	 of	 prevention	 of	 infection	 and	 disease	 efficacy	
combinations,	 the	 division	 in	 the	 literature	 as	 to	 the	 impact	 of	 pre-	 versus	 post-
infection	 vaccines,	 the	 impact	 of	 varying	duration	of	 protection,	 the	dearth	of	 TB	
vaccine	modelling	literature	for	China,	and	the	impact	of	vaccinating	older	adults.		
Understanding	the	relative	impact	of	vaccine	characteristics	and	implementation	is	




China.	 Target	 product	 profiles	 currently	 under	 development	 lacked	 the	modelling	
data	 needed	 to	 inform	 the	 ideal	 and	 minimum	 vaccine	 characteristics,	 thus	 the	
comprehensive	exploration	of	vaccine	characteristics	in	the	research	presented	can	
inform	these	characteristics.	In	particular,	the	results	highlighted	the	importance	of	
prevention	 of	 disease	 vaccines	 effective	 in	 populations	 latently	 infected	 and	
recovered	 from	disease,	which	has	direct	 implications	 for	 clinical	 trial	 design.	 The	
results	highlighted	the	need	for	duration	of	protection	of	at	 least	5	years	with	10-
yearly	mass	adult	vaccination	campaigns,	suggesting	longer	durations	of	trial	follow	














trials.	 Poor	 availability	 of	 epidemiological	 data	 in	 clinical	 trial	 sites	 limits	 data-




based	 electronic	 data-capture	 tool	 for	 identifying	 TB	 patient	 place	 of	 residence,	
developed	 using	 high	 resolution	 satellite	 maps	 developed	 through	 community	
engagement.	For	the	research	site	in	Blantyre	it	provides	the	necessary	data	to	inform	
trial	design,	and	could	be	rapidly	and	inexpensively	translated	to	other	settings.	
Although	 further	 research	 is	 needed	 to	 completely	 fulfil	 the	 two	 epidemiological	
research	 needs	 identified	 in	 the	 TB	 vaccine	 blueprint,9	 the	 research	 in	 this	 thesis	
substantially	moves	forward	the	TB	vaccine	modelling	literature	through	its	attention	
to	 age-specificities	 in	 the	 modelling	 methodology,	 exploration	 of	 age	 targeting	
vaccination	 to	 older	 age	 groups,	 and	 comprehensive	 exploration	of	 the	 impact	 of	
















these	 decisions;	 however,	 it	 is	 hoped	 that	 the	 results	 of	 this	 research	will	 inform	








for	prevention	of	 infection	would	be	 insufficient	 to	 guarantee	high	 incidence	 rate	






















an	 efficacious	 post-infection	 vaccine	 delivered	 to	 older	 adults	 will	 be	 critical	 to	
maximise	population-level	impact	and	would	provide	a	crucial	contribution	towards	
achieving	the	WHO	2050	TB	goals.	Older	adults	should,	therefore,	be	included	in	TB	
vaccine	 clinical	 development	 and	 implementation	 planning.	 To	 allow	 on-label	 use	
following	vaccine	registration,	older	age	groups	need	to	be	included	in	clinical	trials,	















With	 longer	 durations	 of	 vaccine	 protection	 or	 more	 frequent	 revaccination	
strategies,	large	epidemiological	impact	could	be	achieved.	Therefore,	if	duration	of	
protection	 of	 new	 vaccines	 is	 found	 to	 be	 low,	 country-level	 planning	 for	 more	




included	in	whichever	vaccination	campaign	 is	conducted.	 If	resources	are	 limited,	
targeted	vaccination	of	older	adults	may	help	maximise	the	achievable	impact.	Even	
with	 reduced	coverage,	older	adult	 vaccination	was	 the	preferred	vaccination	age	





The	 research	 presented	 in	 this	 thesis	 is	 just	 the	 first	 step	 towards	 fulfilling	 the	
epidemiological	 and	modelling	 research	needs	 for	TB	vaccine	development.	Many	
additional	questions	were	identified	in	the	systematic	review	or	have	arisen	as	this	








a	 declining	 epidemiological	 trend	 due	 to	 successful	 control	 programmes	 but	 is	
insufficient	to	meet	2050	elimination	goals,	and	an	ageing	population.	 In	addition,	










The	 results	 from	 China	 are	 likely	 applicable	 to	 other	 high-burden	 countries	 with	
declining,	 reactivation-driven	 epidemics	 and	 ageing	 populations	 (e.g.	 Thailand,	
Russia).	 However,	 other	 high-burden	 settings	with	 higher	 transmission	 rates	 (e.g.	






















that	 has	 not	 yet	 been	 fully	 explored.	 In	 future	work,	 I	 plan	 to	 conduct	 additional	
analyses	 exploring	 the	 spatial	 distribution	 of	 TB	 in	 Blantyre	 and	 associated	 risk	
factors,	to	help	inform	current	public	health	measures,	and	in	the	hope	of	informing	
future	clinical	trials.	These	analyses	will	include	exploring	risk	factor	data,	employing	
the	 new	 enumeration	 data	 set	 as	 a	 denominator,	 conducting	 observed	 versus	




typhoid	 study,	 it	 would	 be	 of	 interest	 to	 use	 ePAL	 to	 explore	 other	 locations	
associated	 with	M.tb	 transmission	 risk,	 such	 as	 churches,	 bars	 and	 work	 places	








modelling	 research,	 would	 be	 to	 employ	 spatial	 data	 supplied	 by	 ePAL	 to	
parameterise	a	spatial	TB	model	to	explore	impact	of	vaccination	programmes	at	the	














The	 research	presented	 in	 this	 thesis	 informs	 the	development	of	 appropriate	 TB	
vaccines	 and	 target	 populations	 to	 maximise	 future	 population-level	 impact	 and	
accelerate	TB	vaccine	development.	A	prevention	of	disease	vaccine	efficacious	post-
infection	 and	 delivered	 to	 older	 adults	 would	 contribute	 towards	 maximising	
population-level	impact	in	China.	Adolescent-targeted	tuberculosis	vaccines	are	likely	
to	 have	 low	 impact	 in	 ageing,	 reactivation-driven	 epidemics	 like	 China,	 which	
suggests	a	modification	of	the	current	strategic	focus	on	adolescents.	Clinical	trials	
should	assess	disease	endpoints,	include	M.tb-infected	and	older	adult	populations,	




developers,	 clinical	 triallists,	 and	 country-level	 public	 health	 decision	 makers	
prioritise	and	plan	their	approach	to	the	development	and	implementation	of	new	
TB	vaccines.	Continued	development	of	epidemiological	models	and	data	collection	
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be	appropriately	prioritised	 to	ensure	 the	greatest	public	health	 impact	would	be	
achieved	when	new	vaccines	come	to	market.	To-date,	the	body	of	literature	on	this	






















































































































TB	 search	 terms	 and	
manual	search	criteria	
	




































• Disease	 or	 infection	 caused	 by	 Mycobacterium	 bovis	 or	 other	 non-
Mycobacterium	tuberculosis	strain.	
Data	 will	 be	 extracted	 from	 those	 papers	 selected	 for	 final	 inclusion	 using	 a	
standardised	Microsoft	Excel®	database.	Extracted	data	will	include	study	objectives,	
model	 methods	 (e.g.	 model	 structure,	 mixing	 patterns,	 model	 assumptions,	
parameter	data	sources),	intervention	characteristics	(e.g.	vaccine	efficacy,	duration	





studies.	 Fone	 et	 al.	 (2003)	 have	 proposed	 and	 tested	 an	 adapted	 version	 of	 the	
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		 Criterion	 (adapted	 from	
Fone	et	al.	and	Caro	et	al.)	


















2	 Is	 the	 setting	 and	
population	clearly	defined?	
Does	 the	 paper	 clearly	 state	 the	
setting	 (e.g.	 geographical	 location,	
high/low	TB	burden)?	
0	Not	stated	




Does	 the	 paper	 clearly	 state	 the	
modelled	population?	(e.g.	patient	or	
population	group	characteristics)	
Have	 sub-populations	 necessary	 for	
the	 research	 question	 and	 setting	
been	modelled?	
3	 Are	 the	 intervention	 and	
comparators	 adequately	
defined?	






stated	Does	 the	 paper	 clearly	 define	 the	
vaccine	 characteristics	 (e.g.	 vaccine	
efficacy,	 duration	 of	 protection,	
number	of	doses,	waning,	timing)?	
If	 there	 is	a	comparator	 (no	vaccine,	





defined	 and	 answer	 the	
research	question?	





directly	 aligned	 with	 research	
question	
2	 Stated,	 all	 necessary	 details	
stated,	and	aligned	with	research	
question	
Do	 the	 outcomes	 correspond	 to	 the	
research	question?	
5	 Are	 the	 model	 structure	
and	 time	 horizon	 clearly	
described	 and	 appropriate	
for	the	research	question?	
Is	 the	 model	 structure	 clearly	
reported	 and	 appropriate	 for	 the	
research	question?	




appropriate	 in	 part	 for	 research	
question	
2	 Complete	 and	 reproducible,	





	Does	 the	 model	 reflect	 current	
knowledge	of	disease	natural	history?	
Is	 the	 time	horizon	and	 time	step	of	
the	 model	 clearly	 stated	 and	
appropriate	to	the	research	question	













appropriate	 in	 part	 for	 research	
question	
















2	 Complete	 reporting	 of	
parameters,	 ranges	 and	 data	
sources	
8	 Are	 any	 assumptions	
explicit	and	justified?	










Are	 data	 limitations	 discussed?	 Are	
any	 of	 the	 sources	 known	 to	 the	
reviewer	to	be	inappropriate	(e.g.	do	
not	 match	 the	 parameter,	 are	
outdated,	 or	 known	 to	 be	 poor	
quality)?		
0	No	sources	or	uncertainty	
1	 Partially	 addressed,	 and/or	
some	data	inappropriate	
2	Fully	addressed	




10	 Is	 the	 method	 of	 fitting	
described	and	suitable?	




1	 Incomplete	 description	 or	
method	not	optimal	




Is	 the	 method	 of	 model	
fitting/calibration	suitable?	
11	 Has	 the	 model	 been	
validated?	
Has	 an	 assessment	of	 validity	 of	 the	
results	 been	 made	 by	 comparing	
across	 one	 or	more	 different	model	







Have	 the	 results	 been	
clearly	 and	 completely	
Have	 the	 outcome	 values	 and	 their	
uncertainty	 ranges	 for	 each	










1	 Stated,	 but	 ranges	 or	 planned	
sensitivity	 analyses	 missing	






Are	 sensitivity	 analyses	 clearly	
reported?	













in	 context	 and	 is	 generalisability	
considered?	





Is	 the	 funding	 and	 the	 role	 of	 the	
funder	clearly	stated?	















Very	high	 >22	 	 	
High	 19-22	 	 	
Medium	 .14-18	 	 	















Fitting	 methods	 reported	 included	 Sobol	 sequence	 sampling	 and	 approximate	
Bayesian	 computation,14	 Downhill	 simplex	 method,6	 maximum	 likelihood,22	 or	
adjustment	 of	 parameters	 to	 achieve	 required	 equilibrium	 values	 using	 Berkley	
Madonna	“curve	fit”	routine,12,13	generalised	reduced	gradient	non	linear	engine	of	
solver	in	Excel	or	manually.11-13	Fitting	methods	were	unclear	or	not	reported	in	six	







some	 models	 had	 out-dated	 natural	 history	 structures	 or	 inappropriate	 time	
horizons.	Overall,	the	scoring	for	fitting	methods	was	relatively	low,	as	several	studies	






appropriately	 interpreted	 and	 discussed	 in	 context.	 Only	 one	 model	 had	 been	



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As	 discussed	 briefly	 in	 the	 Chapter	 4,	 elderly	 populations	 are	 at	 increased	 risk	 of	
infection	 and	 disease.	 This	 is	 thought	 to	 be	 likely	 due	 to	 a	 combination	 of	
immunosenescence	and	comorbid	conditions	reducing	the	immune	system’s	ability	to	
manage	 infections.1	 Age-associated	 immunosenescence	 has	 been	 shown	 to	 affect	
both	the	innate	(e.g.	reduced	phagocytic	activity)	and	the	adaptive	(e.g.	diminished	
antibody	 response	 to	new	antigens	and	 reduced	T-cell	 output)	 immune	 response.1	
Therefore,	vaccines	may	be	less	efficacious	in	this	age	group,	or	need	to	be	specifically	
designed	or	dosed	to	overcome	known	reduced	responsiveness	in	this	population.2	
Live	 attenuated	 vaccines	 are	 generally	 thought	 to	 induce	 more	 effective	 immune	
responses,	but	in	some	cases	have	been	associated	with	higher	risk	of	adverse	events,	
which	 is	of	concern	 for	older	age	groups.1	For	example,	 the	 live	attenuated	yellow	
fever	vaccine	has	been	associated	with	up	to	10	times	the	risk	of	severe	adverse	events	
in	the	elderly	compared	to	younger	populations.1	
Few	 vaccines	 have	 been	 rigorously	 assessed	 for	 efficacy	 in	 elderly	 populations.	
Influenza	 and	 varicella	 vaccines	 are	 two	 vaccines	 currently	 delivered	 to	 older	 age	
groups.	As	discussed	in	the	main	text,	one	of	the	varicella	vaccines	(Zostavax®)	was	
found	 to	have	declining	 efficacy	by	 age	 in	 the	 elderly,3	 suggestive	of	 an	 impact	 of	
immunosenescence	on	vaccine	efficacy	in	the	70-79	and	≥80	years	age	groups.	In	the	
elderly,	 a	 dose	 approximately	 14	 times	 the	 infant	 does	 was	 delivered.	 However,	
efficacy	of	a	different	zoster	vaccine	was	found	not	to	decline	with	age	in	the	elderly.4	
Therefore,	 effects	 of	 immunosenescence	 can	 potentially	 be	 counteracted	 if	 the	
vaccine	is	appropriately	designed	or	dosed.1	
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coverage	 rates	 and	ensuring	 the	highest	 burden	populations	 are	 vaccinated,	 could	
potentially	overcome	shortfalls	in	intrinsic	vaccine	characteristics.		
Incidence	 rate	 reduction	 ranged	 0.01%	 to	 32%	 with	 feasible	 vaccine	 profiles	 and	
targeted	 vaccination	 strategies	 explored.	 Although	 the	 overall	 impact	 could	 be	
improved	 by	 inclusion	 of	 broader	 mass	 campaigns,	 with	 these	 relatively	 feasible	


































































































Approximately	 6	 month	 period	 following	 the	 run-in	 period	
(below)	 during	 which	 approximately	 196	 consenting	
participants	 will	 receive	 follow-up	 visits	 at	 their	 place	 of	


















Visit	 to	 the	 health	 centre	 as	 part	 of	 routine	 care	 at	 which	












follow	 up,	 but	 these	 data	 are	 rarely	 used	 for	 spatial	 analysis.	 Moreover,	 in	 areas	
without	official	address	systems,	the	accuracy	of	descriptions	is	often	low,	which	is	a	
significant	 obstacle	 for	 patient	 follow-up.	 The	 development	 of	 a	 method	 to	
systematically	 collect	 high-resolution	 TB	 patient	 location	 of	 residence	 could	 allow	
better	 retention	 in	 TB	 treatment	 programmes	 and	 could	 be	 used	 to	 maximise	
efficiency	 of	 local	 TB	 programmes	 through	 targeted	 interventions	 to	 high	 burden	
areas.	
	
In	 this	 study	 we	 aim	 to	 develop	 and	 evaluate	 a	 novel	 electronic	 mapping	 tool	



























































and	maps	 for	data	 collection	will	 be	developed	and	 installed	on	 to	 tablets	 for	 this	
study.	 The	 high	 resolution	 satellite	 photograph	 maps	 used	 in	 this	 software	 for	
identifying	place	of	residence	will	require	the	addition	of	places	of	interest	(POIs)	to	











The	Hit	TB	Hard	 study	 (COMREC	P.011/10/1020)	 is	 an	on-going	active	 case	 finding	
study,	 for	 which	 sputum	 is	 collected	 for	 monitoring	 and	 evaluation	 purposes	
throughout	Blantyre	City.	 The	 sputum	barcode	 from	 the	Hit	 TB	Hard	 study	will	 be	
recorded	to	 link	the	data	collected	 in	this	study	to	the	participant’s	culture	results.	
Data	 will	 be	 stored	 on	 the	 tablet,	 and	 uploaded	 daily	 to	 the	MLW	 server	 via	 3G	
connection.	
	





196	 patients	 will	 be	 enrolled	 during	 the	 evaluation	 period.	 For	 those	 willing	 to	
participate	 in	 the	 evaluation,	 written	 consent	 (or	 witnessed	 thumbprint)	 will	 be	





Data	collection	and	management:	Data	capture	 for	 this	study	 is	mostly	electronic.	















implementation.	 The	 evaluation	 period	 of	 the	 study	 will	 enrol	 approximately	 196	
participants	 to	 assess	 the	 reliability	 of	 ePAL	 versus	GPS	measurements	 of	 place	of	
residence.	Given	the	likely	 inaccuracy	of	 locating	to	the	household	level,	but	taking	
into	account	the	high	density	of	points	of	interest	to	assist	orientation	in	the	map,	the	
















understanding	 of	 the	 distribution	 of	 TB	 cases	 in	 Blantyre	 city	 and	 potential	 for	
improved	 patient	 follow	 up.	 Application	 is	 being	made	 to	 the	 Institutional	 Review	
Boards	 of	 College	 of	Medicine,	 Blantyre	Malawi	 (COMREC),	 and	 London	 School	 of	
Hygiene	And	Tropical	Medicine,	UK.	Risks	from	study	participation	are	minimal,	and	
relate	to	linkage	of	personally	identifiable	information	(PII)	to	sensitive	health	data,	
and	 to	 the	 risk	 of	 revealing	 health	 information.	 All	 possible	 steps	will	 be	 taken	 to	
minimise	these	risks,	such	as	use	of	a	numerical	unique	identifier	instead	of	names	in	
the	 database,	 and	 conducting	 the	 home	 visit	 in	 a	 manner	 that	 minimises	 risk	 of	
revealing	health	status,	by	visiting	at	a	time	agreed	by	the	participant,	not	bearing	any	
labels	indicating	the	field	worker	is	part	of	a	TB	or	HIV	study,	and	ensuring	the	health	





health	 status)	 and	 the	 potential	 for	 harm	 is	 minimal,	 therefore	 verbal	 consent	 is	
considered	 appropriate	 for	 participation	 in	 this	 study.	 Permission	 to	 obtain	 verbal	






differences	 in	 numbers	 of	 cases	 and	 TB	 rates	 between	 some	 census	 enumeration	
areas,	these	may	be	 linked	to	known	risk	factors	for	TB.	Weekly	reports	containing	
interim	summaries	of	 the	data	 collected	 in	 the	main	 study	and	 tool	evaluation,	by	
health	centre	and	for	the	study	as	a	whole,	will	be	sent	to	the	TB	officers	and	nurses	
involved	in	the	study	via	3G	to	the	tablets	at	the	health	centres.	Dissemination	of	final	





regional	 levels	 as	 a	 result	 of	 government	 surveillance	 systems.	 However,	 such	
heterogeneity	is	often	poorly	understood	at	the	local	level,	such	as	between	areas	in	
a	city.	A	small	number	of	studies	in	Sub-Saharan	Africa	have	demonstrated	such	local	
variations	 exist	 for	 TB	 disease.	 For	 example,	 in	 Cape	 Town,	 South	 Africa,	 39	
enumerator	 districts	 (across	 two	 communities)	with	 an	 average	 population	 of	 900	
inhabitants	reported	adult	TB	notification	rates	ranging	between	0	and	2,847/100,000	
adults	per	year.1		Similar	variations	were	reported	in	a	settlement-level	study	in	the	
Gambia,	 where	 rates	 in	 settlements	 of	 4,000-68,000	 people	 ranged	 from	 48	 to	
239/100,000	 population/year.2	 The	 potential	 for	 such	 large	 local	 variations	 in	 TB	
disease	 burden	 demonstrates	 that	 regional	 or	 even	 city-level	 data	 may	 not	 be	




of	 disease	 is	 well	 documented	 for	 many	 diseases.	 Malaria,	 for	 example,	 is	
heterogeneously	distributed	in	certain	settings,	where	it	has	been	demonstrated	that	
using	 local	 epidemiology	 for	 rational	 targeting	 of	 interventions	 is	 essential	 for	
effective	 and	 efficient	 disease	 control.3	 Spatial	 mapping	 and	 an	 analysis	 of	 the	
associated	 risk	 factors	 for	 TB	 could	 play	 an	 important	 role	 in	 understanding	






Existing	 spatial	 studies	 often	 use	 enumerated	 DHS	 populations	 or	 prospectively	
capture	place	of	residence	using	GPS,	which	is	resource-intensive.2,5,6		Therefore,	due	
to	costs	or	logistics,	such	detailed	prospective	TB	case	mapping	in	non-enumerated	




are	 rarely	 used	 for	 spatial	 analysis.	 Moreover,	 in	 areas	 without	 official	 address	
systems,	the	accuracy	of	such	descriptions	is	usually	low	and	patients	often	seek	care	
outside	of	the	TB	clinic	catchment	area	of	their	place	of	residence,	creating	significant	
obstacles	 for	 patient	 follow-up.	 The	 development	 of	 a	 low-cost	 method	 to	












electronic	 data	 capture	 (EDC).	 Therefore,	 to	 improve	 its	 utility	 by	 increased	
throughput	and	automation,	 and	 to	 future-proof	 such	a	 tool,	 an	electronic	 system	
would	be	the	logical	evolution	of	the	paper	mapbook.	In	addition,	it	is	possible	that	an	






routine	case	data	capture	 to	understand	 local-level	 tuberculosis	epidemiology,	and	
target	limited	available	resources	more	effectively.	
	
Although	 Malawi	 has	 experienced	 a	 steady	 decline	 in	 TB	 incidence	 since	 1998,	














Hard	 research	 programme,	 both	 to	 assist	 patient	 follow	 up,	 and	 to	 permit	 spatial	











cases	 in	Malawi.	 In	 this	 study	we	 aim	 to	 develop	 and	 evaluate	 a	 novel	 electronic	
mapping	 tool	 (electronic	 PArticipant	 Locator	 -	 ePAL)	 to	 map	 the	 geographical	
distribution	of	the	place	of	residence	of	people	registering	for	TB	treatment	in	Blantyre	
City,	Malawi.	If	successful,	it	is	envisaged	that	this	tool	could	have	significant	future	
utility	 for	 similar	 mapping	 of	 other	 diseases	 of	 public	 health	 importance,	 and	 for	





Understanding	 local	 variation	 in	 burden	 of	 disease	 and	 associated	 risk	 factors	 can	
permit	 more	 efficient	 selection	 and	 targeting	 of	 limited	 resources	 for	 TB	 disease	
control.	However,	studies	to	generate	these	data	usually	require	existing	enumeration	
of	the	population	of	interest	or	large	budgets	to	conduct	this	ahead	of	the	study.	Such	
studies	 are	 not	 appropriate	 where	 resources	 are	 constrained	 or	 for	 national	
tuberculosis	 programmes	where	 surveillance	 covers	 large	 populations,	 therefore	 a	
low-cost	 methodology	 for	 identifying	 location	 of	 TB	 cases	 in	 the	 context	 of	 the	





















data	 and	 home	 location	 of	 TB	 treatment	 initiators	 using	 the	 ePAL	 tool;	 and	 B)	 an	





residence	of	patients	 ≥18	 years	 initiating	 TB	 treatment	 (TB	notifications)	 using	 the	
ePAL	tool	at	TB	centres	in	Blantyre	City.		
	








refinements	 required	 for	 the	 study	 logistics,	 staff	 training	or	 the	 ePAL	 tool	 can	be	
made.	The	ePAL	 tool	will	 then	be	 rolled	out	across	all	 participating	TB	 registration	
centres	 in	 Blantyre	 City	 (population	 approximately	 661,256)10.	 Enrolment	 will	






























































the	 place	 of	 residence	 of	 microbiologically-confirmed	 adult	 cases	 initiating	
treatment	for	pulmonary	tuberculosis.	
• To	map	 the	 spatial	distribution	of	adult	pulmonary	 tuberculosis	notifications,	
stratified	by	age.	
• To	map	 the	 spatial	distribution	of	adult	pulmonary	 tuberculosis	notifications,	
stratified	by	gender.	









• Criteria/definition:	 Any	 new	 or	 retreatment	 pulmonary	 or	 extra-
pulmonary	 TB	 patient	 aged	 ≥18	 years	 starting	 a	 new	 course	 of	 TB	
treatment.	



















• Criteria/definition	 1:	 Geospatial	 reference	 of	 place	 of	 residence	 as	
determined	by	the	patient	using	ePAL.	
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• Criteria/definition	 2:	 Geospatial	 reference	 of	 place	 of	 residence	 as	

















of	 residence.7	 In	 Blantyre,	 a	 paper	 mapbook	 used	 at	 point	 of	 care	 has	 been	
demonstrated	 to	 allow	 accurate	 and	 rapid	 identification	 of	 whether	 ARV	 therapy	
initiators	are	residents	within	study	clusters.6	Such	a	tool	allows	cluster-level	mapping	
of	 non-enumerated	 populations,	 such	 as	 urban	 Blantyre’s	 informal	 settlements.	
Although	valuable,	paper-based	tools	are	widely	being	phased	out	in	field	studies	in	
favour	of	electronic	data	capture	(EDC).	Therefore,	the	ePAL	tool	to	collect	place	of	
residence	 electronically	 at	 the	 clinic	 will	 increase	 the	 resolution	 to	 which	 this	



















the	 citywide	 sputum	 culture	 testing	 on-going	 as	 part	 of	 the	 Hit	 TB	 Hard	 study,	
microbiologically	 confirmed	 pulmonary	 TB	 is	 a	 viable	 outcome	 of	 interest	 for	 this	
study.	It	is	thus	included	as	a	secondary	outcome	of	interest.	
	
Extra-pulmonary	 TB	 is	 not	 analysed	 in	 isolation	 as	 it	 is	 anticipated	 that	 the	 small	





public	 health	 interventions	 appropriately,	 it	 is	 also	 essential	 to	 understand	 the	




rates.	 However,	 as	 this	 study	 does	 not	 aim	 to	 estimate	 temporal	 trends,	 such	























Study	 start	 is	 anticipated	 in	 3Q	 2014,	 with	 phased	 roll	 out	 across	 health	 centres,	
starting	at	Queen	Elizabeth	Central	Hospital.	The	evaluation	element	will	consist	of	
approximately	2-month	run-in	period	and	approximately	6-month	evaluation	period	
(Figure	 1).	 Data	 collection	 using	 ePAL	 will	 continue	 until	 at	 least	 the	 end	 of	 the	
















Approximately	 344,500	 residents	 are	 ≥18	 years,	 therefore	 this	 study	 will	 be	
implemented	in	the	services	providing	care	to	this	population	of	study-eligible	age.	In	
Malawi,	 TB	 treatment	 is	only	 available	 through	government	 facilities,	 therefore	TB	
treatment	registration	through	these	clinics	should	provide	relatively	comprehensive	









































from	 electronic	 tablets	 based	 in	 the	 health	 centres.	 The	 tool	 will	 consist	 of	 an	
electronic	data	collection	form	to	input	basic	demographic	and	health	status	data	as	





























For	 the	 POIs	 collected	 across	 Blantyre	 City,	 resident	 HSAs	 will	 assist	 with	 the	
identification	of	POIs	 in	 their	 respective	catchment	areas.	An	 introductory	meeting	
will	be	held	with	HSAs	to	introduce	the	study	and	explain	the	methodology	to	follow	
for	 POI	 collection.	 HSAs	 will	 be	 compensated	 2000K	 for	 attending	 the	 meeting.	
Following	HSA	engagement	with	the	local	community	to	identify	POIs,	study	staff	will	
collaborate	 with	 HSAs	 to	 collect	 GPS	 coordinates	 of	 each	 POI	 using	 mobile	 GPS	
handsets.	HSAs	will	be	compensated	3000K	upon	completion	of	POI	GPS	collection.	
These	coordinates	and	POI	name	will	be	uploaded	to	the	tool	maps.	The	software	will	
















































This	 study	 will	 consist	 of	 the	 implementation	 and	 evaluation	 of	 an	 electronic	
participant	location	capture	tool	(ePAL)	in	participating	health	centres	in	Blantyre	City.		
	
TB	 Officers	 and	 nurses	 registering	 TB	 patients	 in	 participating	 TB	 clinics	 will	 be	
responsible	for	data	collection	using	the	ePAL	tool.	Ahead	of	ePAL	implementation,	all	
relevant	staff	will	be	trained	in	collection	and	storage	of	patient	data,	and	push/pull	
of	 data	 and	 updates	 from	 the	 server.	 	 During	 the	 study,	 re-training	 and	 trouble	
shooting	will	be	added	to	the	monthly	meetings	held	with	the	TB	officers.		
Following	ePAL	launch,	all	patients	meeting	the	inclusion/exclusion	criteria	registering	
for	 TB	 treatment	 will	 be	 invited	 to	 participate.	 Following	 the	 usual	 treatment	
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registration	processes	(Figure	3,	grey),	patients	willing	to	participate	will	be	allocated	




Participants	 eligible	 and	 willing	 to	 participate	 in	 the	 main	 study	 will	 be	 verbally	
consented	(For	information	sheet	and	verbal	consent	forms	in	English	and	Chichewa,	





ePAL	 electronic	 data	 collection	 forms.	 	 The	 TB	 officer/nurse	 will	 then	 guide	 the	












For	patients	eligible	and	willing	 to	participate	 in	 the	 tool	evaluation	group,	written	
consent	will	be	requested	(For	information	sheet	and	written	consent	forms	in	English	
and	Chichewa,	see	Appendix	C).	In	this	group	of	participants,	data	collection	will	be	
the	 same	as	detailed	above,	plus	 the	ePAL	data	collection	 forms	will	 include	some	
additional	questions	pertaining	to	SES,	care	seeking	behaviour	and	risk	factors	for	TB	






by	 a	 visit	 to	 the	 place	 of	 residence.	 At	 this	 visit,	 GPS	 coordinates	 of	 the	 place	 of	
residence	will	be	recorded.	GPS	data	will	be	linked	to	the	ePAL	database	based	on	the	













and	 providing	 other	 essential	 participant	 information.	 	 The	 expression	 of	 verbal	
consent	and	the	name	of	the	person	taking	the	consent	will	be	documented.		
For	participants	participating	 in	 the	evaluation	component,	 there	will	be	questions	
included	pertaining	to	SES,	care	seeking	behaviour	and	risk	factors	for	TB	and	a	follow	
up	visit	to	the	patient’s	place	of	residence,	which	is	collection	of	information	beyond	









issues.	Monthly	meetings	are	already	 in	place	 for	 the	Hit	TB	Hard	study,	so	will	be	
extended	 to	 incorporate	 trouble-shooting	of	any	 reported	problems,	 small	 training	
updates,	and	to	provide	 feedback	 to	 the	officers	on	study	progress	and	results.	TB	
officers	will	be	compensated	for	their	time	for	participation	in	these	meetings.	
	

























a	 daily	 live	 link	 to	 LSHTM,	 UK	 for	 additional	 data	 management.	 	 All	 data	 will	 be	
uploaded	daily	from	the	tablets	in	the	clinics	to	the	database	on	the	MLW	server	via	






































All	 tablets	 holding	 patient	 data	 will	 be	 password	 protected,	 with	 passwords	 only	
known	by	study	staff	and	the	TB	officers	and	nurses	trained	to	use	the	tablets	at	the	
clinics.	The	tablets	will	automatically	lock	after	5	minutes	of	inactivity	to	protect	the	

































expected	 from	 GPS	 readings,	 and	 although	 the	 level	 of	 inaccuracy	 is	 currently	
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methods	 and	 the	 area	 of	 the	 house.	 Taking	 this	 into	 account,	 the	 sample	 size	 is	






































	 75	 80	 85	 90	 95	
65	 73	 28	 13	 6	 3	
70	 289	 62	 22	 9	 3	
75	 	 246	 49	 16	 5	
80	 	 	 196	 35	 9	
85	 	 	 	 139	 19	
90	 	 	 	 	 73	
	
Although	TB	officers	will	be	given	training	 in	use	of	 the	tool	and	orientation	 in	 the	
maps,	 it	 is	anticipated	that	TB	officers	will	 improve	at	guiding	patients	through	the	
maps	during	the	run-in	phase	of	the	study.	Data	from	evaluation	visits	will	be	valuable	
during	this	phase	to	 identify	underperforming	areas	to	target	additional	training	or	
map	 POI	 annotation	 improvements.	 Therefore,	 to	 allow	 for	 this	 period	 of	




in	 tool	 evaluation.	 During	 this	 period	 the	 tool	 is	 expected	 to	 be	 a	 consistently	
implemented	 part	 of	 TB	 registration	 visits,	 therefore	 demonstrating	 the	 tool’s	


















will	 be	 used	 to	 identify	 census	 enumeration	 area	 of	 residence	 of	 participating	
residents	 with	 pulmonary	 TB	 registering	 for	 TB	 treatment,	 which	 will	 form	 the	
numerator	of	case	notification	rate	calculations.	The	population	denominator	for	each	
of	the	CEAs	will	be	calculated	as	described	in	Section	0.	These	numbers	will	be	used	to	
calculate	 case	 notification	 rate	 per	 100,000	 population	 per	 year	 for	 each	 census	
enumeration	area.	Exact	95%	confidence	intervals	for	the	case-notification	rates	will	




























trigger	 tool	 improvements	 or	 additional	 staff	 training	 where	 required.	 The	 data	
collected	from	approximately	196	participants	in	the	evaluation	period	will	be	used	




within	 20m	 of	 the	 GPS-recorded	 location	 will	 be	 estimated,	 along	 with	 a	 95%	







No	 laboratory	 tests	will	 be	 conducted	as	part	of	 this	 study.	Results	 from	HIV	 tests	
conducted	as	part	of	routine	care	will	be	collected	wherever	the	patient	is	willing	for	











the	 distribution	 of	 TB	 cases	 in	 Blantyre,	 which	 has	 value	 for	 governmental	 TB	
programmes	 in	 designing	 control	 strategies.	 If	 the	 evaluation	 proves	 the	 tool	 is	










On	 submission	 for	 ethics	 review,	 permission	 for	 verbal	 informed	 consent	 will	 be	
requested	for	participants	taking	part	in	the	main	study	using	ePAL	to	identify	their	
place	of	residence.	The	grounds	for	requesting	verbal	consent	are	that:	TB	patients	
are	 defined	 and	 investigated	 in	 line	 with	 national	 policy.	 In	 this	 study,	 place	 of	
residence	 location	 is	 recorded	 using	 an	 electronic	map	 tool	 as	 opposed	 to	 verbal	
description,	 but	 the	 target	 information	 is	 the	 same	 regardless	 of	 measurement	
method;	The	potential	for	harm	is	minimal.	
	
The	 main	 potential	 for	 risk	 of	 harm	 could	 arise	 if	 patient	 identity	 were	 revealed	
through	 the	 linking	 of	 sensitive	 health	 information	 with	 personally	 identifiable	
information	(the	location	of	residence)	in	the	study	database.	As	the	objective	of	the	
study	is	to	develop	a	tool	to	accurately	identify	the	place	of	residence	when	at	a	TB	
clinic,	 collection	 of	 location	 coordinates	 and	 patient	 information	 is	 unavoidable.	
However,	risk	of	patient	identification	will	be	minimised	by	only	recording	the	unique	
patient	identifier	and	not	the	name	in	the	final	electronic	database.	Only	the	principal	




Information	 leaflets	 will	 be	 provided	 to	 all	 participants,	 specifying	 that	 this	 is	 a	
research	study	(see	Appendix	B)	and	providing	other	essential	participant	information.			




TB	 disease	 status	 to	 be	 revealed	 through	 the	 visit	 to	 the	 place	 of	 residence.	 	 In	
addition,	due	to	the	association	between	TB	and	HIV,	revealing	a	patient’s	TB	status	
could	lead	also	to	assumptions	in	the	community	about	their	HIV	status.	These	risks	
will	be	minimised	by	conducting	 the	home	visit	 in	a	manner	 that	minimises	 risk	of	
revealing	health	status,	such	as	visiting	at	a	time	agreed	by	the	participant,	not	bearing	
any	labels	 indicating	the	field	worker	is	part	of	a	TB	or	HIV	study,	and	ensuring	the	
health	 information	 about	 the	 participant	 is	 not	 communicated	 to	 others	 unless	
express	permission	is	given	by	the	participant.	For	those	participating	in	the	evaluation	
component,	 a	 different	 information	 leaflet	 will	 be	 provided	 (see	 Appendix	 C),	














will	be	made	 freely	available	 through	 the	Malawi-Liverpool-Wellcome	Trust	 (MLW)	
Programme	website.		
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Alongside	 original	 data,	 anonymised	 databases	will	 be	 created	 and	 stored	with	 all	
relevant	data	to	facilitate	any	data	transfer	requests	that	are	made	subsequently.		
Ethical	 clearance	 will	 be	 sought	 before	 data	 are	 transferred	 to	 other	 groups	 for	
secondary	 analysis.	 Priority	will	 be	 given	 to	 local	 investigators	 and	publicly	 funded	







community	 feedback	meetings	 organised	 by	MLW’s	 research	 dissemination	 office,	
and	the	team	will	approach	local	radio	to	propose	a	session	for	presentation	of	results	
with	 a	 community	 phone-in	 session.	 Results	 of	 the	 tool	 evaluation	 and	 final	 data	
analysis	will	be	presented	at	national	research	meetings,	such	as	the	annual	research	
day	held	by	College	Of	Medicine,	and	presented	at	international	research	meetings.		
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TBP02: Evaluation component of using ePAL to locate residence of patients initiating TB treatment 



















You will be given a copy of the information sheet and a signed consent form to keep. 
I voluntarily agree to take part in this study. 
!
Participant!_________________________! TB!Officer!!______________________________!!!!!!








































3. Ndafunsamafunsoonseomwendinalinawookhudzacholinga! cha! kafukufukuyu,!
njirayamakonoyakalondolondowamapukomansondondomekoyotimubwelekunyumbakwang
andipondiliokondwakutindadziwaizi.!








7. Ndikumvetsetsakutingatindikanakutenganawombali! pa! kafukufukuuyu,!
sizikhudzaufuluwangawopezachithandizo! cha! matenda! a! TB!
kuchipatala,tsopanokapenam’tsogolo.!
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Apologies to email against soon, but was wondering if I could also ask for permission to use








On 24 Jul 2017, at 17:02, Rebecca Harris <lsh355020@lshtm.ac.uk> wrote:On 24 Jul 2017, at 17:02, Rebecca Harris <lsh355020@lshtm.ac.uk> wrote:
Dear Chris,
 
I hope this email finds you well.
 
I was wondering whether I could seek permission for including the following image from your
2013 prospects for TB elimination paper within the printed and electronic versions of my
thesis (for submission to the London School of Hygiene and Tropical Medicine). The thesis
will be made available on the  the LSHTM Research Online institutional repository, which is
non-commercial and available to all: http://researchonlint.lshtm.ac.uk/ 
 
If you are not the rights holder for this material, I would be grateful if you could advise me
who to contact.  
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